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chapter 1
 general introduction
Respiratory tract infections (RTIs) form a major burden of disease in children worldwide. 
The World Health Organization estimates there are 150.7 million cases of pneumonia 
each year in children younger than 5 years, with as many as 20 million cases severe 
enough to require hospital admission1. Moreover, mortality (death rates) due to pneumo-
nia in Europe varied from 0.10-1.76 per 100000 between 2000-20102.
A wide range of microorganisms is accepted as potential pathogen of the respira-
tory tract in children, including viruses and bacteria. Streptococcus pneumoniae and 
Mycoplasma pneumoniae are the two most common bacterial causes of lower RTIs in 
hospitalized children (Table) 3, 4. This thesis focuses on M. pneumoniae, the smallest free 
living micro-organism that is responsible for up to 40% of children hospitalized because 
of community acquired pneumonia (CAP) 5.
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introdUction to M. PNEUMONIAE
History and biological characteristics. M. pneumoniae was first isolated from the sputum 
of a patient with primary atypical pneumonia by Eaton et al. in 1944 6. The bacterium 
was thereafter known as the Eaton agent, and was considered a virus until it finally 
became clear that antibiotics could be effective against it. Chanock et al. succeeded in 
culturing the Eaton agent on cell-free medium and proposed the taxonomic designation 
M. pneumoniae in 1963 7. M. pneumoniae is currently classified as a member of 
the family Mycoplasmataceae and order Mycoplasmatales within the bacterial class of 
Mollicutes (lat. soft skin). The common features shared by all the bacteria in this class 
are a permanent lack of a rigid cell wall, small cellular dimensions, and a small circular 
genome with a low G+C content (20-40%) 5, 8, 9.
M. pneumoniae possesses a membrane containing sterols and has a size of approxi-
mately 0.2 µm by 2 µm. So far, the complete genome sequence of three M. pneumoniae 
strains has been determined. Analysis of genomic studies has resulted in the identification 
of two subtypes, i.e. subtype 1 and subtype 2, and variants thereof. The complete 
genome of M. pneumoniae strain M129 (a subtype 1 strain) has a length of 816,394 
bp and contains only 689 open reading frames (ORFs). The genome length of M. 
pneumoniae strain FH and 309 (both subtype 2 strains) is 811,088 bp and 817,176 
bp respectively 10, 11. The limited size of the genomes of mycoplasmas is generally 
considered to be the result of a gradual loss of genome information from a common 
Gram-positive ancestor.
As a consequence of their small genome, M. pneumoniae strains have a limited 
metabolic capacity and activity, and are thus dependent on their host for the production 
of e.g. purines and pyrimidines 8. It is therefore important that M. pneumoniae is in close 
contact with its host to scavenge for such nutrients. To establish close contact with the host 
respiratory epithelium, M. pneumoniae contains a specialized attachment organelle. 
This organelle consists of a number of adhesion proteins and accessory proteins that 
are essential for attachment 12-14. The most important adhesion protein is the P1 protein. 
Together with the P40 and P90 proteins, it is primarily responsible for attachment to the 
host respiratory epithelium 12, 15-17 (Figure). Loss of (a part of) this protein or (a part of) 
one of its counterparts results in the inability to attach to respiratory epithelium and a 
non-virulent phenotype 15, 18.
Antigenic variation of the attachment organelle. The P1 and P40/P90 proteins are 
encoded by the MPN141 gene and the MPN142 gene, respectively 8, 19, 20. Parts of 
the MPN141 and MPN142 genes exist in multiple versions in the genome 9, 21. The 
different versions of these repetitive DNA elements, which are called RepMP elements, 
are similar but not identical in DNA sequence. It is speculated that in order to evade the 
host immune response, M. pneumoniae may change the MPN141 and MPN142 genes 
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and, consequently, the encoded proteins, by homologous DNA recombination between 
the RepMP elements in the genome. This process may result in antigenic variation. In 
addition to the basic subtype of an M. pneumoniae strain (i.e. subtype 1 or subtype 2), 
these recombination events result in additional genetic variation located in the MPN141 
and MPN142 genes. Genetic variation is not only important for immune evasion, but 
might also play a role in pathogeneity of M. pneumoniae. However, the effect of genetic 
variation on pathogeneity has never been demonstrated for M. pneumoniae. One of the 
reasons for this lack in knowledge could be the lacking consensus about how to study 
and interpret genetic variation of M. pneumoniae. Therefore, fi rst a thorough analysis of 
the current genetic variation of M. pneumoniae had to be performed. The analysis of this 
genetic variation is the main subject of part 1 of this thesis.
Epidemiology and clinical syndromes of M. pneumoniae infection. M. pneumoniae is 
an endemic cause of respiratory tract infections unbound to a specifi c season. Cyclic 
epidemics in developed countries occur every 3-7 years and are attributed to decreased 
herd immunity. During an epidemic, local outbreaks are common in schools, military 
institutions and nursing homes 22-25. M. pneumoniae is found particularly in school-aged 
children, but may affect all age groups. M. pneumoniae infection may manifest itself as 
upper RTIs, lower RTIs or a combination of both. The most common upper RTIs due to 
M. pneumoniae are pharyngitis and acute bronchitis. In general, these infections are 
mild and self-limiting. However, up to 40% of patients with CAP are infected with M. 
pneumoniae, which makes CAP the primary burden of disease.
Symptomatic disease usually develops during a couple of days with unspecifi c symptoms 
of RTI indistinguishable from e.g. a viral illness. Symptoms may include cough, fever, 
P1
P40/P90
Sterol membrane
A B
fig.  (Left) Transmission electron microscopy of M. pneumoniae (M) and its attachment organelle (in the red 
box indicated by the arrow). (Right) A simplifi ed schematic representation of the attachment organelle and 
the location of the most important attachment proteins in the sterol membrane. Figures adapted from S. Rot-
tem, Physiology Reviews 14.
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sore throat, headaches, muscle pains, general malaise and fatigue 26. Some symptoms 
(such as chest pain and lack of wheeze) seem to occur more in M. pneumoniae-infected 
children than in children infected with other pathogens 27. Also, a clinical syndrome, 
i.e. ‘walking pneumonia’, has previously been described that was considered to be 
characteristic for M. pneumoniae RTI 5. However, a recent Cochrane review showed 
that a reliable diagnosis of M. pneumoniae RTI cannot be made based on clinical symp-
toms and signs alone 27. After the primary illness, patients may complain of persistent 
unspecific symptoms such as recurring headache, general malaise and fatigue, which 
may last for months. More importantly, also respiratory complaints may last for a longer 
period. It is believed that this is especially true for children with an underlying pulmonary 
illness such as asthma, which led to the notion that there is a possible causal relationship 
between M. pneumoniae infection and the onset of asthma, asthma progression or 
asthma exacerbation 28. This is, however, still a matter of debate.
Besides respiratory tract infections, M. pneumoniae has been associated with a 
number of extra-pulmonary manifestations. It is believed that as many as 25% of persons 
colonized with M. pneumoniae may experience an extra-pulmonary sign or symptom at 
a variable time period after colonization. This is irrespective of the actual occurrence of 
symptoms related to an RTI. The etiology of many of these manifestations is not exactly 
known and they may be of variable severity. Both direct invasion of other sites than the 
respiratory tract and cross-reaction of antibodies or auto-immunity have been suggested 
as an explanation.
Central nervous system diseases have been recognized as the most frequent occurring 
extra-pulmonary manifestations of variable severity. In children, encephalitis is the most 
frequently observed neurological complication, which in theory may be attributed to the 
cross-reaction (molecular mimicry) of anti-M. pneumoniae antibodies and myelin com-
ponents, such as gangliosides 29. Examples of other severe complications, which have 
been described less frequently, are Guillain-Barre syndrome and acute disseminating 
encephalomyelitis 30, 31.
table. Pathogens identified in hospitalized children with community-acquired pneumonia in developed 
countries (total exceeds 100% because co-infections are taken into account) Adapted from Michelow et 
al. 3.
Respiratory syncytial virus and other viruses 58%
Streptococcus pneumoniae 44%
Mycoplasma pneumoniae 14%
Chlamydophila pneumoniae 9%
Mycobacterium tuberculosis 1%
Staphylococcus aureus 1%
No pathogen identified 21%
Chapter 1
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Extra-pulmonary manifestations may further include dermatologic manifestations 
(erythematous maculopapular rash and, rarely, Stevens-Johnson syndrome), hemolytic 
anemias and several forms of arthralgia or arthritis. Very sporadically, renal compli-
cations (e.g. glomerulonephritis, tubulointerstitial nephritis and IgA nephropathy) and 
cardiac complications (e.g. pericarditis, myocarditis and pericardial effusion) have been 
described 5.
Microbiological tools to diagnose M. pneumoniae. The diagnosis of an M. pneumoniae 
infection has been the subject of many studies since the first isolation of this pathogen 
from the sputum of a patient with primary atypical pneumonia in 1944 5. Although the 
media used for culturing M. pneumoniae have been optimized over the years, culturing 
remains an insensitive tool to detect M. pneumoniae in clinical samples, and is successful 
in only 60% of the time in experienced laboratories. Moreover, due to the lack of a rigid 
cell wall and limited metabolic capacity 5, M. pneumoniae is difficult to culture. The 
current diagnosis of M. pneumoniae RTIs therefore relies on the detection of either serum 
antibodies against M. pneumoniae or bacterial DNA in samples of the upper respiratory 
tract (URT), as recommended in the guidelines published by the British Thoracic Society 
and the Infectious Disease Society of America 32, 33.
Serology, i.e. the detection of antibodies against M. pneumoniae proteins in the serum 
of patients, is a widely available diagnostic procedure in microbiological laboratories. 
Although several serological assays are currently available, their outcomes are often 
not comparable. The assays with the highest sensitivity and specificity, however, are 
based on the ELISA technique. As these tests are commercially available, and culture 
is relatively insensitive and time-consuming, ELISA has become the cornerstone of the 
diagnosis of M. pneumoniae infections. Nevertheless, the use of serology also has a 
clear downside since it requires a serum sample taken in the acute phase of the disease 
and a convalescent serum sample taken 2-4 weeks later to provide a reliable result. 
The inherent retrospective diagnosis, after the collection and testing of a second serum 
sample, is not helpful for clinicians to make a therapeutic management decision in the 
acute phase of the infection.
In the past two decades, a solution to the drawbacks of culture and serology has 
seemingly been provided by PCR. Consequently, PCR-based methods are increasingly 
used in daily clinical practice, as well as in clinical studies for the detection of M. 
pneumoniae DNA, because they provide fast and sensitive results in the acute phase of 
an infection. However, if M. pneumoniae would be commonly carried asymptomatically 
in the URT of children, the detection (of DNA) of this bacterial species may not indicate a 
symptomatic infection. There have been some studies that report asymptomatic carriage 
with M. pneumoniae. However, all these studies suffer from inherent shortcomings in 
study design (e.g. lack of a control group or follow-up) or diagnostic methods (e.g. low 
sensitivity of culture methods and serology) 25, 26, 34-36. Nevertheless, the existence of 
13
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asymptomatic carriage would have major implications for the interpretation of the results 
of currently used molecular detection methods for M. pneumoniae, and particularly for 
clinical management of suspected M. pneumoniae RTIs. To overcome the problems in 
previous studies on asymptomatic carriage of M. pneumoniae we conducted a large 
prospective study, using a clearly defined control group and several accepted microbio-
logical tools to detect M. pneumoniae.
Treatment of M. pneumoniae respiratory tract infections. While M. pneumoniae lacks 
a rigid bacterial cell wall, the bacterium is protected by a sterol-containing membrane. 
As a direct result, M. pneumoniae has an innate resistance to any antibiotic that is 
directed to the destruction or disruption of a bacterial cell wall, such as beta-lactams and 
glycopeptides 37. In general, antimicrobials that are directed at the DNA metabolism and 
protein synthesis have a good inhibitory activity against M. pneumoniae. Tetracyclines, 
doxycycline and fluoroquinolones therefore have a good in vitro inhibitory effect against 
M. pneumoniae, but have known side effects and affect the growing bones in children. 
As a consequence, macrolide (ML) antibiotics are the preferred choice of antibiotics 
in children. These antibiotics also have a better MIC value than most other antibiotics 
directed against M. pneumoniae 37.
The past decade has witnessed a growing number of reports on antimicrobial resistance 
of M. pneumoniae. This is particularly the case in Asia, but also in Europe and the 
USA, an increase in the prevalence of ML-resistant M. pneumoniae isolates has been 
observed 38-49. ML resistance is caused by single-nucleotide polymorphisms (SNPs) in 
the bacterial ribosomal RNA gene. Due to these mutations, the attachment of the ML 
molecules to the peptidyl transferase loop of the bacterial ribosome is ineffective. It 
is believed that a high prevalence of ML-resistant strains in a certain area is the result 
of a high use of ML antibiotics. We studied in a large cohort MPML resistence in the 
Netherlands for the first time. In this thesis, we present a first report on M. pneumoniae 
ML-resistance in the Netherlands.
Chapter 1
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introdUction to the Main hypotheses and oBJectives of 
this thesis
It is important to realize that humans are surrounded by millions of different bacteria. 
These bacteria live in our gut, our respiratory tract, or on our skin, and many of them 
are probably not harmful for humans and could even be beneficial under normal circum-
stances. In this theory, bacteria are ‘carried’ by humans without causing disease, which 
we call carriage or asymptomatic colonization. Throughout this thesis, we use both terms 
interchangeably to indicate the unharmful presence of potential pathogens in the respira-
tory tract. These potential pathogens include Streptococcus pneumoniae, Staphylococcus 
aureus, Haemophilus influenzae and Moraxella catarrhalis. Under certain circumstances, 
these bacteria can cause respiratory tract infections, which may even develop into life-
threatening infections such as sepsis and meningitis. These circumstances needed for 
the progression from colonization to invasive disease can be divided in: (1) host factors 
involving a breach of the natural immunological barriers due to local mucosal changes 
or a underlying mucosal immunological disease or immaturity, and (2) pathogen factors 
such as differences in the composition and expression of surface-associated proteins and 
other virulence factors that are needed for acquisition, adherence and invasion 50-54.
Since M. pneumoniae is a bacterium that also causes respiratory tract infections, 
it is not inconceivable that this pathogen has a similar ‘lifestyle’ as the other bacteria 
mentioned above. Indeed, previous studies reported the presence of M. pneumoniae in 
seemingly healthy individuals. However, these studies suffered from drawbacks related 
to either the study design or limitations of the diagnostic assays that were employed 
25, 34-36, 55-58. We therefore initiated a study to confirm the hypothesis that M. pneumoniae 
is able to colonize the human respiratory tract in an asymptomatic fashion.
Due to the absence of specific clinical, biochemical or radiological findings, the 
diagnosis of an M. pneumoniae RTI has to be supported by microbiological findings. At 
the start of our studies and at present, different diagnostic techniques are available, but 
all of these have drawbacks that should be taken into consideration before defining an 
RTI as an M. pneumoniae-induced infection.
Assuming that our hypothesis would be confirmed, we also set out to study whether 
possible asymptomatic carriage could be distinguished from infection using the currently 
available microbiological diagnostic tools for M. pneumoniae. In addition, we sought 
to investigate the genetic composition of different M. pneumoniae strains to identify 
possible factors in the genome that predispose the bacterium to invasiveness in the 
respiratory tract of children. The overall aim of the studies is to find factors that could be 
important in the progression from asymptomatic colonization to invasive infection with 
M. pneumoniae.
15
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Specific aims are:
- To identify asymptomatic colonization by M. pneumoniae using current available 
microbiological tools.
- To find host factors associated with asymptomatic carriage versus symptomatic dis-
ease.
- To classify genetic variation in M. pneumoniae in a concise understandable manner 
and to make a classification system that covers the description of current and future 
possible variants.
- To find specific genetic pathogen variation that is associated with disease and 
disease severity.
- To investigate the upcoming ML-resistance in the Netherlands.
the oUtline of this thesis
This thesis contains two general parts, i.e. Part 1 and Part 2. As a prerequisite for the 
clinical studies, Part 1 contains studies on the genetic variation of M. pneumoniae and 
the classification of adhesion gene variants. Chapter 1 contains a general introduction 
to M. pneumoniae. Chapter 2 is a review in Dutch about the genetic variation of M. 
pneumoniae and of the current molecular methods used for genotyping. This review is 
in part a summary of the findings in chapters 3-6. In Chapters 3-5, genetic variation 
of M. pneumoniae due to homologous DNA recombination is described, including a 
novel classification scheme for genetic variants. In Chapter 6, the design of a convenient 
molecular typing assay for M. pneumoniae is described and optimized for use in clinical 
samples. This assay is partly based on the findings in chapter 3.
Part 2 of this thesis focuses on the clinical aspects of M. pneumoniae colonization, 
infection and epidemiology of various bacterial genotypes and the dissemination of 
macrolide resistance in the Netherlands. Chapter 7 describes our primary study (Myco-
plasma pneumoniae Infection and Colonization in Children, MymIC study), which was 
performed to investigate the existence of carriage and the difference between carriage 
and infection by M. pneumoniae. A continuation on the topic of asymptomatic carriage 
with M. pneumoniae is provided in Chapter 8, in which we describe our genetic search 
for virulence factors in M. pneumoniae strains using Next Generation Sequencing. 
Chapter 9 contains a retrospective study of 12 years in the Netherlands to investigate 
the epidemiology of macrolide resistance. Chapter 10 is a review on the treatment of 
respiratory tract infections caused by M. pneumoniae.
Finally, in Chapter 11, the overall findings and implications of the studies described in 
this thesis are discussed. Chapter 12 provides a summary of the thesis.
Chapter 1
16
references
 1. Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemiology and etiology of 
childhood pneumonia. Bull World Health Organ. 2008 May;86(5):408-16.
 2. Wolfe I, Thompson M, Gill P, Tamburlini G, Blair M, van den Bruel A, et al. Health services for 
children in western Europe. Lancet. Apr 6;381(9873):1224-34.
 3. Michelow IC, Olsen K, Lozano J, Rollins NK, Duffy LB, Ziegler T, et al. Epidemiology and clini-
cal characteristics of community-acquired pneumonia in hospitalized children. Pediatrics. 2004 
Apr;113(4):701-7.
 4. Tsolia MN, Psarras S, Bossios A, Audi H, Paldanius M, Gourgiotis D, et al. Etiology of community-
acquired pneumonia in hospitalized school-age children: evidence for high prevalence of viral 
infections. Clin Infect Dis. 2004 Sep 1;39(5):681-6.
 5. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin 
Microbiol Rev. 2004 Oct;17(4):697-728, table of contents.
 6. Eaton MD, Meiklejohn G, van Herick W. Studies on the Etiology of Primary Atypical Pneumonia : 
A Filterable Agent Transmissible to Cotton Rats, Hamsters, and Chick Embryos. J Exp Med. 1944 
Jun 1;79(6):649-68.
 7. Chanock RM. Mycoplasma pneumoniae: proposed nomenclature for atypical pneumonia organ-
ism (Eaton agent). Science. 1963 May 10;140(3567):662.
 8. Himmelreich R, Hilbert H, Plagens H, Pirkl E, Li BC, Herrmann R. Complete sequence analysis 
of the genome of the bacterium Mycoplasma pneumoniae. Nucleic Acids Res. 1996 Nov 
15;24(22):4420-49.
 9. Ruland K, Himmelreich R, Herrmann R. Sequence divergence in the ORF6 gene of Mycoplasma 
pneumonia. J Bacteriol. 1994 Sep;176(17):5202-9.
 10. Krishnakumar R, Assad-Garcia N, Benders GA, Phan Q, Montague MG, Glass JI. Targeted chro-
mosomal knockouts in Mycoplasma pneumoniae. Appl Environ Microbiol. Aug;76(15):5297-9.
 11. Kenri T, Horino A, Matsui M, Sasaki Y, Suzuki S, Narita M, et al. Complete genome sequence of 
Mycoplasma pneumoniae type 2a strain 309, isolated in Japan. J Bacteriol. Mar;194(5):1253-
4.
 12. Krause DC, Balish MF. Structure, function, and assembly of the terminal organelle of Mycoplasma 
pneumoniae. FEMS Microbiol Lett. 2001 Apr 20;198(1):1-7.
 13. Rottem S, Yogev D. Mycoplasma interaction with eukaryotic cells. Subcell Biochem. 2000;33:199-
227.
 14. Rottem S. Interaction of mycoplasmas with host cells. Physiol Rev. 2003 Apr;83(2):417-32.
 15. Waldo RH, 3rd, Jordan JL, Krause DC. Identification and complementation of a mutation associ-
ated with loss of Mycoplasma pneumoniae virulence-specific proteins B and C. J Bacteriol. 2005 
Jan;187(2):747-51.
 16. Waldo RH, 3rd, Krause DC. Synthesis, stability, and function of cytadhesin P1 and accessory 
protein B/C complex of Mycoplasma pneumoniae. J Bacteriol. 2006 Jan;188(2):569-75.
 17. Catrein I, Dumke R, Weiner J, 3rd, Jacobs E, Herrmann R. Cross-complementation between the 
products of the genes P1 and ORF6 of Mycoplasma pneumoniae subtypes 1 and 2. Microbiol-
ogy. 2004 Dec;150(Pt 12):3989-4000.
 18. Balish MF, Ross SM, Fisseha M, Krause DC. Deletion analysis identifies key functional domains of 
the cytadherence-associated protein HMW2 of Mycoplasma pneumoniae. Mol Microbiol. 2003 
Dec;50(5):1507-16.
17
1
Introduction to Mycoplasma pneumoniae
 19. Su CJ, Chavoya A, Baseman JB. Regions of Mycoplasma pneumoniae cytadhesin P1 structural 
gene exist as multiple copies. Infect Immun. 1988 Dec;56(12):3157-61.
 20. Su CJ, Dallo SF, Chavoya A, Baseman JB. Possible origin of sequence divergence in the P1 
cytadhesin gene of Mycoplasma pneumoniae. Infect Immun. 1993 Mar;61(3):816-22.
 21. Spuesens EB, Oduber M, Hoogenboezem T, Sluijter M, Hartwig NG, van Rossum AM, et al. 
Sequence variations in RepMP2/3 and RepMP4 elements reveal intragenomic homologous DNA 
recombination events in Mycoplasma pneumoniae. Microbiology. 2009 Jul;155(Pt 7):2182-96.
 22. Nir-Paz R. Mycoplasma pneumoniae Outbreaks on Navy Vessels. J Clin Microbiol. 
May;48(5):1990; author reply
 23. Dorigo-Zetsma JW, de Wit M, Szabo JS, Schneeberger PM. [Epidemic of respiratory tract 
infections by Mycoplasma pneumoniae in an institute for mentally disabled, investigated with 
polymerase chain reaction of a throat swab specimen]. Ned Tijdschr Geneeskd. 1999 Jun 
12;143(24):1261-5.
 24. Eun BW, Kim NH, Choi EH, Lee HJ. Mycoplasma pneumoniae in Korean children: the epidemiol-
ogy of pneumonia over an 18-year period. J Infect. 2008 May;56(5):326-31.
 25. Foy HM, Kenny GE, McMahan R, Kaiser G, Grayston JT. Mycoplasma pneumoniae in the com-
munity. Am J Epidemiol. 1971 Jan;93(1):55-67.
 26. Foy HM. Infections caused by Mycoplasma pneumoniae and possible carrier state in different 
populations of patients. Clin Infect Dis. 1993 Aug;17 Suppl 1:S37-46.
 27. Wang K, Gill P, Perera R, Thomson A, Mant D, Harnden A. Clinical symptoms and signs for the 
diagnosis of Mycoplasma pneumoniae in children and adolescents with community-acquired 
pneumonia. Cochrane Database Syst Rev. 2012;10:CD009175.
 28. Watanabe H, Uruma T, Nakamura H, Aoshiba K. The role of Mycoplasma pneumoniae infection 
in the initial onset and exacerbations of asthma. Allergy Asthma Proc. May-Jun;35(3):204-10.
 29. Meyer Sauteur PM, Jacobs BC, Spuesens EB, Jacobs E, Nadal D, Vink C, et al. Antibody 
responses to Mycoplasma pneumoniae: role in pathogenesis and diagnosis of encephalitis? PLoS 
Pathog. Jun;10(6):e1003983.
 30. Tsiodras S, Kelesidis I, Kelesidis T, Stamboulis E, Giamarellou H. Central nervous system manifes-
tations of Mycoplasma pneumoniae infections. J Infect. 2005 Dec;51(5):343-54.
 31. Tsiodras S, Kelesidis T, Kelesidis I, Voumbourakis K, Giamarellou H. Mycoplasma pneumoniae-
associated myelitis: a comprehensive review. Eur J Neurol. 2006 Feb;13(2):112-24.
 32. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, et al. The management 
of community-acquired pneumonia in infants and children older than 3 months of age: clinical 
practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society 
of America. Clin Infect Dis. 2011 Oct;53(7):e25-76.
 33. Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M, et al. British Thoracic Society 
guidelines for the management of community acquired pneumonia in children: update 2011. 
Thorax. 2011 Oct;66 Suppl 2:ii1-23.
 34. Dorigo-Zetsma JW, Wilbrink B, van der Nat H, Bartelds AI, Heijnen ML, Dankert J. Results of 
molecular detection of Mycoplasma pneumoniae among patients with acute respiratory infection 
and in their household contacts reveals children as human reservoirs. J Infect Dis. 2001 Feb 
15;183(4):675-8.
 35. Gnarpe J, Lundback A, Sundelof B, Gnarpe H. Prevalence of Mycoplasma pneumoniae in 
subjectively healthy individuals. Scand J Infect Dis. 1992;24(2):161-4.
Chapter 1
18
 36. Hyde TB, Gilbert M, Schwartz SB, Zell ER, Watt JP, Thacker WL, et al. Azithromycin prophylaxis 
during a hospital outbreak of Mycoplasma pneumoniae pneumonia. J Infect Dis. 2001 Mar 
15;183(6):907-12.
 37. Bebear C, Pereyre S, Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to 
antibiotics. Future Microbiol. 2011 Apr;6(4):423-31.
 38. Averbuch D, Hidalgo-Grass C, Moses AE, Engelhard D, Nir-Paz R. Macrolide resistance in 
Mycoplasma pneumoniae, Israel, 2010. Emerg Infect Dis. 2011 Jun;17(6):1079-82.
 39. Cao B, Zhao CJ, Yin YD, Zhao F, Song SF, Bai L, et al. High prevalence of macrolide resistance 
in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract 
infection in China. Clin Infect Dis. 2010 Jul 15;51(2):189-94.
 40. Cardinale F, Chironna M, Dumke R, Binetti A, Daleno C, Sallustio A, et al. Macrolide-resistant 
Mycoplasma pneumoniae in paediatric pneumonia. Eur Respir J. 2011 Jun;37(6):1522-4.
 41. Chironna M, Sallustio A, Esposito S, Perulli M, Chinellato I, Di Bari C, et al. Emergence of 
macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children. 
J Antimicrob Chemother. 2011 Apr;66(4):734-7.
 42. Dumke R, von Baum H, Luck PC, Jacobs E. Occurrence of macrolide-resistant Mycoplasma 
pneumoniae strains in Germany. Clin Microbiol Infect. 2010 Jun;16(6):613-6.
 43. Hong KB, Choi EH, Lee HJ, Lee SY, Cho EY, Choi JH, et al. Macrolide resistance of Mycoplasma 
pneumoniae, South Korea, 2000-2011. Emerg Infect Dis. 2013 Aug;19(8):1281-4.
 44. Kawai Y, Miyashita N, Kubo M, Akaike H, Kato A, Nishizawa Y, et al. Nationwide surveillance 
of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients. Antimicrob Agents 
Chemother. 2013 Aug;57(8):4046-9.
 45. Morozumi M, Hasegawa K, Kobayashi R, Inoue N, Iwata S, Kuroki H, et al. Emergence of 
macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob Agents 
Chemother. 2005 Jun;49(6):2302-6.
 46. Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, et al. Increased 
macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired 
pneumonia. Antimicrob Agents Chemother. 2008 Jan;52(1):348-50.
 47. Pereyre S, Charron A, Renaudin H, Bebear C, Bebear CM. First report of macrolide-resistant 
strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in 
Mycoplasma pneumoniae clinical strains isolated in France over 12 years. J Clin Microbiol. 
2007 Nov;45(11):3534-9.
 48. Peuchant O, Menard A, Renaudin H, Morozumi M, Ubukata K, Bebear CM, et al. Increased 
macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens 
by real-time PCR and melting curve analysis. J Antimicrob Chemother. 2009 Jul;64(1):52-8.
 49. Zhao F, Liu G, Wu J, Cao B, Tao X, He L, et al. Surveillance of macrolide-resistant Mycoplasma 
pneumoniae in Beijing, China, from 2008 to 2012. Antimicrob Agents Chemother. 2013 
Mar;57(3):1521-3.
 50. Lebon A, Labout JA, Verbrugh HA, Jaddoe VW, Hofman A, van Wamel W, et al. Dynamics 
and determinants of Staphylococcus aureus carriage in infancy: the Generation R Study. J Clin 
Microbiol. 2008 Oct;46(10):3517-21.
 51. Verhaegh SJ, Lebon A, Saarloos JA, Verbrugh HA, Jaddoe VW, Hofman A, et al. Determinants of 
Moraxella catarrhalis colonization in healthy Dutch children during the first 14 months of life. Clin 
Microbiol Infect. Jul;16(7):992-7.
 52. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneu-
mococcal disease. Lancet Infect Dis. 2004 Mar;4(3):144-54.
19
1
Introduction to Mycoplasma pneumoniae
 53. Bogaert D, van Belkum A, Sluijter M, Luijendijk A, de Groot R, Rumke HC, et al. Colonisation 
by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet. 2004 Jun 
5;363(9424):1871-2.
 54. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. 
Lancet. 2009 Oct 31;374(9700):1543-56.
 55. Foy HM, Grayston JT, Kenny GE, Alexander ER, McMahan R. Epidemiology of Mycoplasma 
pneumoniae infection in families. JAMA. 1966 Sep 12;197(11):859-66.
 56. Feikin DR, Njenga MK, Bigogo G, Aura B, Aol G, Audi A, et al. Etiology and Incidence of viral 
and bacterial acute respiratory illness among older children and adults in rural western Kenya, 
2007-2010. PLoS One.7(8):e43656.
 57. Goldwater PN, Martin AJ, Ryan B, Morris S, Thompson J, Kok TW, et al. A survey of nosocomial 
respiratory viral infections in a children’s hospital: occult respiratory infection in patients admitted 
during an epidemic season. Infect Control Hosp Epidemiol. 1991 Apr;12(4):231-8.
 58. Wenzel RP, Craven RB, Davies JA, Hendley JO, Hamory BH, Gwaltney JM, Jr. Protective efficacy 
of an inactivated Mycoplasma pneumoniae vaccine. J Infect Dis. 1977 Aug;136 Suppl:S204-7.
part 1
 genetic variation of Mycoplasma 
pneumoniae
chapter 2
 Moleculaire typering van 
Mycoplasma pneumoniae
E.B.M. Spuesens
N.G. Hartwig
A.M.C. van Rossum
C. Vink
Ned. Tijdschr. Med. Microbiol. 2012;20:1
Chapter 2
24
sUMMary
Mycoplasma pneumoniae is considered to be a uniform bacterium. In addition to the two 
known subtypes of M. pneumoniae, a number of important genetic variations have been 
described in the MPN141 gene, which encodes the major adhesin, the P1 protein, of 
the bacterium.
In this paper, the molecular typing techniques available for M. pneumoniae are de-
scribed on the basis of the known genetic variation. These techniques can be divided 
in techniques that only determine the major subtype of M. pneumoniae (subtype 1 and 
subtype 2) and those that determine the ‘MPN141 type’, which requires sequencing of 
the entire gene. It is important to describe the variation in M. pneumoniae in a systematic 
fashion with the use of the recently published classification system. Future studies should 
be focused on the relation between the different molecular M. pneumoniae types and 
clinical featues, such as severity of disease.
saMenvatting
Mycoplasma pneumoniae is een luchtwegpathogeen die wordt beschouwd als een 
genetisch stabiele bacterie. Naast de twee bekende subtypes van M. pneumoniae 
(subtype 1 en subtype 2), kunnen echter een groot aantal genetische varianten van de 
bacterie worden onderscheiden. Deze varianten verschillen van elkaar in de sequentie 
van het MPN141 gen dat codeert voor een belangrijk oppervlakte eiwit (het P1 eiwit). 
Aan de hand van de bekende genetische variatie in M. pneumoniae, zullen in dit artikel 
de voor deze bacterie beschikbare moleculaire typeringstechnieken worden beschreven. 
Deze kunnen worden ingedeeld in technieken die zijn gericht op het bepalen van het 
subtype of op het bepalen van het ‘MPN141 type’. Het is van belang de variatie tussen 
subtypes en tussen MPN141-types eenduidig te beschrijven met behulp van een recent 
gepubliceerd classificatie systeem. Onderzoeken in de toekomst dienen zicht te richten 
op de relatie tussen de gevonden variatie in M. pneumoniae en klinische parameters 
zoals bijvoorbeeld de ernst van een infectie.
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inleiding
Mycoplasma pneumoniae is een humaan pathogeen en behoort tot de klasse van de 
Mollicutes (lat. zachte huid). De naam van deze klasse refereert aan het feit dat de 
bacteriën die tot deze klasse behoren geen celwand hebben. Een andere belangrijke 
eigenschap van deze bacteriën is dat ze een klein circulair genoom hebben dat een 
grootte heeft tussen de 0,58 en 2,2 megabaseparen (Mbp). Naast Mycoplasma genita-
lium (stam G37; 580.076 bp) is M. pneumoniae (stam M129; 816,394 bp) één van 
de kleinst zelfreplicerende micro-organismen van de klasse Mollicutes.1
M. pneumoniae veroorzaakt verscheidene luchtweginfecties, waaronder tracheo-
bronchitis, faryngitis en pneumonie. Ongeveer 40% van alle gevallen van ‘community-
acquired pneumonia’ wordt veroorzaakt door M. pneumoniae en verreweg de meeste 
van deze gevallen komen voor op de kinderleeftijd (80-85%).1
Tot nu toe is er nog geen associatie gevonden tussen de ernst van infecties en een 
bepaald moleculair type van M. pneumoniae. Kenri et al. beschreven echter dat onge-
veer elke decade een nieuw moleculair type dominant wordt in de populatie.2 Om meer 
te weten te komen over de variatie van M. pneumoniae in relatie tot epidemiologische 
gegevens en klinische gegevens, is moleculaire typering van groot belang. Alvorens de 
moleculaire typering en bijbehorende technieken van M. pneumoniae te bespreken, 
geven wij eerst een overzicht van de mogelijke variatie in M. pneumoniae.
genetische variatie van M. PNEUMONIAE
Van twee M. pneumoniae stammen is tot nu toe de volledige genoom sequentie be-
paald. Deze twee stammen vertegenwoordigen de twee subtypen van M. pneumoniae, 
namelijk subtype 1 en subtype 2 (zie onder subtype variatie). De stam M129 (subtype 
1, ATCC 29342) heeft een genoomlengte van 816.394 bp en de stam FH (subtype 
2, ATCC 15531) heeft een genoomlengte van 811.088 bp. Hoewel er vele verschil-
len zijn tussen de genoomsequenties van de M129 stam en de FH stam, wordt M. 
pneumoniae in het algemeen beschouwd als een genetisch stabiel micro-organisme. 
Er kan echter een grote variatie bestaan tussen stammen in het gen dat codeert voor 
het oppervlakte eiwit P1. Dit gen (MPN141) kan sequentie variatie (antigene variatie) 
ondergaan ten gevolge van homologe DNA recombinatie met sequenties die zich elders 
in het genoom van M. pneumoniae bevinden. Omdat bij de moleculaire typering in de 
literatuur regelmatig verwarring is ontstaan over het bepalen van het subtype van M. 
pneumoniae (subtype 1 en 2) en het bepalen van het ‘MPN141 type’, worden deze 
twee onderwerpen hieronder afzonderlijk behandeld.3, 4
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subtype variatie
Het belangrijkste onderscheid dat met bijna alle toegepaste moleculaire typeringstechnie-
ken kan worden aangetoond is het onderscheid tussen subtype 1 en subtype 2 stammen. 
Dit genetisch onderscheid werd voor het eerst beschreven in het MPN141 gen en werd 
later ook ontdekt in andere genen zoals in het MPN142 gen, het MPN528a gen, het 
MPN535 gen en in het MPN340 gen.5-9 Na analyse van de genoomsequenties van de 
M129 stam en de FH stam is gebleken dat subtype-specifieke sequenties op veel meer 
plaatsen in het genoom te vinden zijn. Veelal zijn dit base substituties en kleinere inserties 
of deleties. Het verschil tussen subtype 1 en subtype 2 stammen is echter zeer uitgebreid 
in het MPN141 gen en het MPN142 gen. In het MPN141 gen beslaat de variatie een 
lengte van 1246 baseparen en in het MPN142 gen 993 baseparen.
variatie als gevolg van homologe dna recombinatie
In 25 verschillende M. pneumoniae stammen zijn repeterende DNA sequenties be-
schreven. 10-12In het algemeen wordt aangenomen dat deze repeterende sequenties 
in alle M. pneumoniae stammen te vinden zijn en elke stam eenzelfde set sequenties 
bevat met daarin kleine onderlinge verschillen. Deze sequenties worden aangeduid met 
‘RepMP’ (repeated element in M. pneumoniae) gevolgd door één of meer getallen. In 
het MPN141 gen bevindt zich een RepMP2/3 element en een RepMP4 element en in 
het MPN142 gen bevindt zich een RepMP5 element (Figuur).
Van elk van deze elementen bestaan meerdere versies in het genoom van M. pneumo-
niae. Omdat deze versies grotendeels overeenkomen met het corresponderende element 
in het MPN141 of MPN142 gen, maar niet identiek zijn, kan uitwisseling tussen de 
elementen door middel van homologe DNA recombinatie optreden. Dit kan vervolgens 
leiden tot een verandering van sequentie in het MPN141 gen en/of het MPN142 en 
daarmee tot een verandering in aminozuurvolgorde van het coderende eiwit, namelijk 
het P1, P40 of P90 eiwit aan het oppervlakte van de bacterie. Aangezien deze drie 
eiwitten zeer immunogeen zijn, leidt een verandering in deze eiwitten mogelijk ook tot 
een verandering in virulentie en/of verspreiding van M. pneumoniae.
Tot nu toe zijn er een aantal varianten van het MPN141 gen gevonden als gevolg 
van homologe DNA recombinatie.13-17 Er zijn echter slechts twee stammen gevonden 
met een variatie in het MPN142 gen.11 Een aantal belangrijke kenmerken zijn overeen-
komstig tussen elke variatie van het MPN141 gen of het MPN142 gen als gevolg van 
recombinatie.
Ten eerste is er tot nu toe bij ieder verandering sprake van eenrichtingsverkeer, waarbij 
de sequentie van een element de plaats inneemt van de homologe sequentie in het 
MPN141 of MPN142 gen, zonder dat de sequentie op de originele locatie wordt 
veranderd. De sequentie die oorspronkelijk aanwezig was in het MPN141 gen of 
MPN142 gen gaat daarbij verloren. Er is dus geen reciproke uitwisseling van sequenties, 
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maar altijd slechts één ‘donor element’ en één ‘ontvangend element’. Dit mechanisme 
van ‘unidirectionele’ homologe DNA recombinatie wordt genconversie genoemd.11, 12
Ten tweede wordt altijd slechts een deel van het donor element gebruikt in de re-
combinatie en verandert ook slechts een deel van de MPN141 gen of MPN142 gen. 
Echter de lengte van de sequentie die wordt overgebracht kan zeer variabel zijn en 
varieert van enkele tientallen tot enkele honderden nucleotiden. Omdat er vanuit elk 
RepMP2/3, RepMP4 of RepMP5 element meerdere kleinere sequenties kunnen worden 
overgedragen naar het desbetreffende gen, is het aantal mogelijke recombinatie gebeur-
tenissen in theorie zeer groot en is het voorspellen van deze gebeurtenissen onmogelijk. 
Het lijkt er echter wel op dat bepaalde locaties in het MPN141 gen en het MPN142 
’hotspots’ zijn voor recombinatie. Behoudens de theoretische mogelijkheid tot overdracht 
van een bepaalde sequentie, is de functie en variatie van het uiteindelijke oppervlakte-
eiwit uiteraard van het grootste van belang. Het is daarom niet ondenkbaar dat ook de 
immunologische respons van een bepaald individu of de immunologische druk vanuit 
de populatie een belangrijke rol speelt in de gevonden variatie in het MPN141 gen en 
MPN142 gen van M. pneumoniae stammen en daarmee hun coderende eiwitten.11, 12
MolecUlaire typering van M. PNEUMONIAE
Op basis van de hierboven beschreven genetische variatie, kan de moleculaire type-
ring van M. pneumoniae worden onderverdeeld in: het bepalen van het subtype en 
het bepalen van het MPN141 type of MPN142 type. In de afgelopen jaren zijn er 
verschillende moleculaire technieken gebruikt om M. pneumoniae te typeren (zie tabel), 
waaronder pyrosequencing, real-time PCR met ‘high resolution melt analysis’ (HRM), 
Multilocus Sequence Typing (MLST), Pulsed Field Gel Electrophoresis (PFGE), PCR-RFLP 
en sequencing.2, 11-13, 15, 17-23 Een aantal van de belangrijkste technieken zal hieronder in 
detail worden behandeld.
MPN141 
(P1 gene) 
RepMP4-c RepMP2/3-d 
180820 182441 182860 184769  185648  Genoom positie: 
fig.  Het P1-gen (MPN141). Daarin bevinden zich twee RepMP elementen. Het MPN142 gen met daarin 
het RepMP5 element bevind zich direct na het MPN141 gen. Voor gedetailleerde informatie over de ge-
noom posities en variaties in deze genen en de RepMP-elementen: zie hoofdstuk 2 & 3 van dit proefschrift.
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subtypering door middel van pyrosequencing
Aangezien de subtype-specifieke sequenties door het hele genoom voorkomen, is het 
niet noodzakelijk om de sequentie te bepalen van grote delen van een bepaald gen, 
zoals het MPN141 gen. In plaats daarvan kan men volstaan met het bepalen van 
een enkel ‘single-nucleotide polymorfisme’ (SNP) in bijvoorbeeld het MPN528a gen of 
het MPN141 gen. Een techniek die hiervoor gebruikt kan worden is pyrosequencing. 
Pyroseqeuncing is een zogenaamde ‘real-time sequencing by synthesis’ techniek, die 
geschikt is om kleine delen van een genoom te bepalen met een maximum van ongeveer 
50 bp. Recent zijn twee pyrosequencing assays beschreven voor het bepalen van het 
subtype van M. pneumoniae.13 Voordelen van deze techniek is de relatief hoge snelheid 
en de directe toepasbaarheid op patiëntenmateriaal.
Mlva- typering
Er is recent ook een studie gepubliceerd waarin Multilocus Variable Number Tandem 
Repeat (VNTR) Analysis (MLVA) is toegepast om M. pneumoniae te typeren.22 Deze MLVA 
assay is ontworpen op basis van de beschikbare genoom sequentie van de M129 stam 
(zie ‘genetische variatie in M. pneumoniae’), waarin een aantal tandem repeats worden 
beschreven. In totaal worden voor deze MLVA assay vijf verschillende tandem repeats 
gebruikt om M. pneumoniae te kunnen typeren. In totaal kunnen hiermee 26 MLVA types 
(A-Z) van M. pneumoniae worden onderscheiden. Deze types kunnen in één van twee 
groepen worden onderscheiden zijn die overeen komen met het subtype waartoe een 
stam behoort.22 Deze techniek kan dus ook gebruikt worden voor het bepalen van het 
subtype. Inmiddels is deze techniek gemodificeerd zodat deze direct toegepast kan 
worden op patiëntenmateriaal.20
Mpn141 typering
Omdat subtypering overal in het genoom mogelijk is, is het niet nodig een bepaald gen 
te typeren. Desondanks zijn de meeste typeringstechnieken gericht op het MPN141 gen. 
Daarnaast kan het bepalen van het MPN141 type belangrijk zijn omdat het een hoger 
discriminerend vermogen heeft en een hogere resolutie kan hebben dan de subtype 
bepaling. Omdat het aantal varianten van P1 dat theoretisch gevormd kan worden zeer 
groot is (zoals hierboven beschreven is) zal de sequentie bepaald moeten worden van 
het gehele variabele deel van het P1 gen, dus zowel het RepMP2/3 als RepMP4 ele-
ment zal gesequenced moeten worden. Dit kan eenvoudig bewerkstelligd worden door 
PCR en sequencing.Een aantal technieken hebben zich echter gericht op de detectie van 
een beperkt aantal sequentie varianten van het P1. Deze technieken zijn gebaseerd op 
real-time PCR in combinatie met High Resolution Melt analysis en op PCR en sequencing 
van slechts een beperkt deel van het gen.
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Ten slotte kan de vraag gesteld worden wat de epidemiologische en evolutionaire 
waarde is van het bepalen van het MPN141 type. Immers, in elke bacterie generatie 
kan de sequentie van het P1 gen via homologe DNA recombinatie veranderen. Een 
dergelijke verandering kan weliswaar grote gevolgen hebben voor het P1 gen, maar 
deze verandering heeft geen invloed op de rest van het bacteriële genoom. Hiermee 
kunnen bacteriën uit dezelfde klonale bacterielijn dus sterk verschillende P1 sequenties 
hebben.
classificatie van M. pneumoniae stammen op basis van Mpn141 
typering
Om de variatie in het MPN141 gen eenduidig te kunnen beschrijven en resultaten van 
MPN141 typeringsstudies beter te kunnen vergelijken hebben wij een classificatie systeem 
opgezet, waarmee zowel bekende variatie in het MPN141 kan worden aangeduid, 
maar ook nieuwe variatie op een structurele manier kan worden beschreven.3, 4, 11, 12 
Voordat dit systeem bestond werden nieuwe MPN141 varianten (M. pneumoniae stam-
men met variatie in het MPN141 gen) vaak aangeduid met cijfers en letters (zoals 
2a, 2b, 2c etcetera). Met deze aanduiding kunnen echter onmogelijk alle mogelijke 
varianten worden beschreven en bovendien geeft de aanduiding geen enkele informatie 
over de sequentie van het gen. In het nieuwe classificatie systeem wordt van elke stam 
niet alleen aangegeven tot welk subtype deze behoort, maar ook welke RepMP4, 
tabel. Verschillende technieken en targets van de afgelopen 10 jaar.
Target Moleculaire techniek Soort typering Literatuur Jaar
MPN141/MPN528a Pyrosequencing Subtypering Spuesens et al. 2010
MPN142/RepMP5 PCR, sequencing Subtypering 
MPN142
Spuesens et al. 2010
MPN141 Real-time PCR, HRM MPN141 Schwartz et al. 2009
MPN141 Real-time PCR, HRM Subtypering Schwartz et al. 2009
MPN141/RepMP4/
RepMP2/3
PCR, sequencing Subtypering 
MPN141
Spuesens et al. 2009
Tandem Repeats MLVA Subtypering Dégrange et al. 2009
MPN141 PCR-RFLP, sequencing MPN141 Kenri et al 2008
MPN141 PCR-RFLP, sequencing MPN141 Pereyre et al. 2007
MPN141/
Householdgenes
MLST, RFLP Subtypering Dumke et al. 2003
MPN141, genoom RFLP, PFGE Subtypering Cousin-Allery et al. 2000
MPN141 PCR-RFLP MPN141 Dorigo-Zetsma et al. 2000
PCR Poymerase Chain Reaction, HRM High Resolution Melt Analysis, MLVA Multi Locus Variable Number Tandem 
Repeat Analysis, RFLP Restriction Fragment Length Polymorphism, MLST MultiLocus Sequence Typing, PFGE Pulsed 
Field Gel Electrophoresis.
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RepMP2/3 elementen in het MPN141 voorkomen en welke RepMP5 elementen in het 
MPN142 gen voorkomen. Elk RepMP4, RepMP2/3 en RepMP5 element heeft daarvoor 
een extra lettercodering gekregen op volgorde van het voorkomen in het genoom (a tot 
en met h voor RepMP4, a-j voor RepMP2/3 en a-h voor RepMP5). Een subtype 1 stam 
met een onveranderd MPN141 gen en een onveranderd MPN142 gen krijgt in deze 
classificatie de codering: 1-P1(4-c, 2/3-d, 5-c). De eerste ‘1’ geeft het subtype aan. 
Dit wordt gevolgd door ‘P1’, hetgeen betrekking heeft op het P1 operon waarin zowel 
MPN141 als MPN142 is gelegen. Vervolgens kan tussen haakjes de volgorde van de 
verschillende RepMP elementen in de twee genen worden aangegeven. Een subtype 
1 stam met een recombinatie tussen het RepMP4-c en het RepMP4-h element kan als 
volgt worden aangeduid: 1-P1(4-c[h]c, 2/3-d, 5-c). De term ‘4-c[h]c’ geeft aan dat 
het originele 4-c element ten dele is vervangen door het RepMP4-h element. Deze term 
kan worden aangevuld met de genoom posities van de verschillende elementen, zodat 
ook duidelijk wordt hoe groot de sequentie is, die is overgedragen naar het RepMP4-c 
element in het MPN141 gen.
MolecUlaire typering van M. PNEUMONIAE in de toeKoMst
Om een onderscheid te maken tussen verschillende M. pneumoniae stammen wordt 
op dit moment zowel de standaard subtypering, MPN141 typering als wel de recent 
beschreven MLVA-typering gebruikt. Afgezien van de vraag welke techniek het beste on-
derscheid maakt tussen verschillende stammen, zijn in de toekomst een aantal aspecten 
van typering van M. pneumoniae van belang. Allereerst dienen de gevonden verschillen 
tussen stammen nauwkeurig beschreven te worden. Dit is met name van belang bij het 
gebruik van de MPN141 typering. Het classificatiesysteem zoals hier nogmaals kort 
werd beschreven kan hierin een belangrijke rol spelen. Op de tweede plaats wordt het 
in de toekomst belangrijk om het moleculaire type (subtype, MPN141-type of MLVA-type) 
van M. pneumoniae te relateren aan kliniek. Tot op heden is nog weinig bekend over 
de relatie tussen moleculair (sub) type van M. pneumoniae en (de ernst van) klinische 
verschijnselen.
conclUsie
In dit artikel hebben we aan de hand van de kennis die er bestaat over de genetische 
variatie van M. pneumoniae, de actuele moleculaire typeringstechnieken voor M. pneu-
moniae beschreven. De belangrijkste conclusies die hierbij getrokken kunnen worden 
zijn de volgende: 1. de genetische variatie van M. pneumoniae is zeer uitgebreid 
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(ondanks dat deze bacterie een ‘minimaal’ genoom heeft); 2. M. pneumoniae stammen 
kunnen worden onderverdeeld in twee genetische subtypes (subtype 1 en subtype 2); 3. 
de M. pneumoniae subtypes kunnen worden onderscheiden met behulp van een grote 
verscheidenheid aan typeringsmethodes; 4. het bepalen van de variatie in het MPN141 
gen is van beperkte betekenis voor het bepalen van de epidemiologische of evolutio-
naire verwantschap tussen M. pneumoniae stammen. Ten slotte is het noodzakelijk dat 
toekomstig onderzoek aan M. pneumoniae zich onder meer richt op de relatie tussen 
bacterieel genotype en zowel de verspreiding als de virulentie van deze bacterie.
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aBstract
The gene encoding major adhesin protein P1 of Mycoplasma pneumoniae, MPN141, 
contains two DNA sequence stretches, designated RepMP2/3 and RepMP4, which 
display variation among strains. This variation allows strains to be differentiated in two 
major P1 genotypes (1 and 2) and several variants. Interestingly, multiple variants of 
the RepMP2/3 and RepMP4 elements exist at other sites within the bacterial genome. 
Because these variants are closely related in sequence, but not identical, it has been 
hypothesized that they have the capacity to recombine with their counterparts within 
MPN141, and thereby serve as a source of sequence variation of the P1 protein. In 
order to determine the variation within the RepMP2/3 and RepMP4 elements, both 
within the bacterial genome and among strains, we analyzed the DNA sequences 
of all RepMP2/3 and RepMP4 elements within the genomes of 23 M. pneumoniae 
strains. Our data demonstrate that: recombination is likely to have occurred between two 
RepMP2/3 elements in four of the strains, and all previously described P1 genotypes can 
be explained by inter-RepMP recombination events. Moreover, the difference between 
the two major P1 genotypes is present in all RepMP elements, such that subtype 1 and 2 
strains can be differentiated on the basis of sequence variation in each RepMP element. 
This suggests that subtype 1 and subtype 2 strains represent evolutionary diverged strain 
lineages.
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introdUction
Mycoplasma pneumoniae is a human pathogen from the bacterial class of Mollicutes 
that represents one of the smallest self-replicating species with respect to both genome 
size and cellular dimensions 1. The limited size of the genome of this species is generally 
considered to be the result of a gradual loss of genome information from a common 
gram-positive ancestor 2. Hitherto, the complete genomic sequence of a single M. 
pneumoniae strain (M129) has been determined. This sequence was reported to have a 
length of 816,394 base pairs (bp), containing 689 open reading frames (ORFs) 3, 4. In 
general, M. pneumoniae is regarded as a genetically highly stable microorganism. This 
view is based on the fi nding of limited sequence diversity between strains as determined 
by various molecular typing techniques, which allowed strains to be divided in two major 
groups (subtype 1 and 2). The molecular discrimination of M. pneumoniae isolates in 
these two subtypes was fi rst described by Dallo et al. 5 and Su et al. 6, who showed the 
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Fig. 1 fig. 1. Distribution of RepMP2/3 and RepMP4 elements.
Structure of the M. pneumoniae MPN141 ORF and distribution of RepMP2/3 and RepMP4 elements within 
the M. pneumoniae genome. The location and orientation of all RepMP2/3 and RepMP4 elements within 
the M. pneumoniae M129 genome is indicated by gray and black boxes, respectively 3. The elements 
are labeled ‘a’ to ‘j’ for RepMP2/3 and ‘a’ to ‘h’ for RepMP4. The location of the P1 gene is indicated 
by the arrow at the top. The nucleotide positions of the elements within the genome are listed in Table S1 
(supplementary tables).
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existence of two different sequence variants of the gene encoding the major adhesin of 
M. pneumoniae, i.e. the P1 protein. The sequence differences between these variants 
were found to reside in two regions within the P1 (or MPN141) gene 7. Interestingly, 
multiple versions of these regions, which were termed RepMP4 and RepMP2/3, respec-
tively, were found at genome sites outside of the P1 gene 3, 8, 9. In total, 8 variants of the 
RepMP4 element and 10 variants of the RepMP2/3 element were found throughout the 
genome of strain M129 (Fig. 1) 3, 9. Because the different variants of a given RepMP 
element are similar in sequence, but not identical, it was hypothesized that homologous 
recombination between the RepMP elements within the P1 gene and those elsewhere in 
the genome could generate alternative sequence variants of the P1 gene 9, 10. Obviously, 
variations within the P1 gene can result in altered P1 proteins at the surface of the 
bacterium. As the P1 protein is the most important immunological protein11-14, alteration 
of the P1 protein could have a major impact on the virulence and/or spread of M. 
pneumoniae.
Despite the relatively high intrinsic potential for variation of the P1 gene by means 
of homologous recombination between the RepMP elements, only a limited number of 
sequence variants of the P1 gene have currently been identified among isolates of M. 
pneumoniae. Apart from the two major subtypes (1 and 2) described above, one variant 
of subtype 1 (variant 1, strain Mp4817) 15 and two variants of subtype 2 (2a and 2b) 
15-18 have been reported, in addition to a single aberrant isolate (Mp3896) that could 
not be classified as a typical subtype 1 or 2 strain 18. Many questions remain as to the 
origin of the variation within the P1 gene of M. pneumoniae strains, including the strains 
mentioned above. There are two main reasons for this: the RepMP sequences both within 
and outside of the P1 gene have not yet been studied systematically, and only a single M. 
pneumoniae genome sequence is currently available. Nevertheless, a study on a variant 
2a strain (strain 309) by Kenri and coworkers 16 suggested that inter-RepMP2/3 element 
recombination had occurred in this strain. This was based on the similarity between the 
variant 2a-specific sequence within the P1 gene and a RepMP2/3 element elsewhere in 
the genome 16. Homologous recombination events have also been suggested to underlie 
the atypical sequences of the P1 gene of strains Mp3896 and Mp4817, although the 
occurrence as well as sequences of RepMP2/3 and RepMP4 elements outside of the P1 
gene were not reported for these strains 15, 18.
In order to increase our understanding of the occurrence as well as dynamics of intrage-
nomic recombination of RepMP2/3 and RepMP4 elements in M. pneumoniae, and to 
shed light on the origins of the subtype 1 and 2 differences among strains, we have 
determined the sequences of all 10 RepMP2/3 and all 8 RepMP4 elements in a set 
of 23 different M. pneumoniae isolates. Our data show that the occurrence of intrage-
nomic recombination of RepMP2/3 elements is a relatively common phenomenon in M. 
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pneumoniae and that all RepMP2/3 and RepMP4 elements carry either a subtype 1- or 
subtype 2-specific signature sequence. As a consequence, the M. pneumoniae genome 
possesses either subtype 1- or subtype 2-specific sequences, but not both, indicating that 
these subtypes represent evolutionary separated strain lineages.
Methods
strains
We used 23 different M. pneumoniae strains as listed in Table 1. These strains were 
described previously by Dorigo-Zetsma and coworkers 15, 19, and were kindly provided 
by Dr. S.A. Zaat (Academic Medical Center, Amsterdam). Since the complete genome 
table 1. Names and P1 genotypes of the M. pneumoniae strains used in this study.
No. Strain P1 genotype
1 M129 (ATCC 29342) 1
2 MAC (ATCC 15492) 2
3 P1 1428 (ATCC 29085) 1
4 Mp5 1
5 Mp22 1
6 Mp72 1a
7 Mp1042 1a
8 Mp1116 1
9 Mp1286 1a
10 Mp1397 1a
11 Mp1842 2
12 Mp2004 2a
13 Mp2018 1a
14 Mp2157 1a
15 Mp4599 2a
16 Mp4817 ‘Variant 1’
17 Mp5181 2a
18 Mp5191 1a
19 Mp5192 1a
20 Mp5194 2
21 Mp5196 2a
22 Mp5245 1a
23 Ofo 2a
a Determined in this study. The genotype of the other strains was described previously 19.
Chapter 3
40
sequence is currently only available for strain M129 (ATCC 29342; a subtype 1 strain), 
we used this strain as a reference for the sequences of the RepMP2/3 and RepMP4 
elements 3, 4. The P1 gene sequence, however, is available for a few other strains. Of 
these, we used PI 1428 (ATCC 29085) and Mp22 as representatives of subtype 1 
strains. Strain Mp4817 was employed as the prototype ‘variant 1’ strain, whereas MAC 
(ATCC 15492) and Mp1842 were regarded as subtype 2 strains.
M. pneumoniae cultures
All strains were cultured in Mycoplasma medium containing 1.4% DifcoTM PPLO broth 
(Becton Dickinson), 0.15% DifcoTM TC Yeastolate, UF (Becton Dickinson), 1.4% glucose, 
20% horse serum, 1,000 U/ml Penicillin G, 500 U/ml Polymyxine B, and 0.02 mg/
ml phenol red. The pH of the medium was adjusted to 7.8-8.0 using a solution of 2 
N NaOH, followed by filter-sterilization. Strains were grown in 3 ml of medium at 
37oC/5% CO2 in 25 cm2 tissue culture flasks (Greiner). Cells were harvested upon color 
change of the medium (from red/orange to yellow).
genomic dna purification
Genomic DNA was isolated from M. pneumoniae cells as follows. Cultures (3 ml) were 
harvested by centrifugation for 10 min in a microcentrifuge at full speed. The cell pellet 
was resuspended and washed in 1 ml of 0.9% NaCl, followed by centrifugation. The 
resulting pellet was resuspended in 400 μl of TE buffer (10 mM Tris-HCl, 1 mM EDTA 
pH 8.0). Then, 70 μl of 10% sodium dodecyl sulfate (SDS) and 5 μl of Proteinase K 
(10 mg/ml) was added. After incubation for 10 min at 65oC, 100 μl of 5 M NaCl 
was added, followed by the addition of 100 μl of a solution of 10% N-cetyl-N,N,N-
trimethylammonium bromide (CTAB) in 0.7 M NaCl. The solution was incubated for 
10 min at 65oC, after which the DNA was extracted from the solution using 500 μl of 
chloroform/isoamyl alcohol (24:1; vol:vol). The DNA-containing aqueous phase was 
transferred to a fresh tube and the DNA was precipitated by the addition of 360 μl of 
isopropanol. Following incubation at -20oC for 30 min, the DNA was precipitated by 
centrifugation for 10 min at full speed in a microcentrifuge. After a wash step with 70% 
ethanol, the DNA was dried, and resuspended in 10 μl of H2O.
Amplification and cloning of RepMP2/3 and RepMP4 elements. In order to sequence 
all 10 RepMP2/3 and all 8 RepMP4 elements from each strain, 18 specific PCR primer 
sets were designed based on the genome sequence of M. pneumoniae strain M129 
(GenBank accession no. U00089). The sequences of the primers, which were synthe-
sized by and purchased from Eurogentec, are listed in Table S1. Of all strains, purified 
chromosomal DNA was used to amplify each RepMP2/3 and RepMP4 element by 
high-fidelity PCR. The PCR mixture (25 µl) contained either 0.5 µM or 1.0 µM primer 1, 
either 0.5 µM or 1.0 µM primer 2, 0.2 mM of each dNTP (Fermentas), 0.02 U/µl Pfu 
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DNA polymerase (Fermentas), 1´Pfu buffer containing MgSO4 (Fermentas) and 10 ng 
of purified M. pneumoniae DNA. For the majority of the PCR reactions, the following 
conditions were used: 5 min at 94°C, followed by 35 cycles of 30 sec at 94°C, 30 
sec at 52°C, and 4 min at 72°C. For amplification of the RepMP2/3-h element, the 
annealing temperature was lowered to 45°C. The resulting PCR fragments, of which the 
lengths are depicted in Table S1, were purified by ethanol precipitation and cloned into 
HincII-digested vector pBluescript SK- (Stratagene). In some cases, purified PCR products 
were used directly in DNA sequencing reactions (below).
Sequencing of RepMP2/3 and RepMP4 elements. Automated DNA sequencing was 
performed using ABI PRISM® BigDye™ Terminator (BDT) Cycle Sequencing Ready Reac-
tion Kits and a 3130xl Genetic Analyzer (Applied Biosystems). Sequencing reactions 
(10 µl), contained 1µl BDT Ready Reaction premix (Applied Biosystems), 5´ sequenc-
ing buffer (Applied Biosystems), 3.2 µM of either the M13 reverse or forward primer 
(Eurogentec), and 1 µl of plasmid DNA or PCR product (150-300 ng). Since most of 
the RepMP elements are larger than 1 kb, new primers were designed in order to close 
all sequences double-stranded using a ‘primer-walking’ strategy. Raw DNA sequence 
data was processed using Chromas version 2.33 software (Technelysium Pty Ltd) and 
assembled using the application SeqManTM II (DNASTAR).
Nucleotide sequence accession numbers. The GenBank accession numbers are de-
picted in Table S2.
resUlts
Amplification and sequencing of RepMP2/3 and RepMP4 elements. In order to deter-
mine the nucleotide sequences of all RepMP2/3 and RepMP4 elements of the 23 M. 
pneumoniae strains, we designed 18 element-specific PCR primer sets (Table S1). The 
sequences of the primers were derived from the genome sequence of strain M129, 
and were chosen such as to include the complete RepMP2/3 and RepMP4 elements 
as defined by Himmelreich and coworkers 3. Each primer set gave rise to specific PCR 
products for each of the 23 strains. Thus, a total of 414 PCR products were generated 
that were each cloned into E. coli plasmid pBluescript SK- and sequenced. If unique 
sequence differences were found between the congruent elements from different strains, 
these differences were confirmed by re-sequencing (using newly amplified DNA frag-
ments). In each of these cases, we could confirm the previously observed differences. 
As a consequence, we did not detect any mutations induced by PCR amplification. We 
did find several examples of putative sequence errors, however, in previously deposited 
GenBank files; these errors are listed in the legends to Fig. 2-5.
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fig. 2. Sequence variation among the 10 RepMP2/3 elements within the 23 M. pneumoniae strains. 
The sequences of the elements RepMP2/3-a to RepMP2/3-j are schematically represented in (a) to (j), 
respectively. The boxes indicate the length (drawn to scale) and orientation of each element and only list 
those nucleotide sequences within a given element that differ among the strains or between any strain and 
sequenced strain M129 3. Below the name of each element, its position within the genome of M129 is 
listed, as derived from GenBank accession no. U00089. The other positions in the figure also refer to this 
sequence. Nucleotides, insertions and deletions (Δ) that are found in all subtype 1 and all subtype 2 strains 
are indicated in blue and red, respectively. Sequence variations that are not subtype-specific are indicated 
in black. At some positions, indicated with an asterisk (*), the M129 sequence from GenBank differed 
from the sequences of M129 and all other strains as determined in this study. We therefore assume that the 
GenBank file is not correct at these positions. The incorrect nucleotides are: in RepMP2/3-b, a T at position 
166239 (should be a C) and an A at position 166249 (should be a C); in RepMP2/3-e, a T at position 
190960 (should be a C); in RepMP2/3-e, a G at position 190969 (should be an A); in RepMP2/3-f, a T 
at position 246188 (should be a C) and a T at position 246197 (should be a C); in RepMP2/3-j, a T at 
position 606121 (should be a C), an A at position 606365 (should be a T), and a C at position 606402 
(should be a G). Since element RepMP2/3-d, which is localized within the P1 gene, is highly variable, the 
sequence variations within this element are depicted in a separate figure (Fig. 3).
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183587(1)AAACCACACCAAGTTCACGAGCGCTACGGGGATGGACCAGCAGGGACAATCAGGTACCTCCGCGGGGAATCCCGACTCGTTAAAGCAGGATAATATTAGTAAGAGTGGGGATAGTTTAACCACGCAGGACGGCAATG
      (2)---CCACACCAAGTTCACGAGCGCTACGGGGATGGGCCAGCAGGAACAATCAGGTACCTCCGCGGGGAATCCCGACTCGTTAAAGCAGGATAAGATTAGTAAGAGTGGGGATAGTTTAACCACGCAGGACGGCAATG
183724(1)CGATCGATCAACAAGAGGCCACCAACTACACCAACCTCCCCCCCAACCTCACCCCCACCGCTGATTGACCGAACGCGCTGTCATTCACCAACAAGAACAACGCGCAGCGCGCCCAGCTCTTCCTCCGCGGCTTGTTG
      (2)CGATGGATCAACAAGAGGCCACCAACTACACCAACCTCCCCCCCAACCTCACCCCCACCGCTGATTGACCGAACGCGCTGTCATTCACCAACAAGAACAACGCGCAGCGCGCCCAGCTGTTCCTGCGCGGCCTGTTG
                A(Mp1842,Mp5194) 
183861(1)GGCAGCATCCCGGTGTTGGTGAATCGAAGTGGGTCCGATTCCAACA---AATTCCAAGCCACCGACCAAAAATGGTCCTACACCGACTTACATTCGGACCAAACCAAACTGAACCTCCCCGCTTACGGTGAGGTGAA
      (2)GGCAGCATCCCGGTGTTGGTTAATAAGTCCGGCCAAGATGATAACAGTAAGTTTAAGGCGGAGGACCAAAAATGGTCCTACACCGACTTACAGTCGGACCAAACCAAACTGAACCTCCCCGCTTACGGTGAGGTGAA
183998(1)TGGGTTGTTGAATCCGGCGTTGGTGGAAACCTATTTTGGGAACACGCGAGCGGGTGGTTCGGGGTCCAACACGACCAGTTCACCCGGTATCGGTTTTAAAATTCCCGAACAAAATA--------ATGAT-TCCAAAG
      (2)TGGGTTGTTGAATCCGGCGTTGGTGGAAACCTATTTTGGGAACACGCGAGCGAGTGGTTCGGGGTCCAACACGACCAGTTCACCCGGTATCGGTTTTAAAATTCCCGAACAAAGTGGCACAAACACAACGTCGAAGG
184135(1)CCACCCTGATCACCCCCGGGTTGGCTTGAACGCCCCAGGACGTCGGTAACCTCGTTGTCAGTGGCACCACGGTGAGCTTCCAGCTCGGCGGGTGGCTGGTCACCTTCACGGACTTTGTCAAACCCCGCGCGGGTTAC
      (2)CTGTGCTGATCACCCCCGGGTTGGCTTGAACGCCGCAAGACGTTGGTAACCTCGTTGTCAGTGGCACCAGCTTCAGCTTCCAGCTCGGCGGGTGGTTAGTTACGTTCACGGACTTTATCAAACCCCGCGCTGGTTAC
184272(1)CTCGGTCTCCAGTTAACGGGCTTGGATGCAAGTGATGCGACGCAGCGCGCC
      (2)CTCGGGCTCCAGTTAACGGGCTTGGATGCAAGTGATGCGACGCAGCGCGCT
                                                        T(Mp22,Mp72)
C
A (2b)
Identical to 190685-191784 of element 
RepMP2/3-e of subtype 1 strains, except for 
a T to G substitution at position 190847
100% identical to position 128421-128821 of 
element RepMp2/3-a of subtype 2 strains
100% identical to position 128725-128821 of 
element RepMP2/3-a of all strains, except for 
a 12 base pair deletion (128784-128795)
100% identical to position 341871-342218 
of element RepMP2/3-g of subtype 2 strains
ΔCCAATTCCCAAA 
(309, Mp3896)
RepMP2/3-d
180820-182441
18
28
60
Subtype 2 variants (according to GenBank)
Subtype 1 variant (Mp4817)
Mp4817
G (T in RepMP2/3-e)
18
33
59
18
35
87
18
43
11
Fig. 3fig. 3. Sequence variation of element RepMP2/3-d within M. pneumoniae strains. All nucleotide positions 
are taken from GenBank fi le U00089. Nucleotides, insertions and deletions (Δ) that are found in all subtype 
1 and all subtype 2 strains are indicated in blue and red, respectively. The box at the top represents the 
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In order to distinguish between the 10 RepMP2/3 and 8 RepMP4 elements, we em-
ployed a novel systematic nomenclature for the elements (Fig. 1 and Table S1) that is 
based on their appearance within the genome and the current numbering of the M. 
pneumoniae M129 genome in the GenBank database. This novel nomenclature was 
necessary because the current genome numbering differs from that originally reported 
by Himmelreich et al. 3. Previously, the elements were not named systematically in the 
literature 16. In order to avoid confusion with this previous labeling, we have proposed a 
nomenclature that includes the suffixes –a to -j for the 10 RepMP2/3 elements and -a to 
-h for the 8 RepMP4 elements.
The sequence variation within RepMP2/3 elements among M. pneumoniae strains. 
The sequences of the RepMP2/3 elements are shown in Fig. 2. One of the most sig-
nificant findings from the analysis of these sequences is that each element possesses 
either a subtype 1 signature (the nucleotides indicated in blue in Fig. 2) or a subtype 2 
signature (the nucleotides indicated in red). Thus, a subtype 1 strain exclusively contains 
subtype 1-specific RepMP2/3 elements and a subtype 2 strain only contains subtype 
2-specific RepMP2/3 elements. The subtype-specificity is defined by single-nucleotide 
polymorphisms (SNPs) (in each element in Fig. 2), by deletions of one nucleotide (twice 
in RepMP2/3-f) or three nucleotides (in RepMP2/3-a and RepMP2/3-j), as well as by 
an insertion of six nucleotides (in RepMP2/3-e). Besides these subtype-specific differ-
ences, almost all elements also differ among strains in a subtype-independent fashion. 
In most cases, these differences are SNPs. The highest level of variation among strains 
was observed in two of the RepMP2/3 elements, i.e. in RepMP2/3-d, which is located 
within the MPN141 gene (Fig. 3), and in RepMP2/3-c (Fig. 2(c)). Most of the nucleotide 
sequence differences within element RepMP2/3-d are subtype-specific. As described 
above, these differences have previously been employed for the classification of strains 
as subtype 1, 2, 2a and 2b. It has been suggested that the RepMP2/3-d element from 
subtype 2a strain 309 contains sequences that are derived from another RepMP2/3 
sequence as found in most strains; the most variable part of this sequence is detailed in the inset at the top, 
in which the upper line shows the sequence of subtype 1 strains (1) and the lower line represents sequences 
of subtype 2 strains (2). The lower two boxes show the sequence organization as found in subtype 1 variant 
strain Mp4817 and in the subtype 2 variants (309, 2b and Mp3896). The insets describe the putative 
origin of sequences that are not found in the RepMP2/3-d elements of most M. pneumoniae strains. The 
published sequence of the RepMP2/3-d element from strain MAC (GenBank accession no. AF290001) 
was found to contain several errors (as was inferred from the sequences that we generated for MAC as well 
as all other subtype 2 strains); these errors were found at position 182872 (G should be A), 183622 (A 
should be G), 183631 (G should be A), 183727 (C should be T), 183728 (C should be G), 183730 
(G should be A), 183746 (T should be C), 183842 (C should be G), 183848 (T should be G), 183855 
(T should be C), and 183882 (G should be T). A single-nucleotide error was also found in the published 
sequence of element RepMP2/3-d of strain Mp1842 (GenBank accession no. AF290002); at position 
182872, a G should be an A.
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element, i.e. RepMP2/3-a 16. Indeed, we also found the sequence between position 
184491 and 184751 within RepMP2/3-d from subtype 2a strains to be identical to 
a sequence within RepMP2/3-a; this sequence is identical in subtype 1 and 2 strains 
(Fig. 3).
Interestingly, the availability of the sequences of all RepMP2/3 elements from both sub-
type 1 and 2 strains enabled the tracing of the putative origin of ‘aberrant’ sequences 
within the MPN141 gene of the other variant strains, i.e. strains Mp4817, Mp3896 
and 2b strains. As shown in Fig. 3, the variable part of the RepMP2/3-d element in 
strain Mp4817 is identical, except for a single nucleotide substitution, to sequences 
from element RepMP2/3-e as found in all subtype 1 strains, including Mp4817. Conse-
quently, in contrast to what has previously been suggested 15, the RepMP2/3-d element 
from Mp4817 exclusively contains subtype 1-specific sequences and is not a hybrid of 
subtype 1- and subtype 2-specific sequences. Within strain Mp3896, the RepMP2/3-d 
element contains sequences that are identical to those of two other RepMP2/3 elements, 
i.e. RepMP2/3-g from subtype 2 strains (between position 183508 and 183852) and 
RepMP2/3-a (between position 184491 and 184751, similarly as found in subtype 
2a strains) (Fig. 3). Finally, subtype 2b strains contain a relatively large sequence within 
their RepMP2/3-d elements (from position 184194 to 184704) that is identical to a 
sequence from element RepMP2/3-a as found in all investigated subtype 2 strains (Fig. 
2(a)).
The second highly variable RepMP2/3 element within our strain collection is 
RepMP2/3-c. In four of the strains, i.e. Mp5, Mp72, Mp2157 and Mp5181, this 
element contains a 1.5-kb sequence that is identical to the sequence of RepMP2/3-h 
from the same strain, except for four single-nucleotide deletions in both Mp72 and 
Mp5181, and 2 single-nucleotide deletions in Mp2157. As a consequence, these 
strains carry two RepMP2/3-h sequences, one of which replaces the RepMP2/3-c 
fig. 4. Sequence variation among the 8 RepMP4 elements within the 23 M. pneumoniae strains. The se-
quences of the elements RepMP4-a to RepMP2/3-h are schematically represented in (a) to (h), respectively. 
The boxes indicate the length (drawn to scale) of each element and only list those nucleotide sequences 
within a given element that differ among the strains or between any strain and sequenced strain M129 
3. Below the name of each element, its position within the genome of M129 is listed. The other positions 
in the figure also refer to this sequence. Nucleotides, insertions and deletions (Δ) that are found in all sub-
type 1 and all subtype 2 strains are indicated in blue and red, respectively. Sequence variations that are 
not subtype-specific, are indicated in black. At some positions, indicated with an asterisk (*), the M129 
sequence from GenBank differed from the sequences of M129 and all other strains as determined in this 
study. We therefore assume that the GenBank file is not correct at these positions. The incorrect nucleotides 
are: in RepMP4-b, a G at position 165853 (should be a C); in RepMP4-f, a T at position 496501 (should 
be an A); in RepMP4-g, a G at position 565802 (should be a C) and a T at position 565843 (should be 
a G); in RepMP4-h, a T at position 609400 (should be a G). Because element RepMP4-c, which is local-
ized within the P1 gene, is highly variable, the sequence variations within this element are depicted in a 
separate figure (Fig. 5).
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sequence typically found in other strains. These data strongly support the hypothesis 
that RepMP2/3 elements can recombine in a nonreciprocal, unidirectional fashion. 
Furthermore, these results show that recombination between these elements can occur at 
genome sites other than MPN141. It is noteworthy that the putative recombination event 
involving RepMP2/3-c and RepMP2/3-h has taken place independently in four different 
strains. This is inferred from the presence of differences between these strains in their 
RepMP2/3-h sequences, which are also copied to their putative second location at the 
RepMP2/3-c locus. Moreover, these four strains include three subtype 1 strains (Mp5, 
Mp72 and Mp2157) and one subtype 2 strain (Mp5181), indicating that this DNA 
rearrangement is not a subtype-specifi c event.
18
24
41
18
14
05
18
08
20
18
13
71
18
13
70
T (PI 1428)
T (Mp1397)
G (others)
100% identical to 609478-610325 of 
element RepMP4-h of subtype 2 strains
18
08
20
18
24
41
18
22
52
Mp3896 
G (others)
181443(1)CTACCGGTTTGCCGTTTTACTCGTGCCGCGCAGCGTGGTGTACTATGAGCAGTTGCAAAGGGGGTTGGGCTTACCACAGCAGCGAACCGAGAGTGGTCAAAATACTTCCACC---ACCGGGGCAATGTTTGGCTTGA
      (2)TTATCGGTTTGCCGTTTTACTCGTGCCGCGTAGCGTGGTGTACTATGAGCAGTTGCAGCGGGGGTTAGCGCTCCCTAACCAAGGGAGTTCGTCAGGCTCAGACAGCACTAACCAAACAGGCGCAATGTTTGGCTTGA
181577(1)AGGTGAAGAACGCCGAGGCGGACACCGCGAAG--AGCAATGAAAAACTCCA-GGGCGCTGAGGCCACTGGTTCTTCAACCACATCTGGATCTGGCCAATCCACCCAACGTGGGGGTTCGTCAGGGGACACCAAAGTC
      (2)AGGTGAAGGATGCAACCGTGGATAGTTCGAAGCAATCAACGGAAAGCTTAAAGGGCGAAGAATCGAGTTCCAGTTCCACCACATCT---TCCACCTCCACCACCCAACGTGGGGGTTCGTCAAATGAAAACAAAGTC
                                                                                                              G(Mp5181)
181711(1)AAGGCTTTAAAAATAGAGGTGAAAAAGAAATC--GGACTCGGAG----------------GACAATGGTCAGCTGCAGTTAGAAAAAAATGATCTCGCCAACGCTCCCATTAAGCGGAGCGAGGAGTCGGGTCAGTC
      (2)AAGGCGTTGCAGGTGGCGGTGAAAAAGAAATCCGGGAGTCAGGGCAACTCCGGTGACCAAGGCACCGAACAGGTGGAACTTGAATCTAATGATTTAGCCAACGCCCCGATTAAACGGGGCTCCAATAACAACCAGCA
181830(1)CGTCCAACTCAAGGCGGACGATTTTGGTACTGCCCTTTCCAGTTCGGGATCAGGCGGCAACTCCAATCCCGGTTCCCCCACCCCCTGAAGGCCGTGGCTTGCGACTGAGCAAATTCACAAGGACCTCCCCAAATGAT
      (2)AGTCCAACTCAAGGCGGACGATTTTGGTACTGCCCCTTCCAGTTCGGGATCAGGCA------CCCAAGATGGCACCCCCACCCCCTGAACGCCGTGGTTAACGACTGAGCAAATTCACAACGACCCCGCCAAATTCG
RepMP4-c
180820-182441
18
14
43
18
19
66
Mp3896 (according to GenBank)
fig. 5. Sequence variation of element RepMP4-c within M. pneumoniae strains. All nucleotide positions are 
taken from GenBank fi le U00089. Nucleotides, insertions and deletions (Δ) that are found in all subtype 
1 and all subtype 2 strains are indicated in blue and red, respectively. The box at the top illustrates the 
sequence of most strains, whereas the box at the bottom describes the sequence of strain Mp3896. The 
inset at the bottom describes the putative origin of the sequence between position 181405 and 182252 
of the RepMP4-c element of this strain.
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The sequence variation within RepMP4 elements among M. pneumoniae strains. The 
sequences of the eight RepMP4 elements from the 23 strains are summarized in Fig. 4. 
Similarly as was found for the RepMP2/3 elements, each RepMP4 element possesses 
either a subtype 1 signature (the nucleotides indicated in blue in Fig. 4) or a subtype 2 
signature (the nucleotides indicated in red). The subtype-specificity is principally defined 
by SNPs (in each RepMP4 element), but also by deletions of one and 12 nucleotides 
(both in RepMP4-a) and by insertions of three and 72 nucleotides (both in RepMP4-d).
We found these 72 nucleotides to also be present in two other elements of subtype 
2 strains, i.e., in RepMP4-a (between positions 131502 and 131573, with a single 
mismatch at position 131522 (C>G)) and in RepMP4-g (between positions 565811 
and 565852, with a mismatch at position 565840 (C>A)).
In addition to these subtype-specific differences, most of the elements also display 
subtype-independent SNPs, albeit to a far lesser extent than do the RepMP2/3 ele-
ments. The element that shows the highest level of sequence variability is the one located 
within the MPN141 ORF, i.e. RepMP4-c (Fig. 5). The variations within this element are 
numerous and are centered on the middle part of the element; these variations have 
previously been used to distinguish between subtype 1 and subtype 2 strains. Indeed, 
the vast majority of the variations found in this element are subtype-specific. Unlike the 
RepMP2/3 elements, the RepMP4 elements within the 23 strains do not show any 
indication of a previous inter-element recombination event. Nevertheless, the obtained 
sequences of the RepMP4 elements did allow us to explain the structure of the aberrant 
MPN141 gene within strain Mp3896, which could previously not be classified as either 
a subtype 1 or subtype 2 strain 18. A region of 848 bp within the RepMP4-c element 
of Mp3896 was found to be identical to the sequence between position 609478 and 
610325 of the RepMP4-h element as found in all subtype 2 strains (Fig. 4(h) and Fig. 
5). Thus, it is likely that strain Mp3896 has acquired RepMP4-h sequences within its 
MPN141 gene by a recombination event in which the RepMP4-h element was used as 
donor sequence. Taken together with the sequence data on the RepMP2/3 elements 
described above, the ‘aberrant’ strain Mp3896 can be described as a subtype 2 strain 
in which the MPN141 gene has undergone three different homologous recombination 
events, one involving its RepMP4 sequence and two involving its RepMP2/3 sequence.
discUssion
The analysis of the DNA sequences of the RepMP2/3 and RepMP4 elements of 
various M. pneumoniae strains has revealed the following three major findings: (i) the 
genetic differences between subtype 1 and subtype 2 strains are reflected in each of 
the RepMP2/3 and RepMP4 elements within the M. pneumoniae genome, (ii) a similar 
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fig. 6. Schematic representation of the confi guration and structure of RepMP2/3 and RepMP4 elements in 
all M. pneumoniae strains published to date. The top panel describes subtype 1 strains, whereas the lower 
panel describes subtype 2 strains. Each colored block represents the sequence of a particular RepMP ele-
ment, either RepMP4-a to -h (at the top within each panel) or RepMP2/3-a to -j (at the bottom). The blocks 
are not drawn to scale. A color change within a specifi c block indicates a putative DNA rearrangement 
event in which sequences from a specifi c element have been transferred to another element. For instance, 
within strain Mp4817, RepMP2/3-e sequences (in dark green) have been transferred to RepMP2/3-d (in 
light green). The colors of the elements labeled as ‘All strains’ or ‘Most strains’ were used as reference. In 
the ‘Subtype 1’ panel, ‘All strains’ refers to all subtype 1 strains that have been examined in this study. ‘Most 
strains’ refers to all subtype 1 strains (top panel) or subtype 2 strains (bottom panel) that were studied, with 
the exception of the strains named separately in each panel. For the strains marked with an asterisk (*), 
i.e. strain 309 (2a (309)) 16, the 2b strains 17 and Mp3896 18, the sequences of only a limited number of 
RepMP elements have been determined. These elements include those located within the P1 gene and, in 
the case of strain 309, also the RepMP2/3-a element. The elements that have not been sequenced have 
been left blank.
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homologous recombination event has occurred between two RepMP2/3 elements in four 
of the examined strains, and (iii) all previously described P1 genotypes can be explained 
by inter-RepMP recombination events.
M. pneumoniae subtype 1 and 2 strains represent separate 
genetic lineages.
With regard to the first finding listed above, it is important to discriminate between the 
‘P1 genotype’ and the ‘subtype’ of a strain. This is crucial because two M. pneumoniae 
isolates with a virtually identical genetic composition can have a significantly different 
P1 genotype as a consequence of a single recombination event between a RepMP 
element within the P1 gene and an element elsewhere in the genome. For instance, strain 
Mp4817 has previously been classified as an aberrant ‘variant 1a’ strain, because 
the DNA sequence of the RepMP2/3 element within its P1 gene (‘P1 genotype’) was 
considerably different from that of other strains 15. Due to the unavailability of the DNA 
sequences of other RepMP elements within this strain, the unusual structure of this RepMP 
element was even considered to be the result of a combination of subtype 1 and subtype 
2 sequences 15. By contrast, our data indicate that strain Mp4817 is a typical subtype 
1 strain with respect to the sequences of all of its RepMP2/3 and RepMP4 elements. 
This strain does, however, differ from other subtype 1 strains because its RepMP2/3-e 
element has recombined with, and donated sequences to, the RepMP2/3-d element 
within the P1 gene. Similar considerations can be made for the other variant strains that 
have been isolated thus far, as summarized in Fig. 6.
Thus, while strain Mp4817 should be classified as a subtype 1 strain, the variant 2a 
and 2b strains, as well as strain Mp3896, should be classified as subtype 2 strains. 
Nevertheless, because these variant strains carry a P1 gene with a structure different 
from that of other subtype 2 strains, we have proposed a M. pneumoniae strain clas-
sification method in which subtype annotation is separated from the annotation of the P1 
gene structure, as outlined in Table 2. Because the sequence data strongly indicate that 
subtype 1 and subtype 2 strains of M. pneumoniae represent separate and relatively 
conserved genetic entities, it is highly unlikely that isolates of a mixed subtype will be 
found in the near future.
In order to correctly type M. pneumoniae isolates, it seems sufficient to determine the 
sequences of the variable (RepMP) regions within the P1 gene and compare those to the 
sequences of the RepMP elements described in this study. Based upon the high level of 
sequence conservation that was found among the different RepMP elements within both 
subtype 1 and subtype 2 strains, we anticipate that the origins of ‘novel’ sequences 
within the P1 gene of new isolates can be traced back using the sequence library of 
RepMP elements that we have generated.
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Nevertheless, we cannot exclude the possibility that novel, deviant RepMP2/3- and 
RepMP4-like elements will be found in the future. It is also important to note that we did 
not thoroughly investigate the putative presence of RepMP elements at genome positions 
other than those known for reference strain M129.
table 2. Classification of M. pneumoniae strains on the basis of the origins of the RepMP sequences within 
the MPN141 or P1 gene.
Strain/
isolate
Subtypeb
Classification
Sequence typec Short typed
M129 1 1-P1(4-c; 2/3-d) 1-P1(4-c; 2/3-d)
PI 1429 1 1-P1(4-c; 2/3-d) 1-P1(4-c; 2/3-d)
Mp4817 1 1-P1(4-c; 2/3-d[183681]e[190685-191784;G190847]
d[184761])
1-P1(4-c; 2/3-d[e]d)
Mp5a 1 1-P1(4-c; 2/3-d) 1-P1(4-c; 2/3-d)
Mp72a 1 1-P1(4-c; 2/3-d) 1-P1(4-c; 2/3-d)
Mp2157a 1 1-P1(4-c; 2/3-d) 1-P1(4-c; 2/3-d)
MAC 2 2-P1(4-c; 2/3-d) 2-P1(4-c; 2/3-d)
Mp3896 2 2-P1(4-c[181405]h[609478-610325]c[182252]; 2/3-
d[183508]g[341871-342218]d[183852-184491]a[128725-
128821;Δ128784-128795]d[184751])
2-P1(4-c[h]c; 2/3-d[g]
d[a]d)
309 (2a) 2 2-P1(4-c; 2/3-d[184491]a[128725-128821;Δ128784-128795]
d[184751])
2-P1(4-c; 2/3-d[a]d)
2b 2 2-P1(4-c; 2/3-d[184194]a[128421-128821]d[184704]) 2-P1(4-c; 2/3-d[a]d)
Mp5181a 2 2-P1(4-c; 2/3-d) 2-P1(4-c; 2/3-d)
a Although these strains carry a recombined RepMP2/3 element (as summarized in Fig. 6), this element is 
not located within the P1 gene. Hence, these recombination events are not reflected in their ‘sequence type’.
b The subtype 1 and 2 annotation listed here is based on sequence differences found between subtype 1 
and 2 strains in each RepMP2/3 and RepMP4 element.
c A sequence type is composed of a subtype number (either 1 or 2), followed by the arrangement of RepMP 
sequences (between brackets) within the P1 gene; ‘4-c’ refers to the RepMP4-c element and ‘2/3-d’ refers 
to the RepMP2/3-d element. If these elements contain sequences derived from other RepMP elements, 
the nucleotide positions of the insertion sites are indicated between brackets; the inserted sequences are 
indicated by their positions within the RepMP element of origin (between brackets). In the sequence type of 
strain Mp4817, ‘G190847’ indicates that the nucleotide at position 190847 is replaced by a G nucleotide. 
The identity of the RepMP elements of origin are indicated by the letters ‘a’ to ‘j’ for RepMP2/3 and by ‘a’ 
to ‘h’ for RepMP4, as introduced in Table S1.
d The short sequence types only list the origins of the RepMP sequences and not their full sequence details. 
Thus, elements with inserted sequences of different lengths, such as 309 and the 2b strains, have the same 
name. The letters in brackets refer to the origin of the inserted sequences; e.g. for strain Mp4817, ‘2/3-d[e]
d’ indicates that sequences from element RepMP2/3-e are inserted into RepMP2/3-d sequences.
53
3
Intragenomic homologous DNA recombination events in M. pneumoniae
homologous recombination between repMp elements.
In four of the investigated strains, including three subtype 1 strains (Mp5, Mp72, 
Mp2157) and one subtype 2 strain (Mp5181), sequences from element RepMP2/3-h 
appeared to be transferred to the RepMP2/3-c element. As the original sequence of 
element RepMP2/3-c seems to be lacking in these strains and the information from 
the RepMP2/3-h element is copied to the ‘RepMP2/3-c location’, we infer that these 
elements may have recombined by gene conversion. To our knowledge, it is the first time 
that putative homologous recombination events between RepMP2/3 elements outside of 
the P1 gene have been detected. As these DNA rearrangements do not include known 
operons or expressed genes, it is tempting to generalize that recombination among 
RepMP elements within the M. pneumoniae genome is governed solely by similarity in 
DNA sequence and is not executed in a directed fashion. Since a similar recombination 
event has occurred independently in four different strains, which represented 17% of all 
strains in this study, it is possible that this event is highly favorable, either because the 
local genomic structure surrounding elements RepMP2/3-c and RepMP2/3-h is easily 
accessible for the enzymatic recombination machinery or because these elements share 
a higher level of sequence similarity with each other than with any other RepMP2/3 
element within the genome. However, there is no support for this latter notion, as all 
elements share significant similarity in at least part of their sequences.
Gene conversion events were also hypothesized to have occurred in strain Mp4817 
(described above) and strain 309, in which element RepMP2/3-d was found to carry 
sequences derived from element RepMP2/3-a 16. Although the sequences of the RepMP 
elements outside of the P1 gene have not yet been determined for ‘2b’ strains and 
strain Mp3896, it is likely that gene conversion-like events have also taken place in 
these strains. In more general terms, the current data on the dynamics of the exchange 
of sequence information among RepMP2/3 and RepMP4 elements suggests that these 
DNA rearrangements occur by (unidirectional) gene conversion and not by reciprocal 
exchange of homologous DNA sequences.
In conclusion, our data strongly support the hypothesis that the recombination of 
RepMP2/3 and RepMP4 elements forms the basis of antigenic variation of the P1 pro-
tein of M. pneumoniae 15, 16. The RepMP elements that are scattered around the bacterial 
genome appear to constitute a wealthy source for P1 sequence variability.
It is therefore highly likely that novel variants of the P1 gene will continue to appear. 
This view stresses the importance of the availability of an adequate, universal typing 
method for M. pneumoniae strains as described in this study. It is clear, however, that 
the biological and evolutionary constraints on a recombination event within the P1 ORF 
are stringent, as the encoded P1 protein plays an essential role in the life cycle of M. 
pneumoniae. Each recombination event within the P1 ORF must therefore eventually result 
in the expression of a functional P1 protein. Nevertheless, we assume that recombination 
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among RepMP elements within the P1 gene may occur far more frequently than would be 
deduced from the relatively infrequent detection of P1 sequence variation among either 
subtype 1 or subtype 2 strains. Clearly, recombination events leading to non-functional 
P1 proteins will have a biological disadvantage and not be selected for. The extent to 
which RepMP recombination occurs within the M. pneumoniae genome will therefore 
have to be studied in a context in which biological selection against ‘unfavorable’ DNA 
rearrangements is reduced to a minimum. We are currently exploring such contexts.
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Mycoplasma pneumoniae is a human pathogen that causes a range of respiratory 
tract infections. The first step in infection is adherence of the bacteria to the respiratory 
epithelium. This step is mediated by a specialized organelle, which contains several 
proteins (cytadhesins) that have an important function in adherence. Two of these cytad-
hesins, P40 and P90, represent the proteolytic products from a single 130-kDa protein 
precursor, which is encoded by the MPN142 gene. Interestingly, MPN142 contains a 
repetitive DNA element, termed RepMP5, of which homologs are found at seven other 
loci within the M. pneumoniae genome. It has been hypothesized that these RepMP5 
elements, which are similar but not identical in sequence, may recombine with their 
counterpart within MPN142 and thereby provide a source of sequence variation for this 
gene. As this variation may give rise to amino acids changes within P40 and P90, the 
recombination between RepMP5 elements may constitute the basis of antigenic variation 
and, possibly, immune evasion by M. pneumoniae. To investigate the sequence variation 
of MPN142 in relation to inter-RepMP5 recombination, we determined the sequences 
of all RepMP5 elements in a collection of 25 strains. The results indicate that: (i) inter-
RepMP5 recombination events have occurred in seven of the strains, and (ii) putative 
RepMP5 recombination events involving MPN142 have induced amino acid changes 
in a surface-exposed part of the P40 protein in two of the strains. We conclude that 
recombination between RepMP5 elements is a common phenomenon that may lead to 
sequence variation of MPN142-encoded proteins.
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introdUction
Mycoplasma pneumoniae is a common pathogen of the human respiratory tract that 
can cause both upper and lower respiratory tract infections, in particular in childhood 
and adolescence 1. The first and crucial step in colonization and infection with M. 
pneumoniae is attachment of the bacterium to the epithelium of the respiratory tract. An 
essential role in this process is played by a specialized attachment organelle at the tip 
of M. pneumoniae cells. This attachment organelle (also referred to as ‘terminal tip’) 
is composed of a complex of adherence and accessory proteins. The loss of function 
of one of the proteins from this complex almost invariably results in a non-functional 
attachment organelle and, hence, a non-virulent phenotype of the bacteria 2. One of 
the most prominent adherence proteins in the attachment organelle is the ~170-kDa 
P1 protein. This protein forms a complex with two accessory proteins, called P40 and 
P90 3, which function at the distal tip of the attachment organelle and are required for 
the correct localization of P1 4, 5. In line with this close functional relationship, it was 
shown that the genes encoding the P1, P40 and P90 proteins are linked at both the 
transcriptional and translational level and are located in a single operon 6. In this operon, 
the MPN141 gene encodes the P1 protein, whereas the MPN142 gene encodes a 
130-kDa precursor protein which is cleaved into an ‘N-terminal’ protein of ~40 kDa 
(P40) and a ‘C-terminal’ protein of ~90 kDa (P90) 5, 7, 8.
Apart from the functional linkage of MPN141 and MPN142, these genes also share 
an important structural feature. Both genes contain stretches of DNA of which homologous 
sequences exist at other loci within the M. pneumoniae genome. These stretches of DNA 
and their homologous counterparts are known as RepMP elements (or repetitive DNA 
elements). The MPN141 gene contains a RepMP4 element and a RepMP2/3 element, 
of which respectively seven and nine versions are present at other loci in the genome. 
The MPN142 contains a RepMP5 element of which seven other versions are present 
throughout the genome of M. pneumoniae strain M129 9, 10 (Fig. 1). These elements 
range in size from 1825 to 3360 bp (supplementary Table S1) and share 48% to 91% 
identity among each other (supplementary Table S2). It has been hypothesized that these 
elements could rearrange with their homologous counterparts by means of homologous 
DNA recombination. Obviously, such rearrangements could generate sequence varia-
tion within the MPN141 and MPN142 genes and potentially give rise to amino acid 
changes in the proteins they encode 11, 12. As the surface-exposed P1, P40 and P90 
proteins are immunogenic 5, 8, 13-17, it is tempting to speculate that amino acid changes 
within these proteins could play a role in immune evasive strategies of M. pneumoniae.
Currently, there is strong evidence that recombination among RepMP2/3 elements 
and RepMP4 elements indeed occurs in M. pneumoniae strains 18, 19 and that these 
recombination events are characterized by a unidirectional DNA sequence transfer 
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mechanism reminiscent of gene conversion 18-21. Moreover, in several clinical strains 
such recombination events have likely led to sequence changes within the MPN141 
gene, resulting in amino acid sequence alterations within the P1 protein 18-22. While 
there is considerable knowledge on the mechanism underlying sequence variation of the 
MPN141 gene, not much is known about the dynamics of variation of the MPN142 
gene. The potential role of the MPN142-localized RepMP5 element in this process is yet 
also unclear. This is remarkable, because this element, which has a length of ~2.7 kb, 
spans a significant part of the 5’ end of the MPN142 open reading frame (ORF), and 
includes the sequence that encodes the proposed cleavage site that separates the P40 
and P90 proteins (Fig. 3) 5, 7, 8, 23. Nevertheless, homologous recombination between 
RepMP5 elements has previously been hypothesized to occur on the basis of two obser-
vations: (i) the finding that the sequence of the MPN142-borne RepMP5 element from 
strain FH differs significantly from that of strain M129, and (ii) the finding that the variant 
sequence of this element from strain FH was also found at a site distant from MPN142 
within the bacterial genome, in both strain FH and M129 23. In this regard, it is important 
to note that strain FH is a so-called subtype 2 strain, whereas strain M129 is a subtype 
1 strain. Subtype 1 and subtype 2 strains represent distinct evolutionary lineages of M. 
pneumoniae that can be distinguished on the basis of DNA sequence differences (mostly 
single-nucleotide polymorphisms, small deletions and insertions) throughout the bacterial 
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fig. 1. The localization and orientation of all RepMP5 elements from M. pneumoniae strain M129 (Gen-
Bank file U00089.2) 9. The RepMP5 elements are drawn as black boxes and labeled ‘a’ to ‘h’. Specific 
nucleotide positions of the RepMP5 elements are shown in Table S1 and Fig. 2.
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genome; these differences between subtype 1 and 2 strains were also found in all 
variants of RepMP2/3 and RepMP4 18.
To investigate the sequence variation among RepMP5 elements in M. pneumoniae, as 
well as the putative role of these elements in antigenic variation of the surface-exposed 
P40 and P90 proteins, we have determined the sequences of all eight RepMP5 elements 
in a collection of 25 M. pneumoniae strains. Our data give novel insights into the 
antigenic variation potential of two surface exposed proteins and the actual protein 
sequence variation of one surface exposed protein in M. pneumoniae.
Methods
Strains. A total of 25 different M. pneumoniae strains, including 15 subtype 1 and 
10 subtype 2 strains, were used in this study. The names and characteristics of these 
strains are listed in Table 1. All strains, except strain R003, were described previously 
by Dorigo-Zetsma and coworkers 22 and were isolated in Denmark and the Netherlands 
between 1962 and 1995. Strain R003 was isolated in Germany in 1991 and was 
described previously by Dumke et al. and Maquelin et al. 16, 24. The complete genome 
sequence of M. pneumoniae strain M129 (ATCC 29342; a subtype 1 strain) was used 
as a reference 9, 10. In addition, we used strain PI 1428 (ATCC 29085) as a representa-
tive of subtype 1 and Mac (ATCC 15492) and FH (ATCC 15531) as representatives of 
subtype 2 strains.
M. pneumoniae cultures and genomic DNA purification. Strains were grown in 3 ml 
Mycoplasma medium containing 1.4% DifcoTM PPLO broth (Becton Dickinson), 0.15% 
DifcoTM TC Yeastolate, UF (Becton Dickinson), 1.4% glucose, 20% horse serum, 1,000 
U/ml Penicillin G, 500 U/ml Polymyxine B, and 0.02 mg/ml phenol red, at 37oC/5% 
CO2 in 25 cm2 tissue culture flasks (Greiner). Cells were harvested upon color change 
of the medium (from red/orange to yellow). Genomic DNA was isolated from M. pneu-
moniae cells as described by Spuesens et al. 18.
Amplification and cloning of RepMP5 elements. Eight specific PCR primer sets were 
designed on the basis of the genome sequence of M. pneumoniae strain M129 (Gen-
Bank file U00089.2). The primers, which were synthesized by and purchased from 
Eurogentec, are listed in Table S1. Of all strains, purified chromosomal DNA was used 
to amplify each RepMP5 element by high-fidelity PCR. For most elements, the PCR mixture 
(25 µl) contained 0.4 µM primer 1, 0.4 µM primer 2, 0.2 mM of each dNTP (Fer-
mentas), 0.02 U/µl Pfu DNA polymerase (Fermentas), 1×Pfu buffer containing MgSO4 
(Fermentas) and 10 ng of purified M. pneumoniae DNA. For the majority of the PCR 
reactions, the following conditions were used: 5 min at 94°C, followed by 35 cycles 
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fig. 2. Sequence variation among the eight RepMP5 elements in 25 M. pneumoniae strains. Nucleotide 
positions are derived from GenBank file U00089.2. The sequences of RepMP5-a to -h are schematically 
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represented in figures (a) to (h), respectively. Only subtype-specific polymorphisms, tandem repeats and 
putative inter-RepMP5 recombination events are shown. Subtype-independent sequence polymorphisms are 
available online (supplementary table). The arrowed boxes indicate the length (to scale) and orientation 
of each element. Elements RepMP5-b, -f, -g and -h are directly flanked by a RepMP4 element, whereas 
RepMP5-e is flanked by a RepMP1 element; these flanking elements are indicated in grey. A detailed 
description of RepMP5-c is shown in Fig. 3. Open reading frames (ORFs) that were identified within the ele-
ments are shown as grey bars (including their ORF numbers). Subtype-specific polymorphisms are indicated 
below the arrowed boxes in two rows. The top row represents the subtype 1 signature sequence (1) and 
the bottom row the subtype 2 sequence (2). A ‘Δ’ indicates a deletion. Putative recombination events were 
found in four elements (RepMP5-c, -d, -g and -h) in seven strains and are represented by black bars accom-
panied by insets stating the putative donor sequence; details on RepMP5-c are listed in Fig. 3.
table 1. Names, genotype and P1 subtype of M. pneumoniae strains used in this study
No. Strain Genotype or subtypea P1 operon subtypeb
1 M129 (ATCC 29342) 1 1-(4-c; 2/3-d; 5-c)
2 Mac (ATCC 15492) 2 2-(4-c; 2/3-d; 5-c)
3 PI1428 (ATCC 29085) 1 1-(4-c; 2/3-d; 5-c)
4 Mp5 1 1-(4-c; 2/3-d; 5-c)
5 Mp22 1 1-(4-c; 2/3-d; 5-c[a/f]c)
6 Mp72 1 1-(4-c; 2/3-d; 5-c[a/f]c)
7 Mp1042 1 1-(4-c; 2/3-d; 5-c)
8 Mp1116 1 1-(4-c; 2/3-d; 5-c)
9 Mp1286 1 1-(4-c; 2/3-d; 5-c)
10 Mp1397 1 1-(4-c; 2/3-d; 5-c)
11 Mp1842 2 2-(4-c; 2/3-d; 5-c)
12 Mp2004 2 2-(4-c; 2/3-d; 5-c)
13 Mp2018 1 1-(4-c; 2/3-d; 5-c)
14 Mp2157 1 1-(4-c; 2/3-d; 5-c)
15 Mp4599 2 2-(4-c; 2/3-d; 5-c)
16 Mp4817 1 1-(4-c; 2/3-d[e]d; 5-c)
17 Mp5181 2 2-(4-c; 2/3-d; 5-c)
18 Mp5191 1 1-(4-c; 2/3-d; 5-c)
19 Mp5192 1 1-(4-c; 2/3-d; 5-c)
20 Mp5194 2 2-(4-c; 2/3-d; 5-c)
21 Mp5196 2 2-(4-c; 2/3-d; 5-c)
22 Mp5245 1 1-(4-c; 2/3-d; 5-c)
23 Ofo 2 2-(4-c; 2/3-d; 5-c)
24 FH (ATCC 15531) 2 2-(4-c; 2/3-d; 5-c)
25 R003 2 2-(4-c; 2/3-d[a]d; 5-c)
aThe genotype or subtype of the strains was previously determined by Dorigo Zetsma et al. 22, Dumke et al. 
16, and Spuesens et al. 18.
bThe ‘P1 operon subtype’ was defined according to the classification scheme of Spuesens et al.. 18.
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of 30 sec at 94°C, 30 sec at 55°C, and 5 min at 72°C. For amplification of the three 
elements with an expected length of >3 kb (i.e. RepMP5-d, RepMP5-e and RepMP5-h), 
a long template PCR protocol was used, in which the PCR mixture (25 µl) contained both 
Thermostable DNA polymerase and Pfu DNA polymerase in a ratio of 10:1. Specifi-
cally, this mixture contained 0.4 µM of primer 1, 0.4 µM of primer 2, 0.2 mM of each 
dNTP (Fermentas), 0.04 U/µl of Thermostable DNA polymerase (Integro), 0.004 U/µl 
of Pfu DNA polymerase (Fermentas), 1× reaction buffer (Integro), 2 mM MgCl2 and 10 
ng of purified M. pneumoniae DNA. The conditions for the long template protocol were 
as follows: 5 min at 94°C, followed by 25 cycles of 10 sec at 94 °C, 30 sec at 55 
°C, and 4 min at 68 °C, with an increment of 10 sec per cycle for the last 15 cycles. All 
resulting PCR fragments, of which the lengths are depicted in Table S1, were purified by 
ethanol precipitation and cloned into HincII-digested vector pBluescript SK- (Stratagene). 
In some cases, purified PCR products were used directly in DNA sequencing reactions 
(as described below).
Sequencing of RepMP5 elements. Automated DNA sequencing was performed using 
ABI PRISM® BigDye™ Terminator (BDT) Cycle Sequencing Ready Reaction Kits and a 
3130xl Genetic Analyzer (Applied Biosystems). Sequencing reactions (10 µl), contained 
1µl BDT Ready Reaction premix (Applied Biosystems), 5× sequencing buffer (Applied 
Biosystems), 3.2 pmol of either the M13 reverse or forward primer (Eurogentec), and 1 
µl of plasmid DNA or PCR product (150-300 ng). Since most of the RepMP5 elements 
are larger than 2 kb, new primers were designed in order to close all sequences double-
stranded using a ‘primer-walking’ strategy. Raw DNA sequence data was processed and 
assembled using the application SeqManTM II (DNASTAR). Alignments were made with 
the online multiple sequence alignment program ClustalW, available at http://www.
ebi.ac.uk/clustalw/ClustalW/.
fig. 3. Sequence variation in the RepMP5-c element of M. pneumoniae strains. (a) Schematic represen-
tation of the MPN142 gene (the arrowed box). The nucleotide positions are derived from GenBank file 
U00089.2. The (positions of the) N- and C-terminal amino acids of the P40 and P90 proteins, which are 
encoded by MPN142, are shown below the arrowed box. The C-terminal amino acid of the P40 protein 
(V?) was inferred from the determined molecular mass of the P40 protein 7. (b) Sequence variation within 
the RepMP5-c element of M. pneumoniae strains. Only subtype-specific polymorphisms are shown. Strain-
specific sequence polymorphisms are listed online (supplementary table). The inset shows the sequence 
between position 186547 and 187540, which displays the highest variability between subtype 1 strains 
(the top line) and subtype 2 strains (the bottom line). The putative C-terminal amino acid of the P40 protein 
(V?) and the N-terminal amino acid of the P90 protein (R) are indicated above the corresponding DNA 
sequences, i.e. the codons GTC and CGT, respectively. Identical nucleotides are boxed. (c) The amino acid 
sequences encoded by the RepMP5-c sequence of subtype 1 (top line) and subtype 2 strains (bottom line) 
between position 169 and 599. Identical amino acids are boxed.
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resUlts
Amplification and sequencing of RepMP5 elements. To determine the nucleotide se-
quences of the RepMP5 elements within the genomes of the 25 M. pneumoniae strains, 
we designed eight element-specific PCR primer sets (Table S1). The sequences of the 
primers were derived from the complete genome sequence of strain M129 9, and were 
selected such as to allow specific amplification of all known RepMP5 elements. Since 
no systematic nomenclature for the RepMP5 elements was available, the elements were 
provided with a suffix, i.e. -a to -h, respectively, similarly as described previously for 
the RepMP2/3 and RepMP4 elements 18 (Table S1). This nomenclature is based on the 
consecutive appearance of each repetitive element within the genome of M. pneumoniae 
strain M129 (GenBank file U00089.2) (Himmelreich et al., 1996).
During the selection of appropriate PCR primer sequences, we found the DNA sequence 
homology between some of the RepMP5 elements to extend beyond the boundaries 
that were initially determined for these elements (Himmelreich et al., 1996). Conse-
quently, the borders of some of the elements (RepMP5-d and -e) had to be redefined 
such that these elements turned out to be considerably larger than reported previously 
(Table S1). In addition, for two of the RepMP5 elements (RepMP5-e and -h) it was not 
possible to design unique PCR primers targeting the exact borders of the elements, as 
these elements were joined at one side to another repetitive element (a RepMP1 and a 
RepMP4 element, respectively). The PCR primers targeting elements RepMP5-e and -h 
were therefore designed in such a way that RepMP5-e would be amplified jointly with 
the neighboring RepMP1 element, and RepMP5-h would be amplified together with the 
adjacent RepMP4 element.
All eight RepMP5 element-specific primer sets gave rise to PCR products of expected 
lengths for all 25 investigated strains. Thus, a total of 200 PCR products were produced. 
Subsequently, the PCR products were cloned into E. coli plasmid pBluescript SK- and 
sequenced using a ‘primer walking’ strategy. To minimize the occurrence of sequencing 
errors due to infidelity of the (proofreading) Pfu DNA polymerase, duplicate sequencing 
reactions were performed on independently produced PCR fragments in case a unique 
polymorphism was encountered in a single strain.
Strain subtype-dependent sequence variation among RepMP5 elements. The sequences 
of the RepMP5 elements from all 25 strains are represented schematically in Fig. 2. 
Similarly as described previously for the RepMP2/3 and RepMP4 elements within the 
M. pneumoniae genome 18, each RepMP5 element was found to have either a subtype 
1-specific or a subtype 2-specific sequence. This subtype differentiation corresponded 
completely with that derived previously from the P1 gene sequences of these strains 
(Table 1). This signifies that subtype 1 and subtype 2 strains can be distinguished on the 
basis of single-nucleotide polymorphisms (SNP) in all RepMP5 elements as well as by 
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single-nucleotide deletions (in RepMP5-a; Fig. 2a) and a single insertion (in RepMP5-e; 
Fig. 2e). The most abundant subtype-specific variation was observed in the RepMP5-c 
element, which is located in the MPN142 gene (Fig. 3). This variation was previously 
also observed in a study in which the RepMP5-c sequences from strains M129 and 
FH were compared 23. The sequence differences between subtype 1 and subtype 2 
strains give rise to significant differences in the predicted amino acid sequences of the 
MPN142-encoded P40 and P90 proteins (Fig. 3c).
Subtype-independent sequence differences in RepMP5 elements. The sequences of 
the RepMP5 elements also differ among strains in a subtype-independent fashion. The 
observed differences (or mutations) include nucleotide transitions and transversions, as 
well as insertions and deletions (Table S2). Taken together, 83.4% of the mutations was 
unique to a given RepMP5 element within a strain, whereas 16.6% of the mutations 
was shared with the corresponding element from at least one other strain. It is interesting 
to note that differences were also found between strain M129 sequences deposited 
in GenBank and those determined in this study in four of the eight RepMP5 elements 
(RepMP5-e to -h). These differences may originate either from sequencing errors or from 
the accumulation of mutations within the genome of laboratory strain M129 during 
prolonged culturing. Nevertheless, repeated amplification and sequencing of elements 
RepMP5-e to -h from strain M129 did not indicate the occurrence of amplification and/
or sequencing errors in this study.
RepMP5-c (185747 – 188447) 
Mp22 and Mp72 
18
84
47
 
18
62
52
 
18
62
96
 
18
57
47
 
GDQGSNGKGSLYKTLQ 
DDQGSNGKGSLYTTLK 
(M129) 169 184 
(Mp22 & Mp72) 169 184 
100% identical to positions 114210 - 114254 of 
element RepMP5-a and 497922 - 497966 of 
element RepMP5-f of all subtype 1 strains. 
fig. 4. Structure of the RepMP5-c element from strains Mp22 and Mp72. A putative recombination event, 
which introduced sequences from either RepMP5-a or RepMP5-f into the RepMP5-c element, is indicated by 
the black box. The amino acid sequence changes that are predicted to occur in the P40 protein due to this 
recombination event are depicted at the bottom of the figure, in which the amino acid sequences from strains 
Mp22 and Mp72 are aligned to those of strain M129. Identical amino acids are boxed.
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Another interesting observation that was made in two of the eight RepMP5 elements 
was the presence of tandem repeats of varying lengths. Within element RepMP5-b, the 
sequence 5’-ATC-3’ was found to be present in tandems of either three (in 19 strains), 
four (in four strains), five (in one strain) or six (in one strain) (Fig. 2b). Another tandem 
repeat was identified in element RepMP5-e. While a single copy of this 12-bp repeat 
(5’-CGCCGAGCTAAG-3’) was found in 20 of the strains, two to five tandem copies of 
this repeat were detected in the remaining five strains (Fig. 2e).
Recombination between RepMP5 elements. Within four of the eight RepMP5 elements 
(RepMP5-c, -d, -g, and -h) from seven of the 25 strains, sequence stretches were identi-
fied that differed significantly from those of their corresponding elements in other strains. 
Conversely, these sequence stretches were found to be identical to sequences found in 
other RepMP5 elements from the same strain. Specifically, the RepMP5-d element from 
subtype 2 strain Mp2004 contains a 199-bp fragment that is identical to a sequence 
found in element RepMP5-h (Fig. 2d). In this strain, as well as in three other strains (the 
Most 
strains 
Mp22 
Mp72 
a b c d e f g h 
Mp4817 
RepMP5 elements 
Subtype 1 strains 
Most 
strains 
a b c d e f g h 
Mp2004 
Mp4599 
Mp5196  
MAC 
RepMP5 elements 
Subtype 2 strains 
fig. 5. Schematic representation of the structure of the RepMP5 elements in 25 M. pneumoniae strains. 
This representation is based on the scheme published previously for the RepMP2/3 and RepMP4 elements 
within the M. pneumoniae genome 18. Each box represents the sequence of a single RepMP5 element. Each 
row of boxes represents all RepMP5 elements as found in one or more strains (subtype 1 strains in the top 
panel and subtype 2 strains in the bottom panel). The different patterns within the boxes indicate putative 
recombination events; each pattern refers to the donor element from which a particular sequence may have 
been derived. The presence of a box with two different patterns indicates that the sequences may have 
originated from either of two different donor
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subtype 1 strain Mp4817 and subtype 2 strains Mp4599 and Mp5196), the RepMP5-
g element was found to contain a 127-bp sequence that is identical to a sequence 
from either RepMP5-f or RepMP5-h (these two elements are identical in this sequence; 
Fig. 2g). Furthermore, in subtype 2 strain Mac, a 61-bp sequence was identified in 
RepMP5-h that is identical to a sequence from the RepMP5-e element (Fig. 2h). The 
most significant finding, however, was the identification of a 45-bp aberrant sequence 
within the MPN142-localized RepMP5-c element of two subtype 1 strains (Mp22 and 
Mp72); this sequence was found to be identical to a sequence from either RepMP5-a or 
RepMP5-f (these two elements are identical in this sequence; Fig. 4). Together, these data 
strongly support the hypothesis that RepMP5 elements may rearrange within the M. pneu-
moniae genome by virtue of homologous DNA recombination. In addition, as the ‘donor’ 
DNA elements appeared to have remained unaltered by the presumed recombination 
events, the results also suggest that the rearrangement of RepMP5 sequences may have 
occurred in a nonreciprocal, unidirectional fashion, similarly as proposed previously for 
the RepMP2/3 and RepMP4 elements 18, 19. The putative homologous recombination 
events that have occurred in the investigated M. pneumoniae strains are summarized 
schematically in Fig. 5.
P40 amino acid sequence variation induced by RepMP5 rearrangements. As the 
putative recombination events that involved the RepMP5-c elements of strains Mp22 
and Mp72 could influence the protein coding capacity of the MPN142 genes of these 
strains, we compared the predicted amino acid sequences derived from these genes with 
those derived from the MPN142 gene of reference strain M129. As shown in Fig. 4, 
the MPN142-encoded amino acid sequence from strains Mp22 and Mp72 differs from 
that of strain M129 at three positions within a 16-amino acid stretch, between amino 
acid positions 169 and 184 of the P40 protein. The three mutations include a Gly to 
Ala substitution at position 169, a Lys to Thr substitution at position 181, and a Gln to 
Lys substitution at position 184. Importantly, these amino acid residues are located in a 
surface-exposed region of the P40 protein 5, 8. These findings therefore indicate that the 
rearrangement of RepMP5 elements can result in modification of surface-exposed parts of 
the M. pneumoniae P40 protein, which may influence the recognition of P40 by human 
antibodies.
discUssion
The characterization of the RepMP5 elements from a set of 25 M. pneumoniae strains has 
led to the following main conclusions: (i) the genetic difference between subtype 1 and 
subtype 2 strains of M. pneumoniae can be observed in each RepMP5 element within the 
bacterial genome, (ii) DNA sequences can be transferred from one RepMP5 element to 
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another, most likely by unidirectional (non-reciprocal) homologous DNA recombination, 
and (iii) RepMP5 rearrangements can lead to amino acid sequence changes in surface-
exposed regions of the P40 protein, which may contribute to antigenic variation of M. 
pneumoniae. Although the actual occurrence of recombination events between RepMP5 
elements was not monitored in ‘real time’ in this study, the aforementioned conclusions 
are justified because the sequences of the RepMP5 sequences among subtype 1 strains 
and among subtype 2 strains are relatively stable.
Strain subtype-specific sequence differences among repetitive DNA elements were previ-
ously also reported for each copy of the RepMP2/3 and RepMP4 elements from M. 
pneumoniae 18. In most RepMP elements, the sequence differences between subtype 1 
and subtype 2 strains are represented by SNPs. However, within the RepMP elements 
located within the P1 operon (i.e., RepMP4-c and RepMP2/3-d within ORF MPN141 
and RepMP5-c within MPN142), the sequence differences between the two subtypes 
are much more pronounced. Nevertheless, it is clear that the difference between these 
subtypes can already be observed at the single-nucleotide level, a notion that is useful in 
the design of molecular typing assays 25. The genetic differences between the subtypes 
are, however, not solely restricted to RepMP elements, as differences are also found in 
‘regular’ ORFs, such as MPN528a 26, 27.
Apart from the subtype-specific differences between strains in the sequences of their 
RepMP5 elements, several subtype-independent as well as strain-specific differences 
were found among these elements. The most prominent subtype-independent difference 
that was observed was the occurrence of variable numbers of tandem repeats in two of 
the elements. The significance of (the variable number of) these repeats is yet unknown, 
in particular because the elements in which they reside have not been shown to be 
translated into protein. However, it is interesting to note that the part of RepMP5-b 
that contains the trinucleotide tandem repeat from M129 has previously been cloned 
within the RepMP5-c element such as to mimic a putative recombination event within 
the MPN142 gene 28. The recombinant M. pneumoniae strain carrying this modified 
MPN142 gene was found to be virulent in an animal model and to express both the 
P40 and P90 protein 28. Regardless of the putative function of the tandem repeats in 
the pathogenesis of M. pneumoniae infection, trinucleotide repeats have previously also 
been described within genes of other microorganisms, such as the TAC repeats within 
the iaaL gene from Pseudomonas savastanoi pv. savastanoi 29.
Although the RepMP5 elements that are located outside the P1 operon all harbor one 
or more ORFs (Fig. 2) it is currently unknown whether some or all of these ORFs are 
translated into protein. The RepMP5-c element appears to be the only RepMP5 sequence 
that is actually protein-coding. In line with current hypotheses, the other seven RepMP5 
elements could serve as a source of variant sequences, which may be transferred to 
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other RepMP5 elements (including RepMP5-c) by homologous recombination. Indeed, 
we were able to identify a total of four different putative recombination events that had 
occurred in seven of the 25 investigated strains. It was previously shown that the region 
of the P40 protein containing such a recombination event, is extracellularly expressed 
and carries antigenic determinants 5. Whether or not the sequence may actually be 
targeted by the humoral immune response is not known because putative epitopes within 
this region have not yet been identified. Regardless, this finding is the first to demonstrate 
a modification of the MPN142 sequence, as well as the MPN142-encoded amino acid 
sequence, by virtue of the exchange of RepMP5 sequences.
Previously, a recombination event was hypothesized to have occurred in the MPN142 
gene of M. pneumoniae strain FH 23. It was suggested that the difference between strain 
M129 (a subtype 1 strain) and strain FH (a subtype 2 strain) in their RepMP5-c sequences 
was caused by the introduction of sequences from a distal RepMP5 element (the donor 
element) into the RepMP5-c element of strain FH. The donor element was found to be 
present within the genomes of both strain FH and strain M129 23. Indeed, we found 
this putative donor element, which is RepMP5-h, to be present in all investigated M. 
pneumoniae strains. However, because all subtype 2 strains analyzed to date have a 
similar RepMP5-c sequence (Fig. 3), this putative recombination event is likely to have 
taken place early in the evolution of M. pneumoniae, concurrently with, or immediately 
following, the divergence of the two main strain lineages of M. pneumoniae (subtype 1 
and subtype 2). In contrast, the putative recombination events of RepMP5 elements that 
were identified in this study are likely to have occurred more recently.
It is interesting to note that two of the investigated strains that harbor putative RepMP5 
rearrangements (Mp4817 and Mp72) were previously also found to contain rearrange-
ments in other repetitive elements 18. While strain Mp4817 was found to have sequences 
from RepMP2/3-e inserted into RepMP2/3-d (which is localized within MPN141), 
strain Mp72 was reported to contain RepMP2/3-h sequences within RepMP2/3-c 18. 
The putative recombination events that occurred in these strains were probably not linked 
because the elements that were involved in these events are located at distant sites within 
the M. pneumoniae genome.
As the primary structure of the MPN142 ORF of a given M. pneumoniae isolate may 
have clinical and/or epidemiological consequences, it may be useful to include informa-
tion on this structure in the classification system that was previously proposed for M. 
pneumoniae strains 18. This system contains data on both the subtype of a strain as well 
as the structure of the MPN141 gene 18, 25, 26. On the basis of the current knowledge on 
the organization of the MPN142 gene, we expanded the M. pneumoniae classification 
system to address the overall structure of all three RepMP elements within the P1 operon. 
For instance, strains Mp22 and Mp72 can be classified as 1-P1(4-c; 2/3-d; 5-c[a/f]c). 
In this classification, ‘1’ refers to the general subtype of the strains (i.e., subtype 1) and 
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‘P1(4-c; 2/3-d; 5-c[a/f]c)’ refers to the structure of the P1 operon, in which RepMP4-c 
(‘4-c’) and RepMP2/3-d (‘2/3-d’) do not contain significant sequence rearrangements 
as opposed to reference strain M129, whereas element RepMP5-c contains an insertion 
of a sequence identical to that of either element RepMP5-a or RepMP5-f (‘5-c[a/f]c’). In 
Table 1 this classification system is applied to all strains from this study.
In conclusion, we have found that putative recombination events between RepMP5 
elements can result in amino acid sequence changes in surface-exposed parts of the M. 
pneumoniae P40 protein. Because the RepMP5-c element spans ~74% of the MPN142 
ORF and overlaps with sequences encoding both P40 and P90, it is likely that recom-
bination events involving RepMP5-c can also lead to amino acids changes in the P90 
protein. We hypothesize that such events, as well as other, novel inter-RepMP recombina-
tion events, will continue to emerge among clinical isolates of M. pneumoniae.
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classification of M. PNEUMONIAE strains
Our data in chapter 2 and 3 have indicated that M. pneumoniae strains can geneti-
cally and evolutionary be divided into two lineages, i.e. a subtype 1 and a subtype 
2 lineage1, 2. The major variations in sequences within the MPN141 gene that have 
previously been detected appear to be due solely to intra-genomic, inter-RepMP ele-
ment recombination events. The variation in sequences of the RepMP elements that we 
have described allows for strains to be classified, analyzed and named in a more 
comprehensive and systematic fashion than was previously possible. We designed a 
new classification system in which we described the subtype and RepMP organization. 
For example, strain M129 may be classified as a strain of ‘sequence type’ 1-P1(4-c; 
2/3-d), in which ‘1’ indicates the subtype of the strain (in this case subtype 1) and 
P1(4-c; 2/3-d) denotes the RepMP4 (4-c) and RepMP2/3 (2/3-d) organization within 
the P1 (MPN141) gene. Strain Mp4817 may be described as 1-P1(4-c; 2/3-d[183681]
e[190685-191784;G190847]d[184761]), in which ‘d[183681]’ and ‘d[184761]’ indicate the nucleotide 
positions of the RepMP2/3-d element between which sequences from an RepMP2/3-e 
element (e[190685-191784;G190847]) have been inserted; ‘G190847’ indicates the presence of 
a G nucleotide (instead of a T nucleotide) at position 190847 of the inserted sequence. 
In short, strain Mp4817 may be referred to as a 1-P1(4-c; 2/3-d[e]d) strain. A short 
name may be particularly useful when different elements have donated sequences to a 
single RepMP element within the MPN141 gene. For example, strain Mp3896 may be 
classified in short as a 2-P1(4-c[h]c; 2/3-d[g]d[a]d) strain. We applied this classification 
system to the strains studied in the previous chapters. The classification is depicted in 
table 2 of chapter 3 and table 1 of chapter 4.
Clear advantages of this method of classification is that: it relies directly on DNA 
sequence information, and it is also applicable to newly identified strains possessing a 
yet unknown arrangement of RepMP sequences within their P1 gene. At least two publi-
cations by other authors underline the value of this classification system. First, Schwartz et 
al.3 reported on a new real time PCR high resolution melting (HRM) technique that allows 
the identification of P1 variants of M. pneumoniae. With this technique they identified a 
new genetic P1 variant, which was then sequenced. On the basis of the sequence data, 
the isolate was suggested to exhibit an “intermediate” genotype between subtypes 1 
and 2. It was subsequently referred to as ‘isolate 3’. Subsequently, using our proposed 
classification system and available RepMP sequence data, we determined that the new 
P1 gene found by Schwartz et al. contained a recombination event identical to a variant 
which was already described by Dumke et al., and referred to as strain 2b. In this 
strain, a putative homologous DNA recombination event has transferred sequences from 
element RepMP2/3-a to the RepMP2/3 element within the P1 gene, i.e., RepMP2/3-d. 
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The strain can be classified as 2-P1(2/3-d[a]d). The RepMP4 element sequence was 
not available.
Second, Zhao et al.4 described the sequence of the P1 gene from 60 Mycoplasma 
pneumoniae strains. Within these strains they identified novel P1 gene sequences. When 
further characterized it was determined that a rearrangement of RepMP4 sequences had 
taken place, which resulted in the novel P1 gene sequence. Moreover, this study under-
lines the importance to clearly distinguish the “subtype” to which an M. pneumoniae strain 
belongs from the “P1 sequence type” of this strain. M. pneumoniae strains can be classi-
fied as subtype 1 or subtype 2 strains; these subtypes can be discriminated on the basis 
of relatively small sequence differences that are found throughout the bacterial genome. 
However, the variation of the P1 sequence type is likely determined by homologous DNA 
recombination events among RepMP4 elements and RepMP2/3 elements, which are 
subtype-independent processes (and can occur in both subtype 1 and subtype 2 strains). 
This clear distinction leaves no room for ambiguity and confusion in the molecular typing 
of M. pneumoniae. More importantly, it leaves no room for the suggestion by Zhao et al. 
that a subtype 1 variant strain would harbor subtype 2-specific sequences. As described 
previously, the P1 gene sequence variation of this subtype 1 strain is merely the result of 
a recombination event between RepMP2/3 sequences and is not the result of horizontal 
DNA transfer between a subtype 1 strain and a subtype 2 strain.
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aBstract
The first choice antibiotics for treatment of Mycoplasma pneumoniae infections are mac-
rolides. Several recent studies, however, have indicated that the prevalence of macrolide 
(ML)-resistance, which is determined by mutations in the bacterial 23S rRNA, is increas-
ing among M. pneumoniae isolates. Consequently, it is imperative that ML-resistance in 
M. pneumoniae is rapidly detected to allow appropriate and timely treatment of patients. 
We therefore set out to determine the utility of pyrosequencing as a convenient technique 
to assess ML-resistance. In addition, we studied whether pyrosequencing could be useful 
for molecular typing of M. pneumoniae isolates. To this end, a total of four separate 
pyrosequencing assays were developed. These assays were designed such as to de-
termine a short genomic sequence from four different sites, i.e. two locations within the 
23S rRNA gene, one within the MPN141 (or P1) gene and one within the MPN528a 
gene. While the 23S rRNA regions were employed to determine ML-resistance, the latter 
two were used for molecular typing. The pyrosequencing assays were performed on a 
collection of 108 M. pneumoniae isolates. The ML-resistant isolates within the collection 
(n=4) were readily identified by pyrosequencing. Moreover, each strain was correctly 
typed as either a subtype 1 or subtype 2 strain by both the MPN141 and MPN528a 
pyrosequencing test. Interestingly, two recent isolates from our collection, which were 
identified as subtype 2 strains by the pyrosequencing assays, were found to carry novel 
variants of the MPN141 gene, having rearrangements in each of the two repetitive 
elements (RepMP4 and RepMP2/3) within the gene. In conclusion, pyrosequencing is a 
convenient technique for ML-resistance determination as well as molecular typing of M. 
pneumoniae isolates.
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introdUction
Mycoplasma pneumoniae is a common bacterial agent of upper and lower respiratory 
tract infections (RTIs), especially in children. About 20-40% of all community-acquired 
pneumonias is caused by this small, cell wall-less bacterium 1. Effective treatment of M. 
pneumoniae infections is usually achieved by the use of macrolides (MLs), which are 
generally considered as the first choice antibiotics in both children and adults for two 
reasons: (1) M. pneumoniae lacks a cell wall and is therefore intrinsically resistant to cell 
wall targeting drugs such as penicillin, and (2) MLs have little side effects and are easy 
to administer, which is of particular importance in children. However, the widespread 
empirical use of these antibiotics in treatment of RTIs may eventually lead to an increase 
in the prevalence of ML-resistance of M. pneumoniae. Indeed, a recent study 2 reported 
a dramatic increase of ML-resistance among M. pneumoniae isolates, from 0% in 2002 
to over 40% in 2008, following the increased use of ML in Japan. In concurrence with 
this finding, ML-resistant M. pneumoniae isolates have also been reported to emerge 
in other countries 3-5. Given the apparent increase in the prevalence of ML-resistance, 
it is crucial that ML-resistant isolates are detected in a timely fashion to allow targeted 
treatment adjustments for M. pneumoniae-induced RTIs and to create more awareness of 
this upcoming problem in the general clinical community.
The ML-resistant phenotypes are defined by specific point mutations in the V domain 
of the single-copy 23S rRNA gene of M. pneumoniae. The mutations in this gene that 
induce a high-level of ML-resistance include an A to G transition at position 2063 and 
an A to C transversion at position 2064 6. Low-level ML-resistance is induced by an A 
to G transition at position 2067 and a C to G or A transversion at position 2617 of 
the 23S rRNA gene 7, 8. The presence of these mutations can be detected by PCR of 
the 23S rRNA gene followed by dideoxy chain termination sequencing. This procedure, 
however, can be laborious and time-consuming. Other methods, such as those based 
on real-time PCR followed by (high resolution) melt analysis, have clear advantages over 
previous assays, in particular regarding the speed at which data can be obtained 3, 9. 
Nevertheless, these methods often rely on the execution of multiple rounds of PCR and 
require ample experience in interpretation of the results. It is therefore important to seek 
novel, convenient molecular tests for the detection of ML-resistance.
Because molecular diagnostic tests have already proven their value in both detection 
and genotyping of M. pneumoniae, it would be useful to design assay platforms in which 
these tests can be combined with those aimed at the determination of ML-resistance. 
Currently, real-time PCR is the predominant technique used for the detection of M. pneu-
moniae in clinical microbiological laboratories. The methods and approaches used for 
genotyping of M. pneumoniae, however, are more diverse. The majority of these meth-
ods are aimed at the detection of variation within the MPN141 gene. This gene, which 
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encodes the immunodominant and essential cytadhesin P1, contains two DNA elements, 
termed RepMP4 and RepMP2/3, which are variable among M. pneumoniae isolates 
10-14. It is hypothesized that recombination between these elements and their homologs 
located at other positions in the bacterial genome is the cause of this variation. In total, 
the genome of M. pneumoniae strain M129 was found to include 8 variants of RepMP4 
and 10 variants of RepMP2/3 15. In principle, the determination of the structure of the 
variable regions (RepMP4 and RepMP2/3) within the MPN141 gene can address two 
separate questions. First, it addresses whether sequences from another RepMP element 
within the genome have been introduced into the MPN141 gene 14. This information 
may be clinically and epidemiologically useful if the changes on the DNA level lead to 
an altered P1 amino acid sequence, which could have an influence on the virulence 
of M. pneumoniae isolates. Second, the sequences of the RepMP elements within the 
MPN141 gene indicate to which of the two major M. pneumoniae subtypes (subtype 1 
and 2) an isolate can be classified. However, the sequence differences between subtype 
1 and 2 strains can be observed throughout the genome of M. pneumoniae, including all 
RepMP elements, and are not restricted to the MPN141 gene 14, 16, 17. The two subtypes 
of M. pneumoniae therefore appear to represent two separate evolutionary lineages 14. 
In this respect, it is important to discriminate between determination of the subtype of 
isolates on the one hand, and determination of the MPN141 genotype on the other. In 
principle, a ‘genotype switch’ of MPN141 can occur at any given moment in a single 
bacterium within a population due to a RepMP recombination event. This switch can 
occur irrespective of the subtype of the bacterium. However, a bacterium cannot switch 
from subtype 1 to subtype 2 (or the reverse). From an evolutionary point of view it is 
therefore primarily important to classify isolates on the basis of their subtype. With this in 
mind, we set out to evaluate whether the application of the pyrosequencing technique 
would be useful in the design of a simple and reliable molecular procedure aimed at: (1) 
the determination of the subtype of M. pneumoniae isolates, and (2) the detection of 23S 
rRNA mutations responsible for ML-resistance. The pyrosequencing technique, which is 
a real-time sequencing-by-synthesis method, is of particular interest because it is highly 
suitable for the generation of relatively short DNA sequences.
In this study, we describe the design and evaluation of a set of four different pyro-
sequencing assays. Two of these were aimed at the determination of the subtype of 
M. pneumoniae strains by exploiting single-nucleotide polymorphisms (SNPs) between 
subtype 1 and subtype 2 strains. The other two assays were used for the detection of the 
aforementioned ML-resistant genotypes. We report that these assays are convenient and 
reliable, providing a 100% correlation with conventional molecular methods for typing 
and ML-resistance determination. In addition, we describe the identification of two M. 
pneumoniae isolates carrying novel MPN141 variants, having rearrangements in both 
the RepMP2/3 and RepMP4 element of the MPN141 gene.
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Materials and Methods
M. pneumoniae strains, culturing and DNA isolation. A total of 108 M. pneumoniae 
isolates were used in this study. These isolates included the three reference strains M129 
(ATCC 29342), MAC (ATCC 15492) and FH (ATCC 15531) and 100 clinical isolates, 
obtained between 1973 and 2005, (kindly provided by R. Dumke) 17, 18. Briefly, these 
included 69 subtype 1 strains (one of which carrying an MPN141 rearrangement) 
and 31 subtype 2 strains (four of which with an MPN141 rearrangement). Three of 
the isolates were found to have a ML resistant phenotype (MIC > 100 µg/µl). In addi-
tion, five M. pneumoniae-positive clinical specimens (throat swabs and nasopharyngeal 
washings) were used that were recently collected in the Netherlands. The names of all 
isolates are shown in Table 1. The culturing of, and DNA extraction from M. pneumoniae 
strains was performed as previously described 14. DNA isolation from clinical specimens 
was performed using the QIAamp DNA mini kit (QIAGEN, the Netherlands) according 
to the manufacturer’s recommendations, except that phocine herpesvirus was added 
before isolation as an internal control for real-time PCR 19. The DNA was eluted with 
elution buffer AE (10 mM Tris-HCl pH 9.0, 0.5 mM EDTA) in a volume of 50 µl.
M. pneumoniae detection and quantification of bacterial load. The clinical specimens 
used in this study were first investigated for the presence of M. pneumoniae DNA by 
an in-house developed, quantitative real-time (TaqMan®) PCR assay. This assay targets 
a conserved region of the MPN141 gene and produces an amplicon of 73 bp. Primer 
and probe sequences are listed in Table 2. Reactions were performed in a final volume 
of 25 µl, containing 0.4 µM forward primer, 0.6 µM reverse primer, 0.2 µM probe, 
1´Taqman® Universal Master Mix containing UNG (Applied Biosystems) and 5 µl of 
template DNA. The cycling conditions for each PCR were as follows: 2 min at 50°C, 10 
min at 90°C, followed by 40 cycles of 5 sec at 90°C and 10 sec at 60°C.
For quantification of the load of M. pneumoniae in clinical specimens, the real-time 
PCR amplicon obtained from strain M129 was cloned into HincII-digested vector pBlue-
script SK- (Stratagene). The resulting construct, pBSK--P1-73, was used in serial dilutions in 
order to quantify purified genomic DNA of strain M129 by real-time PCR. Ten-fold serial 
dilutions of the quantified genomic M129 DNA were subsequently used in every PCR 
run in order to determine the bacterial DNA load in clinical specimens 19. These bacterial 
loads are expressed as M. pneumoniae genome copies per ml original sample. The 
real-time PCR assay was used to determine the limits of detection of the pyrosequencing 
assays described below.
M. pneumoniae genotyping by RFLP and sequencing. The genotype of most clinical 
isolates was previously determined by PCR-restriction fragment-length polymorphism 
(PCR-RFLP) analysis and sequencing of the MPN141 gene 17. A similar PCR-RFLP method 
was performed on M. pneumoniae isolates cultured from five novel clinical specimens. 
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table 1. Subtyping and pyrosequencing results of all M. pneumoniae isolates used in this study.
Strain Subtypea ML-susc.b
Pyrosequencingc
MPN141 MPN528a 23S rRNA 1 23S rRNA 2
184,991 650,584 2,063 2,064 2,067 2,617
M129 1 S T A A A A C
MAC 2 S C C A A A C
FH 2 S C C A A A C
M155/98 2 S C C A A A C
M192/98 2 S C C A A A C
M885/97 2 S C C A A A C
R035g 1 ND T A A C A C
M384/98 2 S C C A A A C
M234/98 1 S T A A A A C
M13/98 2 S C C A A A C
D3142 1 S T A A A A C
M88460/99 1 S T A A A A C
M88408/99 1 S T A A A A C
R003 2d S C C A A A C
R022 1 S T A A A A C
R023 1 S T A A A A C
R024 1 S T A A A A C
R013 1 S T A A A A C
R027 1 S T A A A A C
R008 1 S T A A A A C
R014 1 S T A A A A C
R002 1 S T A A A A C
R007 1 S T A A A A C
R010 1 S T A A A A C
R004 1 S T A A A A C
R011 1 S T A A A A C
R033 1 S T A A A A C
R028 1 S T A A A A C
R018 1 S T A A A A C
R005 1 S T A A A A C
R026 1 S T A A A A C
R034 2 S C C A A A C
R006 2 S C C A A A C
R025 1 S T A A A A C
R030 1 S T A A A A C
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table 1. Subtyping and pyrosequencing results of all M. pneumoniae isolates used in this study. (continued)
Strain Subtypea ML-susc.b
Pyrosequencingc
MPN141 MPN528a 23S rRNA 1 23S rRNA 2
184,991 650,584 2,063 2,064 2,067 2,617
R012 1 S T A A A A C
R015 1 S T A A A A C
R009 1 S T A A A A C
R020 1 S T A A A A C
R031 1 S T A A A A C
R019 1 S T A A A A C
R021 1 S T A A A A C
M88521/99 1 S T A A A A C
M79060/00 1 S T A A A A C
M79692/00 2d S C C A A A C
M88558/99 1 S T A A A A C
M88566/99 1 S T A A A A C
M88579/99 1 S T A A A A C
M88587/99 1 S T A A A A C
M88708/99 2 S C C A A A C
M79378/00 1 S T A A A A C
D 91/00 2 S C C A A A C
P 2530 2 S C C A A A C
P 535 2 S C C A A A C
R016 1 S T A A A A C
M79461/00 2 S C C A A A C
M814/97 2 S C C A A A C
Mp4817 1e S T A A A A C
R017 1 S T A A A A C
M759/97 1 S T A A A A C
PIF59 2d S C C A A A C
M667/97 1 S T A A A A C
M602/97 1 S T A A A A C
M762/97 1 S T A A A A C
M726/97 1 S T A A A A C
P05/132b 1 R T A A G A C
D479 2 S C C A A A C
M727/97 1 S T A A A A C
M826/98 1 S T A A A A C
M765/98 2 S C C A A A C
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table 1. Subtyping and pyrosequencing results of all M. pneumoniae isolates used in this study. (continued)
Strain Subtypea ML-susc.b
Pyrosequencingc
MPN141 MPN528a 23S rRNA 1 23S rRNA 2
184,991 650,584 2,063 2,064 2,067 2,617
M729/97 1 S T A A A A C
M586/97 1 S T A A A A C
D22 1 S T A A A A C
R032 1 S T A A A A C
M529/97 1 S T A A A A C
M713/96 1 S T A A A A C
M509/97 1 S T A A A A C
R001 2d S C C A A A C
T71 1 S T A A A A C
T72 1 S T A A A A C
T73 1 S T A A A A C
T74 1 S T A A A A C
PIA75 1 S T A A A A C
PIA76 1 S T A A A A C
T77 1 S T A A A A C
T78 2 S C C A A A C
T79b 2 R C C G A A C
T80 2 S C C A A A C
T81 2 S C C A A A C
T82 1 S T A A A A C
T83 2 S C C A A A C
T84 2 S C C A A A C
F51 2 S C C A A A C
F52 1 S T A A A A C
F54 2 S C C A A A C
F55 1 S T A A A A C
F56 1 S T A A A A C
F57 2 S C C A A A C
F58 2 S C C A A A C
F60 2 S C C A A A C
M468/97 1 S T A A A A C
M688/98b 2 R C C G A A C
R029 1 S T A A A A C
R1108/01 2f,g ND C C A A A C
R0109/01 2f,g ND C C A A A C
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Briefly, the PCR-RFLP was carried out as follows. The RepMP2/3 and RepMP4 elements 
from the MPN141 gene were first amplified as described previously 14 (the primers used 
are listed in Table 2). The resulting PCR fragments were then digested with HaeIII and 
analyzed by 2% agarose gel electrophoresis followed by ethidium bromide-staining. 
Isolates R1108/01 and R0109/01 could not be correctly classified as either subtype 
1 or 2 based on this RFLP method (data not shown). The PCR products that were ob-
tained from these strains were therefore sequenced by the dideoxy chain termination 
method. The GenBank accession numbers of these new sequences are: HM447036 
(R1108/01, RepMP4-c), HM447037 (R1108/01, RepMP2/3-d), HM447038 
(R0109/01, RepMP4-c) and HM447039 (R0109/01, RepMP2/3-d).
Determination of ML-resistant genotypes and subtype of M. pneumoniae isolates by 
pyrosequencing. To identify ML-resistant genotypes, two pyrosequencing assays were 
developed that target domain V of the 23S rRNA gene. The first assay (23S rRNA 1) was 
developed to detect five point mutations at three positions within the gene, i.e. A2063G 
(in which the ‘normal’ A nucleotide at position 2063 is changed into a G), A2063C, 
A2064G, A2064C and A2067G. The second assay (23S rRNA 2) was developed to 
detect two mutations at a single position, i.e. C2617A and C2617G.
table 1. Subtyping and pyrosequencing results of all M. pneumoniae isolates used in this study. (continued)
Strain Subtypea ML-susc.b
Pyrosequencingc
MPN141 MPN528a 23S rRNA 1 23S rRNA 2
184,991 650,584 2,063 2,064 2,067 2,617
R0609/02 1f ND T A A A A C
H002 1f ND T A A A A C
H003 1f ND T A A A A C
a The subtyping of strains was performed previously by PCR-RFLP and sequencing. Subtype 2 strains are 
highlighted in grey.
b ML susceptibility (S = sensitive, R = resistant, ND = not determined) of the strains (Dumke et al. 2010). 
Strains R035, M688/98, P05/132 and T79 contain point mutations associated with ML-resistance.
c The positions of the indicated nucleotides are derived from either the complete genome sequence of M. 
pneumoniae M129 (for the P1 and MPN528a assays) (GenBank file U00089.2) or the 23S rRNA gene 
sequence of M129 (for the 23S rRNA 1 and 2 assays) (GenBank file X68422.1). Nucleotide positions 
2,063, 2,064, 2,067 and 2,617 correspond to nucleotide positions 122,119, 122,120, 122,123 and 
122,673, respectively, of GenBank file U00089.2.
d Strains R003, M79692/00, PIF59 and R001 contain a RepMP2/3-d[a]d rearrangement as described 
previously in detail (Kenri, et al, 1999, Spuesens, et al, 2009).
e Strain 4817 contains a RepMP2/3-d[e]d rearrangement as described previously in detail (Spuesens, et 
al, 2009).
f Strains R1108/01, R0109/01, R0609/01, H002 and H003 are isolated in this study.
g Strains R1108/01 and R0109/01 contain rearrangements in both RepMP4-c and RepMP2/3-d and are 
described in this study in detail.
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To discriminate between M. pneumoniae isolates on the basis of their subtype (i.e. 
subtype 1 and 2), two different pyrosequencing assays were developed. The first one 
targets a subtype-specific nucleotide at position 184,991 in the genomic sequence of 
M. pneumoniae M129; at this position, which is located in a conserved region near 
the 3’ end of the MPN141 gene, a T is found in subtype 1 strains and a C in subtype 
2 strains. The second pyrosequencing assay is targeted at a subtype-specific nucleotide 
in the MPN528a gene, at position 650,584 of the M129 genome, which is an A 
in subtype 1 strains and a C in subtype 2 strains. PCR and sequence primers for all 
pyrosequencing assays were designed using PyroMark™ Assay Design Software 2.0 
and are listed in Table 2.
The pyrosequencing procedure. In short, the pyrosequencing procedure consists of 
four general steps: (1) generating 5’-biotinylated PCR products, (2) processing the PCR 
products to obtain single-stranded (ss)DNA, (3) annealing of the sequence primer to the 
ssDNA, and (4) sequencing, followed by analysis of the results. The PCR reactions from 
step 1 are performed as follows. PCR mixtures (25 µl) contained 0.4-0.8 µM of each 
primer (one of which is biotinylated; see Table 2 for the detailed conditions of each of 
the four PCR reactions), 0.2 mM of each dNTP, 1-3.5 mM MgSO4 (Table 2), 0.02 U/µl 
Pfu DNA polymerase (Fermentas), 1´Pfu buffer (Fermentas) and either 5 µl of purified M. 
pneumoniae DNA or 5 µl of a diluted suspension of an M. pneumoniae culture in H2O. 
The following cycling conditions were used for all assays: 5 min at 94°C, followed by 
30 cycles of 10 sec at 94°C, 30 sec at 55°C and 30 sec at 72°C.
The resulting, biotinylated PCR products were immobilized to Streptavidin Sepharose™ 
High Performance beads (GE healthcare) and processed to yield high quality ssDNA 
using the PyroMark™ Vacuum Prep Workstation, according to the manufacturer’s instruc-
tions. Briefly, 10 µl of PCR product was added to a mixture of 2 µl streptavidin beads, 
40 µl of binding buffer (10 mM Tris-HCl, 2 M NaCl, 1 mM EDTA, 0.1% Tween 20, 
pH 7.6) and 28 µl H2O and mixed for 15 minutes by shaking. After immobilization to 
the beads, PCR products were washed successively with 70% ethanol (for 10 sec), 0.2 
M NaOH (10 sec), and 10 mM Tris-acetate (pH 7.6) (30 sec). Single-stranded DNA 
was then released into a PSQ™ HS 96 Plate containing 0.3 µM sequence primer in 
12 µl annealing buffer (20 mM Tris-acetate, 2 mM Mg-Acetate, pH 7.6) per well. The 
plate was heated for 2 min at 80°C and slowly cooled down to room temperature to 
allow sequence primer annealing. The pyrosequencing reactions and sequence analysis 
were performed using the PyroMark™Q96MD sequencer (Biotage) and accompanying 
software.
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Sequence: 5’ -  G    -  AAA G    -     A    -    - CCCCG   -    T   G  AA - 3' 
M129 (with a ‘non-resistant’ genotype) 
Strain M688/98 (with mutation A2063G) 
5’ - A  GGG -    -      -    -     A   CC  AA  CC - 3’ Sequence: 
A 
5’ -  GG  -    AA  G  -      A    -    - CCCCG  -     T   G  AA - 3’ Sequence: 
B 
5’ -     G   -    A   G    -    A    G   A CCCCG  -    T    G  AA - 3’ Sequence: 
C 
5’ -     G   -    A    -    C   A    G   ACCCCG   -    T   G  AA - 3' Sequence: 
D 
E 
2062 2076 
M129 (with a ‘non-resistant’ genotype) 
2619 2609 
2062 2076 
Strain P05/132 (with mutation A2064G) 
2062 2076 
Strain R035 (with mutation A2064C) 
2062 2076 
fig. 1. Pyrograms obtained with the 23S rRNA 1 (A-D) and 23S rRNA 2 (E) pyrosequencing reactions. 
Pyrograms from the 23S rRNA 1 assay are executed on isolates M129, M688/98, P05/132 and 
R035. The pyrogram in (A) shows the 23S rRNA gene sequence that is typical of ‘normal’, ML-sensitive M. 
pneumoniae isolates at positions 2061-2075. The pyrograms in (B-D) show the corresponding sequences 
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resUlts
Identification of ML-resistant genotypes in M. pneumoniae by pyrosequencing. In the 
design of a pyrosequencing procedure that is suitable for the detection of all 23S rRNA 
mutations known to be involved in ML-resistance, two different pyrosequencing reactions 
were developed. This was required because pyrosequencing produces DNA sequences 
with lengths up approximately 60 nucleotides, whereas the mutations involved in ML-
resistance are situated approximately 550 bp apart, around positions 2065 and 2617 
of the 23S rRNA. The first pyrosequencing reaction (termed 23S rRNA 1; Table 2) was 
therefore targeted at the region around position 2065 (to detect putative point mutations 
at positions 2063, 2064 and 2067), while the second reaction (23S rRNA 2) was 
targeted at position 2617.
The two assays were performed on a total of 108 M. pneumoniae isolates. Three of 
the isolates (T79, M688/98 and P05/132) were previously reported to have an ML-
resistant genotype as well as phenotype, as defined by their resistance to erythromycin 
at a minimum inhibitory concentration (MIC) value of >100 µg/ml 3. As shown in Fig. 
1 and Table 1, the 23S rRNA 1 pyrosequencing reaction could readily identify these 
ML-resistant isolates in the collection. The pyrograms showed an A2063G transition in 
strains T79 and M688/98 (Fig. 1B) and an A2064G transition in strain P05/132 
(Fig. 1C). The sequences that were obtained for these isolates corresponded completely 
with those that were determined previously by conventional methods 3, 7. Another isolate, 
R035, was also diagnosed as an ML-resistant isolate by the 23S rRNA 1 test. This 
strain was found to harbor an A2064C mutation in the 23S rRNA (Fig. 1D). Although 
the actual antibiotic resistance phenotype of this isolate was not tested, the A2064C 
mutation was previously reported to induce a MIC value of 100 µg/ml erythromycin in 
other strains 7. The other strains from the collection were not found to carry any of the 
ML-resistance mutations around position 2065 of the 23S rRNA gene (Table 1).
obtained with isolates M688/98, P05/132 and R035, displaying the ML-resistance mutations A2063G, 
A2064G and A2064C, respectively. On the X-axis (below the figures) the nucleotide (A, C, G and T) 
dispensing order is depicted. E and S show the dispensing of the enzyme solution and substrate solution, 
respectively. The values on the Y-axis represent relative light units, as detected by the PyroMark™Q96MD 
sequencer. Above the figures, the actual sequence that was derived from the pyrograms by the PyroMarkTM 
software is shown. The numbers above the first and last nucleotide are corresponding positions in the 23S 
rRNA gene. The regions within the pyrograms containing possible SNP-related peaks are highlighted in 
grey. The pyrogram in (E) shows the 23S rRNA gene sequence that is typical of ‘normal’ ML-sensitive M. 
pneumoniae isolates at position 2617. Here the pyrogram from the 23S rRNA 2 assay performed on isolate 
M129 is shown. The 23S rRNA 2 assay targets the region surrounding the nucleotide at position 2617 of 
the M. pneumoniae 23S rRNA gene. The labeling of the figure is similar as in (A-D). The results that were 
obtained with the 23S rRNA 1 assay and 23S rRNA 2 assay for all M. pneumoniae isolates used in this 
study are listed in Table 1.
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The 23S rRNA 2 reaction produced similar results for each of the 108 isolates in the 
collection, demonstrating that none of the isolates possessed a mutation at position 2617 
in the 23S rRNA (Table 1). A typical pyrogram of the ‘normal’ 23S rRNA gene sequence 
around this position is shown in Fig. 1E. Because of the unambiguous nature of the results 
obtained for each of the strains using the 23S rRNA 2 assay, it should readily allow the 
identification of isolates carrying mutations at position 2617.
Both the 23S RNA 1 and 23S RNA 2 assay were performed on DNA isolated from 
bacterial cultures and required a minimal bacterial DNA load of 5×102 M. pneumoniae 
genome copies/ml. This DNA load corresponds to a cycle threshold (Ct) value of 35 in 
our real-time PCR assay.
Subtype determination of M. pneumoniae by pyrosequencing. To evaluate the useful-
ness of pyrosequencing in determination of the subtype of M. pneumoniae isolates, we 
designed two separate pyrosequencing reactions. Both reactions were devised such as 
to identify SNPs between subtype 1 and subtype 2 strains. The first of these assays, the 
MPN141 assay, was targeted at the identification of the nucleotide at position 184,991 
(within the MPN141 gene). At this position, a T is present in subtype 1 strains and a 
C in subtype 2 strains. The second assay, the MPN528a assay, was targeted at the 
nucleotide at position 650,584 of the M. pneumoniae genome, which is located within 
the MPN528a gene. We sequenced this gene, which encodes a homologue of RecU 
Holliday junction resolving enzymes (data not shown), from three subtype 1 and three 
subtype 2 strains and found the subtype 1 strains to have an A at position 650,584 
and the subtype 2 strains to have a C at this position. The evaluation of the MPN528a 
pyrosequencing assay was therefore primarily aimed at addressing whether or not this 
putative SNP in the MPN528a gene would be characteristic for all isolates in our 
collection.
As shown in Fig. 2A and Table 1, the MPN141 pyrosequencing assay readily divided 
the isolates into two groups, i.e. those with a T nucleotide and those with a C nucleotide 
at position 184,991 within the MPN141 gene. These results corresponded with the 
sequence information that was previously obtained for these strains by conventional 
molecular methods 14, 17. Also, the five novel clinical isolates were correctly typed as 
either subtype 1 isolates (isolates R0609/01, H002 and H003; Table 1) or subtype 2 
isolates (R1108/01 and R0109/01). Thus, the MPN141 pyrosequencing reaction was 
able to differentiate unambiguously between subtype 1 and subtype 2 M. pneumoniae 
isolates.
The subtyping results obtained with the MPN141 pyrosequencing assay corresponded 
completely with those obtained with the MPN528a assay (Fig. 2B and Table 1). All iso-
lates classified as subtype 1 strains by the MPN141 pyrosequencing assay were found 
to carry an A at position 650,584 within the MPN528a gene, whereas all isolates 
defined as subtype 2 strains were found to have a C at this position. The implications 
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of these results are twofold. First, the SNP at position 650,584 of the MPN528a gene 
can be used to discriminate between subtype 1 and subtype 2 M. pneumoniae strains. 
Second, subtype 1 strains are unable to express a full-length protein product from the 
MPN528a gene, because the nucleotide at position 650,584 in this gene forms part 
of a TAA translation termination codon. Subtype 2 strains, however, are able to express 
a full-length protein from the MPN528a open reading frame, as they contain a TAC 
codon (encoding tyrosine) at the position of the TAA codon in subtype 1 strains. The 
consequences of this crucial difference between subtype 1 and 2 strains is described 
elsewhere20.
In conclusion, both the MPN141 assay and MPN528a assay are convenient assays 
that are suitable for the classifi cation of M. pneumoniae isolates as either subtype 1 
or subtype 2 strains. Because these assays target highly conserved sequences within 
either subtype 1 or subtype 2 strains, they are not infl uenced by putative recombination 
events that may have occurred within the RepMP4 and/or RepMP2/3 elements of the 
MPN141 gene. Thus, every M. pneumoniae isolate, including isolates carrying rear-
rangements of the RepMP2/3 and/or RepMP4 element within the MPN141 gene, such 
as strains R001, R003, M79692/00, PIF59, an Mp4817 (Table 1), can be classifi ed 
MPN528a MPN141 
AA 5’ - G T G A C - 3’ - - 
AA 5’ - G G A C - 3’ C - - 
AA 5’ - T - GG G TT - 3’ - Subtype 1: T 
Subtype 2: 
Subtype 1: 
A 5’ - T C GG G TT - 3’ - T Subtype 2: 
A B 
fig. 2. Pyrograms obtained with the MPN141 and MPN528a pyrosequencing assays. (A) Pyrograms 
from the MPN141 assay executed on isolates M129 (top; a subtype 1 strain) and MAC (bottom; a subtype 
2 strain). (B) Pyrograms from the MPN528a assay executed on isolates M129 (top; a subtype 1 strain) and 
MAC (bottom; a subtype 2 strain). The labeling of the fi gures is similar as in Fig. 1. The results obtained 
with the MPN141 assay and MPN528a assay for all M. pneumoniae isolates used in this study are listed 
in Table 1.
Chapter 6
100
180820 
184751 
184769 
182441 
182310 
182226 
R
ep
M
P
4-
c 
10
0%
 id
en
tic
al
 to
 p
os
iti
on
 5
65
87
5 
– 
56
59
66
 o
f e
le
m
en
t R
ep
M
P
4-
g 
of
 R
11
08
/0
1 
184491 
R
ep
M
P
2/
3-
d 
 
10
0%
 id
en
tic
al
 to
 p
os
iti
on
 1
28
72
5 
– 
12
88
21
 o
f e
le
m
en
t R
ep
M
P
2/
3-
a 
of
 R
11
08
/0
1,
 e
xc
ep
t f
or
 a
 1
2b
p 
de
le
tio
n 
(1
28
78
4 
– 
12
87
95
) 
181012 
181708 
A 
A
D
>N
 
V
>I
 
D
N
A 
se
qu
en
ce
 c
ha
ng
es
: 
A
m
in
o 
ac
id
 s
eq
ue
nc
e 
ch
an
ge
s:
 
A 
* 
**
 
**
 
* 
E
K
T
G
F
D
V
D
N
S
E
N
T
K
Q
G
F
Q
K
E
A
D
S
D
K
S
 
(m
os
t s
tra
in
s)
 
T
Q
T
G
F
D
T
D
D
T
D
N
K
K
Q
G
F
R
K
Q
G
E
Q
S
-
P
 
(R
11
08
/0
1)
  
183353 
183382 
183717 
182860 
A 
A 
G
 
T>
A 
T>
N
 
G
>S
 
B
 
F
Q
V
S
V
V
E
A
S
A
Y
K
P
N
T
S
S
G
Q
T
Q
S
T
N
S
S
P
[
4
a
a
]
V
[
5
a
a
]
I
Q
S
D
K
L
D
D
D
[
3
9
a
a
]
T
S
 
(m
os
t s
tra
in
s)
 
Y
Q
I
S
Y
T
D
K
D
S
Y
K
A
S
T
-
-
-
Q
G
S
G
Q
N
N
S
L
[
4
a
a
]
I
[
5
a
a
]
E
S
T
T
Q
L
D
Q
G
[
3
9
a
a
]
A
M
 
(R
11
08
/0
1)
 
fi
g
. 
3
. 
Sc
he
m
at
ic
 r
ep
re
se
nt
at
io
n 
of
 th
e 
str
uc
tu
re
 o
f 
th
e 
Re
pM
P4
-c
 e
le
m
en
t (
A
) 
an
d 
Re
pM
P2
/
3-
d 
el
em
en
t (
B)
 w
ih
in
 th
e 
M
PN
14
1 
ge
ne
 o
f 
str
ai
ns
 R
11
08
/
01
 a
nd
 
R0
10
9/
01
. T
he
 a
rro
w
 b
ar
s 
re
pr
es
en
t t
he
 R
ep
M
P4
-c
 a
nd
 R
ep
M
P2
/
3-
d 
el
em
en
ts 
as
 s
eq
ue
nc
ed
 in
 th
is 
stu
dy
. S
in
ce
 a
 c
om
pl
et
e 
ge
no
m
e 
se
qu
en
ce
 o
f a
 s
ub
ty
pe
 2
 s
tra
in
 
is 
no
t y
et
 a
va
ila
bl
e,
 a
ll 
nu
cl
eo
tid
e 
po
sit
io
ns
, i
nd
ic
at
ed
 b
y 
ve
rti
ca
l l
in
es
, a
re
 d
er
iv
ed
 fr
om
 th
e 
fu
ll 
ge
no
m
e 
se
qu
en
ce
 o
f M
. p
ne
um
on
ia
e 
su
bt
yp
e 
1-
str
ai
n 
M
12
9 
(G
en
Ba
nk
 
fil
e 
U
00
08
9.
2)
. 
Th
e 
gr
ey
 a
re
as
 in
 th
e 
ar
ro
w
 b
ar
s 
in
di
ca
te
 th
e 
re
gi
on
s 
w
ith
in
 th
e 
Re
pM
P4
-c
 a
nd
 R
ep
M
P2
/
3-
d 
el
em
en
ts 
th
at
 a
re
 r
ic
h 
in
 s
ub
ty
pe
-sp
ec
ifi
c 
se
qu
en
ce
s;
 
th
es
e 
re
gi
on
s 
ha
ve
 b
ee
n 
an
al
yz
ed
 b
ef
or
e 
in
 d
et
ai
l (
Sp
ue
se
ns
, 
et
 a
l, 
20
09
). 
St
ra
in
s 
R1
10
8/
01
 a
nd
 R
01
09
/
01
 h
av
e 
a 
su
bt
yp
e-
2 
sig
na
tu
re
 a
nd
 a
re
 id
en
tic
al
 to
 o
th
er
 
su
bt
yp
e 
2 
str
ai
ns
 e
xc
ep
t f
or
 th
e 
str
ai
n-
sp
ec
ifi
c 
SN
Ps
 in
di
ca
te
d 
by
 th
e 
ve
rti
ca
l l
in
es
. 
In
 a
dd
iti
on
, 
as
 il
lu
str
at
ed
 b
y 
th
e 
bl
ac
k 
bo
xe
s,
 s
tra
in
s 
R1
10
8/
01
 a
nd
 R
01
09
/
01
 
co
nt
ai
n 
re
ar
ra
ng
em
en
ts 
as
 c
om
pa
re
d 
to
 m
os
t o
th
er
 s
ub
ty
pe
 2
 s
tra
in
s.
 A
 p
ar
t o
f R
ep
M
P4
-c
 is
 re
pl
ac
ed
 b
y 
se
qu
en
ce
s 
fro
m
 R
ep
M
P4
-g
 (A
) a
nd
 a
 p
ar
t o
f R
ep
M
P2
/
3-
d 
is 
re
pl
ac
ed
 b
y 
se
qu
en
ce
s 
fro
m
 R
ep
M
P2
/
3-
a 
(B
). 
Th
e 
la
tte
r D
N
A
 re
ar
ra
ng
em
en
t i
s 
id
en
tic
al
 to
 th
at
 re
po
rte
d 
pr
ev
io
us
ly
 fo
r M
. p
ne
um
on
ia
e 
str
ai
n 
30
9 
(K
en
ri,
 e
t a
l, 
19
99
). 
Th
e 
am
in
o 
ac
id
 s
eq
ue
nc
es
 o
f t
he
 p
ut
at
iv
e 
P1
 p
ro
te
in
s 
fro
m
 s
tra
in
s 
R1
10
8/
01
 a
nd
 R
01
09
/
01
 th
at
 d
iff
er
 fr
om
 th
e 
P1
 s
eq
ue
nc
es
 o
f o
th
er
 s
ub
ty
pe
 2
 s
tra
in
s 
ar
e 
de
ta
ile
d 
at
 th
e 
bo
tto
m
 o
f t
he
 fi
gu
re
. T
he
 in
se
ts 
sh
ow
 th
e 
am
in
o 
ac
id
 (a
a)
 s
eq
ue
nc
e 
ch
an
ge
s 
th
at
 re
su
lt 
fro
m
 th
e 
de
sc
rib
ed
 D
N
A
 re
ar
ra
ng
em
en
ts.
 In
 b
ot
h 
in
se
ts,
 th
e 
up
pe
r s
eq
ue
nc
e 
is 
th
e 
on
e 
fo
un
d 
in
 m
os
t s
ub
ty
pe
 2
 s
tra
in
s,
 w
he
re
as
 th
e 
lo
w
er
 s
eq
ue
nc
e 
is 
th
e 
on
e 
fo
un
d 
in
 b
ot
h 
R1
10
8/
01
 a
nd
 R
01
09
/
01
. 
Bl
ac
k 
bo
xe
s 
in
 th
e 
al
ig
nm
en
ts 
in
di
ca
te
 
id
en
tic
al
 a
m
in
o 
ac
id
s.
101
6
Molecular typing by pyrosequencing
unambiguously by these assays. Both the MPN141 assay and MPN528a assay were 
found to have a similar lower detection limit as the ML-resistance assays described above 
(5×102 M. pneumoniae genome copies/ml sample).
DNA template requirements for pyrosequencing. The results described above were 
obtained after amplification and pyrosequencing of DNA purified form M. pneumoniae 
cultures. To investigate whether the assays could also be performed directly on colonies 
or liquid cultures of M. pneumoniae without prior DNA purification, the following experi-
ments were performed. Colonies of M. pneumoniae grown on PPLO agar were picked 
and resuspended in 100 µl of phosphate-buffered saline (PBS). In parallel, grown liquid 
cultures (4 ml) of bacteria were centrifuged and the bacterial pellets were resuspended 
in 100 µl PBS. Then, five µl of a 1/104 dilution of these suspensions was included 
directly in the four different pyrosequencing PCR reactions. An amplicon was obtained 
in each PCR assay for each bacterial suspension. The pyrosequencing results obtained 
with these amplicons were highly reliable, and were of similar quality as the results 
obtained after PCR and sequencing of purified M. pneumoniae DNA (data not shown). 
The pyrosequencing assays can therefore be performed directly on diluted colonies or 
diluted broth of M. pneumoniae without the need for DNA purification.
The identification of isolates carrying novel MPN141 rearrangements. As described 
above, the five novel clinical isolates that were investigated in this study were each 
readily subtyped by the pyrosequencing assays. For three of these strains (the subtype 
1 strains), the typing data corresponded with those obtained by PCR-RFLP (Table 1). 
However, for the other two strains (R1108/01 and R0109/01), which were classified 
as subtype 2 strains by pyrosequencing, an aberrant PCR-RFLP banding pattern was 
found. These strains could therefore not be classified correctly by PCR-RFLP. Because the 
aberrant PCR-RFLP results indicated that these strains harbored variations in their RepMP4-
c and RepMP2/3-d elements (the RepMP elements located in the MPN141 gene), 
these elements were completely sequenced and compared to all known RepMP elements 
by BLAST analysis. While the RepMP4-c elements and RepMP2/3-d elements of both 
strains clearly contained M. pneumoniae subtype 2-specific sequences, novel MPN141 
sequences were found between position 182,226 and 182,310 within RepMP4-c and 
between position 184,491 and 184,751 within RepMP2/3-d. BLAST analysis of the 
‘novel’ sequence within RepMP4-c revealed this sequence to be 100% identical to part 
of the RepMP4-g element of subtype 2 strains. The ‘novel’ sequence within RepMP2/3-d 
was found to be 100% identical, apart from a 12-bp deletion, to sequences from the 
RepMP2/3-a element of subtype 2 strains 14. These results indicated that the RepMP2/3-
d element and RepMP4-c element of strains R1108/01 and R0109/01 were both 
rearranged as a consequence of homologous DNA recombination. Interestingly, the 
rearrangement within the RepMP2/3-d element of these strains was found to be identical 
to that reported for strain 309, which was previously described as a ‘2a’ strain 11. 
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The structures of the RepMP4-c and RepMP2/3-d elements of strains R1108/01 and 
R0109/01 are shown schematically in Fig. 3. This figure also illustrates the consequences 
of the rearrangements within these elements for the P1 amino acid sequences that are 
encoded by the MPN141 genes of strains R1108/01 and R0109/01. The introduc-
tion of RepMP4-g sequences within RepMP4-c resulted in 15 amino acid changes within 
a stretch of 25 amino acids of the P1 protein. As described before for strain 309, the 
changes in RepMP2/3-d resulted in modification of 29 out of 87 amino acids. Thus, the 
rearrangements within RepMP4-c and RepMP2/3-d have a major influence on the amino 
acid sequence of the P1 protein of strains R1108/01 and R0109/01.
To further investigate the nature of the RepMP rearrangements that occurred in strains 
R1108/01 and R0109/01, we determined the sequences of the donor elements that 
were hypothesized to be involved in these DNA rearrangements, i.e. the RepMP4-g and 
RepMP2/3-a elements. The sequences of these elements were found to be identical to 
those of the RepMP4-g and RepMP2/3-a elements from most other subtype 2 strains, 
as determined previously 14. Thus, the novel, aberrant sequences within the MPN141 
genes of both isolate R1108/01 and R0109/01 are hypothesized to be the result 
of unidirectional homologous DNA recombination events. Based on the classification 
scheme of Spuesens et al. 14, the two strains with the novel MPN141 structure, which 
were both isolated in Rotterdam, The Netherlands, can be classified as 2-P1(4-c[g]c; 
2/3-d[a]d) strains.
discUssion
In this study, we have demonstrated that pyrosequencing is highly useful for the genetic 
analysis of M. pneumoniae. Specifically, we showed that pyrosequencing can have 
two important diagnostic applications, i.e. (i) the detection of mutations within the 23S 
rRNA gene that are known to be involved in ML resistance of M. pneumoniae, and (ii) 
the molecular typing (or subtyping) of M. pneumoniae isolates. The main advantages of 
pyrosequencing as opposed to other sequencing protocols are that: (i) the technique is 
rapid; a regular pyrosequencing run will produce results within less than 15 min (irrespec-
tive of the number of samples, with a maximum of 96 samples per run), and (ii) only 
a very short DNA sequence is produced, which can easily be processed, in particular 
when handling a large number of samples. It is also important to note that up to 96 
samples can be sequenced simultaneously on the PyroMark™Q96MD pyrosequencing 
platform and that different sequencing reactions can be analyzed in parallel using a mi-
crotiter plate format. In the current workflow of the microbiological diagnostic laboratory, 
the pyrosequencing assays will generally only be performed after a clinical specimen 
has been tested as M. pneumoniae-positive by both (real-time) PCR and culture. Clearly, 
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the pyrosequencing tests could also be applied directly on DNA purified form clinical 
samples. This, however, will require an increased sensitivity of the PCR reactions that 
precede the actual sequencing steps. Attempts to improve this sensitivity are currently 
underway.
Because ML-resistance is governed by specific mutations in the V domain of the 23S 
rRNA and is not influenced by, for instance, the inactivation and/or efflux of antibiot-
ics, it is appropriate to apply molecular methods in the detection of these mutations. 
Previously, several of these methods have been reported to be suitable for the detection 
of these mutations within the M. pneumoniae genome. These techniques rely either on 
amplification and dideoxy chain termination sequencing of the entire 23S rRNA gene 2 
or on PCR of relatively small parts of the 23S rRNA gene, followed by (high-resolution) 
melt curve analysis 3, 5, 9. Although these techniques are useful, they have significant 
disadvantages. The major disadvantage of the dideoxy sequencing technique is that it is 
rather time-consuming and generates considerably more information than required. The 
drawback of melt curve analysis is that the data can be difficult to interpret, in particular 
in cases where novel mutations have emerged in the 23S rRNA gene. In contrast to 
these techniques, pyrosequencing is a convenient technique that generates unambiguous 
results, as the output is a short DNA sequence. Moreover, the evaluation and interpreta-
tion of the sequence data is performed directly by the PyroMark™ software, and does 
not require any interpretation by the operator of the pyrosequencing machine.
The 23S rRNA 1 and 2 pyrosequencing assays were designed such as to detect all 
mutations known to be involved in ML-resistance. These mutations are localized around 
positions 2065 and 2617 of the 23S rRNA gene. Although two separate pyrosequenc-
ing reactions are required to target these two regions, this is not a problem, because the 
PCR and pyrosequencing reactions were devised such as to employ a universal cycling 
and pyrosequencing protocol. In effect, these two assays only differ in some reaction 
parameters (Table 2), but can be executed in the same PCR and pyrosequencing runs. 
Another advantage of pyrosequencing is that it has the capacity to detect mutations at 
the target sites that differ from all known mutations. Thus, novel point mutations that may 
arise in the future will also be detected by the 23S rRNA 1 and 2 assays.
The recent characterization of all RepMP4 and all Rep2/3 elements in 23 different 
M. pneumoniae isolates has demonstrated that the differences between subtype 1 and 2 
strains are reflected in the sequences of each of these elements 14. Moreover, these differ-
ences are also found outside of the RepMP elements in the M. pneumoniae genome, as 
inferred from the results of bacterial typing studies and the sequences of individual genes, 
such as the MPN528a gene described here. We found this gene to have a subtype-
specific SNP that allowed us to differentiate between subtype 1 and subtype 2 isolates. 
This SNP was therefore found to be an ideal target for a pyrosequencing assay aimed 
at discrimination between the two M. pneumoniae subtypes. Another pyrosequencing 
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assay that we designed, the MPN141 assay, was similarly able to make the distinction 
between subtype 1 and 2 isolates; this assay was directed at a subtype-specific SNP 
within a conserved part of the MPN141 gene. The results obtained with both assays 
correlated with subtyping data obtained using other, conventional molecular methods. 
Both the MPN528a assay and MPN141 assay can therefore be used individually in 
order to conveniently determine the subtype of M. pneumoniae isolates.
It is obvious that the MPN528a and MPN141 subtyping assays are not aimed at 
the identification of rearrangements of RepMP elements, which may give rise to se-
quence variations in the RepMP elements of the MPN141 gene. However, as any of 
the 8 RepMP4 elements and any of the 10 RepMP2/3 elements have the capacity to 
recombine with their counterparts within the MPN141 gene, it is practically unfeasible 
to design a simple assay aimed at the identification of all potential variations within the 
MPN141-localized RepMP elements. These variations can only be identified unambigu-
ously by sequencing the complete RepMP4 and RepMP2/3 elements within the MPN141 
gene (RepMP4-c and RepMP2/3-d, respectively), as discussed previously 14. Again, it is 
important to emphasize that the differentiation between M. pneumoniae isolates on the 
basis of their subtype should be distinguished from the discrimination between isolates 
on the basis of differences within their MPN141-localized RepMP elements 13. This 
notion was stressed again by the finding of two isolates with a novel MPN141 structure. 
While these isolates were readily identified as subtype 2 strains by the MPN528a and 
MPN141 pyrosequencing assays, they were found to have an aberrant structure of the 
MPN141 gene as determined by a PCR-RFLP technique targeted at the MPN141 gene. 
Both strains (R1108/01 and R0109/01) were found to have a novel organization 
within the RepMP4-c element and a known variation (‘2a’) of the RepMP2/3-d element 
of the MPN141 gene. While the RepMP4-c element had acquired sequences derived 
from element RepMP4-g, the RepMP2/3-d element contained sequences derived from 
element RepMP2/3-a 14. This is the first time that RepMP4-g sequences are reported to 
be involved in DNA rearrangement events in M. pneumoniae. This rearrangement further 
represents the second homologous recombination event ever observed in any RepMP4 
element. The first isolate that was identified carrying an ‘aberrant’ sequence within ele-
ment RepMP4-c was strain Mp3896 12, in which sequences from the RepMP4-h element 
were likely transferred to RepMP4-c 12, 14.
The discovery of two strains with yet another, unique configuration of the MPN141 
gene once again demonstrates that the exchange of homologous DNA can occur 
between any two RepMP elements within the M. pneumoniae genome. It is therefore 
likely that novel genotypes will continue to emerge due to inter-RepMP recombination 
events. Consequently, it is not sufficient that assays directed at the determination of the 
‘P1 genotype’ are only capable of detecting known genotypes. Regarding the novel 
recombination events in isolates R1108/01 and R0109/01, it is important to mention 
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that these events appear to be the result of a unidirectional DNA recombination event, 
such as gene conversion. This observation is in line with all other RepMP recombination 
events that have previously been analyzed, which were found to be the result of a 
unidirectional transfer of genetic information 11, 14.
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aBstract
Background
Mycoplasma pneumoniae is thought to be a common cause of respiratory tract infections 
(RTIs) in children. The diagnosis of M. pneumoniae respiratory tract infections currently 
relies on serological methods and/or the detection of bacterial DNA in the upper respira-
tory tract (URT). It is conceivable, however, that these diagnostic methods also yield 
positive results if M. pneumoniae is carried asymptomatically in the URT. Positive results 
from these tests may therefore not always be indicative of a symptomatic infection. The 
existence of asymptomatic carriage with M. pneumoniae has not been established. We 
hypothesized that asymptomatic carriage in children exists and investigated whether 
colonization and symptomatic infection could be differentiated by current diagnostic 
methods.
Methods and findings
This study was conducted at the Erasmus MC-Sophia Children’s Hospital and the out-of-
hours General Practitioners Cooperative (GPC) in Rotterdam, The Netherlands. Asymp-
tomatic children (n = 405) and 321 children with RTI symptoms aged 3 months-16 years 
were enrolled in a cross sectional study from July 2008 – November 2011. Clinical 
data, pharyngeal and nasopharyngeal specimens, and serum samples were collected. 
The primary objective was to differentiate between colonisation and symptomatic infec-
tion with M. pneumoniae by current diagnostic methods, especially real-time PCR. M. 
pneumoniae DNA was detected in 21.2% (95% CI 17.2% - 25.2%) of the asymptomatic 
children and in 16.2% (95% CI 12.2% - 20.2%) of the symptomatic children (p = 0.11). 
Neither serology nor quantitative PCR or culture differentiated asymptomatic carriage 
from infection. A total of 202 children were tested for the presence of other bacterial 
and viral pathogens. Two or more pathogens were found in 56% (63/112) of the 
asymptomatic children and in 55.5% (50/90) of the symptomatic children. Finally, 
longitudinal sampling showed persistence of M. pneumoniae in the URT for up to four 
months. Fifteen of the 21 asymptomatic children and 19 of the 22 symptomatic children 
in this longitudinal follow-up tested negative after one month.
conclusions
Although our study has limitations such as a single study site and limited numbers, our 
data clearly indicate that the presence of M. pneumoniae in the URT is common in 
asymptomatic children. The current diagnostic tests for M. pneumoniae are unable to 
differentiate between asymptomatic carriage and symptomatic infection.
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introdUction
Mycoplasma pneumoniae is considered a major cause of upper and lower respira-
tory tract infections (RTIs) and disease (RTD) in humans, and particularly in children. 
Over one third of the childhood cases of community-acquired pneumonia that require 
hospitalisation are thought to be caused by M. pneumoniae 1, 2. The current diagnosis of 
M. pneumoniae infections relies on the detection of either serum antibodies against M. 
pneumoniae or bacterial DNA in samples of the upper respiratory tract (URT) as recom-
mended in the guidelines published by the British Thoracic Society and the Infectious 
Disease Society of America 1, 2.
PCR based methods are increasingly used in daily clinical practice, as well as in clini-
cal studies for the detection of M. pneumoniae, because they provide fast and sensitive 
results in the acute phase of an infection 3-5. However, RTD caused by other common 
bacterial pathogens (such as Streptococcus pneumoniae) cannot yet be diagnosed by 
PCR, because these pathogens are asymptomatically carried in the human population at 
high rates. Likewise, if M. pneumoniae would be commonly carried asymptomatically in 
the URT of children, the detection of this bacterial species may not indicate a symptomatic 
infection. This would have major implications for the interpretation of the results of cur-
rent diagnostic methods for M. pneumoniae RTIs and their use in clinical management. 
Clinical management of M. pneumoniae RTI in children mainly consists of administration 
of macrolides, because M. pneumoniae is not susceptible to penicillins. In an increasing 
number of countries resistant strains of M. pneumoniae are rapidly emerging, and these 
are associated with prolonged disease. In Asia, up to 90% of M. pneumoniae derived 
from clinical samples is currently macrolide-resistant 6. The frequent use of macrolides in 
children probably contributes significantly to the selection of macrolide-resistant strains 7. 
Decreasing the use of macrolides by better (interpretation of) diagnostic methods might 
therefore help to prevent macrolide resistance.
In contrast to numerous published studies on carriage of S. pneumoniae in children, 
studies that specifically address asymptomatic carriage with M. pneumoniae have 
hitherto not been performed. To our knowledge, this is the first study in which the current 
state of the art diagnostic method for M. pneumoniae, i.e. PCR, is evaluated using a 
symptomatic and an asymptomatic group of children during a three years period of 
sampling. To our knowledge, this is also the first study to investigate the presence of M. 
pneumoniae in both symptomatic and asymptomatic children in a longitudinal fashion, 
including data on the occurrence of symptomatic infection during carriage. Although 
previous studies have reported the presence of M. pneumoniae in seemingly healthy 
individuals, these studies all suffered from drawbacks related to the study design (such 
as the lack of an appropriate control group and/or the lack of a follow-up study), or to 
limitations of the diagnostic assays that were employed 8-15. As a consequence, clear 
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conclusions concerning the existence and dynamics of carriage with M. pneumoniae 
could thus far not be drawn. We hypothesized that asymptomatic carriage in children 
exists and investigated whether colonisation and symptomatic infection could be differ-
entiated by current diagnostic methods. Secondary objectives of the present study were 
to assess the possible association between acute symptomatic M. pneumoniae infection 
and children’s age, and to determine the influence of M. pneumoniae genotype as well 
as viral and bacterial co-infections on the severity of M. pneumoniae RTIs.
Methods
ethics statement
This cross-sectional study was approved by the Medical Ethics Review Board of the 
Erasmus MC (NL20418.078.08) and conducted at the Erasmus MC-Sophia Children’s 
Hospital and the out-of-hours General Practitioners Cooperative (GPC) in Rotterdam, The 
Netherlands. Written informed consent was obtained from all parents and from children 
above the age of 12.
study design and population
Study participants, aged 3 months to 16 years were enrolled between July 2008 and 
November 2011 in two groups. The first group, which will be referred to as ‘the asymp-
tomatic group’, was enrolled during admission for a planned elective surgical procedure, 
unrelated to RTD at the short-stay department of the hospital. Exclusion criteria were a 
current respiratory tract infection (based on questionnaires and physical examination 
by the attending anaesthesiologist), the use of antibiotics in the past two days (seven 
days for azithromycin), and severe concomitant disease (e.g. chronic lung disease, 
cardiovascular disease, neoplasia, liver disease, kidney disease, metabolic disease or 
psychomotor impairment). Baseline characteristics (Table 1) and information about RTIs 
in the previous two months were recorded using a standardized questionnaire. Two 
study-team members collected respiratory and blood samples just prior to the start of the 
surgical procedure while the child was under general anaesthesia. Three to four weeks 
later, a questionnaire was completed by phone on development of respiratory tract 
infections in the weeks after enrolment.
In the second group, i.e. ‘the symptomatic group’, children diagnosed with RTI were 
enrolled at either the Emergency Department (ED) of the hospital or the out-of-hours GPC. 
Exclusion criteria were the same as for the asymptomatic group, except for having a 
current RTI. A standardized questionnaire was used to record baseline characteristics, 
clinical symptoms and diagnosis at discretion of the attending physician. Respiratory 
specimens and a capillary blood sample were collected. Three to four weeks later, a 
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second capillary blood sample was collected and information was recorded about the 
duration of the RTI, treatment and hospitalisation. Children who tested positive for M. 
pneumoniae by PCR were invited to participate in a longitudinal follow-up study, from 
August 2010 to November 2011. After informed consent was obtained, each child was 
tested monthly for the presence of M. pneumoniae in the URT until the test was negative 
on two consecutive occasions.
study procedures
From each child, a pharyngeal swab (BD, BBLTM CultureSwabTM EZ) was taken by gently 
stroking between the palatine arches superior to the tonsils. The swab was stored in 
phosphate-buffered saline. Subsequently, two nasopharyngeal specimens were taken. 
First, a flexible swab (Copan) was inserted into one nostril, guided to the posterior 
nasopharyngeal wall, removed and stored in Amies transport medium. Second, one 
millilitre of normal saline was instilled into each nostril and then suctioned by a flexible 
catheter applied to a container. The catheter was rinsed with two millilitres of normal 
saline. Specimens were kept at 4ºC until further preparation within hours of collection.
To prevent contamination of samples, we took the following precautions. First, the 
two members of the study-team who performed all procedures tested M. pneumoniae 
PCR-negative throughout the study period. Second, samples were prepared and tested 
in different subunits of the laboratory. In a ‘nucleic acid-free’ laboratory, the samples 
were divided in aliquots used for culture, nucleic acid isolation and storage. In other 
table 1. Baseline characteristics of 726 study participants
Asymptomatic group Symptomatic group
Total
N = 405
Total
N = 321
ED
n = 131
GPC
n = 190
Age 5.17 (4.76) 2.65 (3.48) 2.18 (3.38) 2.97 (3.50)
Female 137 (34.1) 155 (48.0) 58 (44.3) 95 (50.0)
Immunisation 383 (96.0) 307 (95.3) 124 (95.4) 183 (96.3)
Parental Smoking 145 (36.4) 132 (41.1) 42 (31.8) 90 (47.6)
Family size ≥ 5 163 (39.6) 74 (23.2) 33 (25.2) 41 (21.6)
Daycare attendance 121 (30.5) 160 (50.5) 75 (58.1) 86 (45.7)
RTI prior 129 (31.5) NA NA NA
LRTI NA 64 (20.4) 38 (29.5) 26 (14.1)
Pneumonia NA 35 (10.9) 27 (20.6) 8 (4.2)
Hospitalisation NA 41 (13.5) 32 (25.2) 9 (5.1)
Data are mean (SD) or n (%). (RTI Respiratory tract infection, ED Emergency Department, GPC General Prac-
titioner Cooperative, AHR Airway hyperresponsiveness, LRTI Lower respiratory tract infection (including pneu-
monia), NA Not applicable). Immunisation refers to the national immunisation program in the Netherlands.
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laboratory subunits, samples were either cultured or used for nucleic acid isolation. Each 
step in the PCR procedure, i.e. the preparation of real-time PCR premixes, the addition of 
purified nucleic acids to these premixes, and the actual PCR reactions, were carried out 
in different laboratories. Finally, each PCR run contained positive and negative controls.
Detection of M. pneumoniae in the URT was performed by real-time PCR and culture 
on both the pharyngeal swabs and the nasopharyngeal washings. DNA isolation was 
performed on 200 µl of the original samples using the QIAamp DNA mini kit (QIAGEN). 
A quantitative real-time (TaqMan®) PCR assay was used to detect and quantify M. 
pneumoniae genomic DNA, as described 16. Adequate negative control samples were 
included in each PCR run. Culture was performed using 100 µl of the original sample 
17. Molecular (sub)typing of M. pneumoniae was performed on M. pneumoniae-positive 
samples, using a pyrosequencing-based assay 16. Rest material was stored at -80ºC until 
further use.
Serum was stored at -80ºC. Detection of anti-M. pneumoniae-specific antibodies was 
performed using Serion ELISA classic M. pneumoniae kits (Clindia Benelux).
The nasopharyngeal swabs were used for the detection of S. pneumoniae, Staphylo-
coccus aureus, Haemophilus influenzae and Moraxella catarrhalis, following standard 
microbiological procedures 18.
The batch-wise detection of viral nucleic acids was performed after the enrolment 
was closed. As all samples were stored at -80ºC, selected samples were thawed. For 
the detection of viral nucleic acids, 60 µl of the original sample from a pharyngeal 
swab was diluted 10-fold with Dulbecco’s Modified Eagle Medium to a total of 600 µl. 
Internally controlled nucleic acid extraction (input volume 200ul, output volume 100ul), 
subsequent (multiplex) real-time PCRs and its quality control were performed as described 
before 19. A cycle threshold below 40 was considered a positive result. These viruses 
were determined in all M. pneumoniae PCR-positive children and in M. pneumoniae 
PCR-negative children matched with respect to month and year of sampling as well as 
age. Of 30 M. pneumoniae-positive participants, material was unavailable and could 
therefore not be included in this analysis.
outcome variables and statistical analyses
All data were analysed using software package SPSS version 16.0.1. The protocol-
defined objectives were: (1) to determine the distribution of genomic copy loads in 
both the asymptomatic group and the symptomatic group to differentiate carriage from 
infection and (2) to assess age distribution of the presence of M. pneumoniae in both 
symptomatic children and asymptomatic children, and to determine the influence of M. 
pneumoniae genotype as well as viral and bacterial co-infections on the severity of M. 
pneumoniae RTIs.
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The prevalence of a positive test result for M. pneumoniae was calculated in both 
groups and compared using the χ2 test. Groups were compared for the distribution of 
bacterial loads (genomic copy number) using the Mann-Whitney U test. P-values below 
0.05 were considered significant. Within the symptomatic group, a child was defined as 
having a M. pneumoniae infection when at least one of the samples from this child was 
found to be M. pneumoniae-positive by serology, culture or PCR. Within the asymptom-
atic group, M. pneumoniae carriage was defined by a M. pneumoniae-positive result 
obtained by either culture or PCR.
The children in the symptomatic group with a M. pneumoniae infection were divided 
into two groups carrying the two M. pneumoniae subtypes (i.e. subtype 1 and subtype 
2), and into two groups according to the presence of co-infections. Diagnosis (upper or 
lower RTI) and hospitalisation were used as proxies for severity of disease. Groups were 
compared for these variables using the χ2 test.
To identify possible factors that could determine the presence of M. pneumoniae, 
subgroup analyses were done for variables that could reasonably have an effect on M. 
pneumoniae prevalence including age, gender, season and year of enrolment, family 
size, active or passive smoking and day-care attendance. Additional variables in the 
symptomatic group were: diagnosis and hospitalisation. Additional variables in the 
asymptomatic group were: RTI prior to enrolment, or just following enrolment. These 
variables were entered in multiple logistic regression analysis regardless of their bivariate 
association. Because these were all exploratory analyses, we did not adjust for multiple 
comparisons. To test for collinearity we calculated condition indices (CI) for the multivari-
ate analyses. We found a CI of 9.9 for the asymptomatic group and a CI of 12.1 for 
the symptomatic group. Because both values are below the generally accepted warning 
signal of 15, and there were no strong correlations between the covariates, we believe 
that multicollinearity was not a major problem in this study.
To allow the inclusion of a sufficiently high number of M. pneumoniae-infected children 
below the age of five, we used a pre-calculated sample size of 400 children ≤5 years 
and 100 children >5 years in the symptomatic group based on an estimated prevalence 
of M. pneumoniae of 10%. In the asymptomatic group we took the same number. After 
enrolment of a total of 412 children in the asymptomatic group, it was apparent that 
the study question on the existence of carriage could be addressed. This was due to a 
higher prevalence of M. pneumoniae than anticipated in the asymptomatic group, and 
in the symptomatic group. Because additional enrolments would not have a significant 
influence on these outcomes of the study, it was deemed unethical to subject additional 
children to the study and the enrolment was subsequently discontinued.
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resUlts
726 children, aged 3 months to 16 years, were enrolled in this study from July 2008 
until November 2011 (Figure 1 and 2). 405 children were enrolled in the asymptomatic 
group. Enrolment for this group started in January 2009. In the symptomatic group, 
321 children were enrolled. On the basis of age, sex or time of enrolment of study 
participants, there were no differences between the group for which consent was given 
and the group for which consent was not given (Table S1).
We found that the prevalence of M. pneumoniae by real-time PCR did not differ 
significantly (p = 0.11) between the asymptomatic group (21.2%, 95% CI 17.2% - 
25.2%, n=85) and the symptomatic group (16.2%, 95% CI 12.2% - 20.2%, n=51). A 
significant difference between the groups was also not found by culture; 4 (1.0%, 95% 
CI 0.03% - 1,97%) of the asymptomatic children and 5 (1.6%, 95% CI 0.23% - 2.97%) 
of the symptomatic children were M. pneumoniae-positive (p = 0.52). In the symptomatic 
group, the prevalence of M. pneumoniae by real-time PCR did not differ significantly (p 
= 0.85) between the children with a lower RTI (15.6%, 95% CI 11.6% - 19.6%, n=10) 
and the children with an upper RTI (15.9%, 95% CI 11.9% - 19.9%, n=41).
In the asymptomatic group, multiple logistic regression analysis showed that season and 
year of enrolment were significantly related to prevalence of M. pneumoniae (Table 2). In 
the symptomatic group, we found the presence of M. pneumoniae to be positively associ-
ated with enrolment in 2010 and 2011. As shown in table 3 none of the variables were 
independently related to the prevalence of M. pneumoniae. The presence of M. pneumoniae 
206 children screened
133 children enrolled
73 children excluded
53 no informed consent
18 not eligible
  2 logistical problems
2 children excluded
2 withdrawn informed 
consent
131 children
    3 incomplete specimens
  22 incomplete study
524 children screened
190 children enrolled
334 children excluded
216 no informed consent
  63 not eligible
  14 physicians choice
  41 logistical problems
190 children
    4 incomplete specimens
    8 incomplete study
790 children screened
412 children enrolled
378 children excluded
230 no informed consent
  26 not eligible
  94 admission cancelled
  28 logistical problems
7 children excluded
2 not eligible
1 admission cancelled
4 logistical problems
405 children
  39 incomplete specimens
Symptomatic group - ED Symptomatic group - GPC Asymptomatic group 
figure 1. Enrolment flow diagram
Emergency Department (ED). General Practitioners Cooperative (GPC).
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was not significantly associated with age or asthma-like symptoms (Tables 2 and 3). The two 
subtypes of M. pneumoniae were equally distributed between the two groups (Table S4).
A similar distribution of M. pneumoniae DNA loads was observed among the as-
ymptomatic and symptomatic children (Figure 3A and B). We did not find a significant 
correlation between bacterial load in nasopharyngeal and pharyngeal samples (Figure 
3C). The distribution of bacterial loads was different among children with a lower RTI 
and children with an upper RTI (Figure 3D and 3E). However, both very high and very 
low bacterial loads were detected in both subgroups. The study was not powered to 
perform a statistical subgroup analysis for this item.
To investigate how long M. pneumoniae can persist in the respiratory tract of children, 
a longitudinal follow-up study was performed. In this study, 43 (68%) of the 63 children 
who were eligible for inclusion participated in the follow-up study. Of these 43 children, 
21 children originated from the asymptomatic group and 22 from the symptomatic group.
The most important reason not to participate in the follow-up study was distance from 
home to the study site (10/20 (50%)). 15 of the 21 (71%) asymptomatic children and 
19 of the 22 (86%) symptomatic children in this longitudinal follow-up study tested nega-
tive after one month. Six of the asymptomatic children also tested positive at 2 months 
and 2 children also tested positive at 3 months. Three of the symptomatic children tested 
positive at 2 months and none tested positive at 3 months (Figure 4). To confirm their 
negative status, children were tested an additional time after becoming negative.
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figure 2. Monthly enrolments during the course of the study
The enrolments for the symptomatic group are represented in the upper panel of the figure by a red dotted 
line. The enrolments for the asymptomatic group are represented in the lower panel by a blue dotted line. 
The straight lines in the respective panels represent the absolute number of M. pneumoniae positive partici-
pants. Enrolment for the asymptomatic group started in January 2009.
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table 2. Results from the multiple logistic regression analysis for a positive M. pneumoniae PCR in the 
asymptomatic group
Odds ratio (95% CI) P-value
Age (≥ 5) 0,96 (0,47-1,96) 0,91
Gender (girl) 1,44 (0,81-2,56) 0,22
Season <0,001 (overall)
Spring vs. Winter 0,81 (0,33-1,97) 0,64
Summer vs. Winter 7,43 (3,09-17,85) <0,001
Autumn vs. Winter 2,90 (1,26-6,70) 0,01
Year (2009 versus 2010 and 2011) 3,31 (1,75-6,27) <0,001
Family size (≥ 5 family members) 1,55 (0,77-3,13) 0,22
Smoking (active or passive) 0,70 (0,38-1,26) 0,23
Presence or history of wheezing 2,30 (0,69-7,61) 0,17
Daycare attendance 0,82 (0,38-1,77) 0,62
RTI prior enrolment 0,95 (0,50-1,79) 0,86
RTI post enrolment 0,59 (0,29-1,20) 0,15
RTI Respiratory tract infection. The variable ‘Immunisations’ was not entered in the regression analysis be-
cause the vast majority of the children were immunized (> 95%).
table 3. Results from the multiple logistic regression analysis for a positive M. pneumoniae PCR in the 
symptomatic group
Odds ratio (95% CI) P-value
Age (≥ 5 years) 1,56 (0,604-4,02) 0,36
Gender (girl) 0,93 (0,46-1,87) 0,84
Season 0,87 (overall)
Spring vs. Winter 0,80 (0,35-1,81) 0,59
Summer vs. Winter 0,54 (0,11-2,67) 0,45
Autumn vs. Winter 0,85 (0,39-2,16) 0,74
Year (2009 versus 2010 and 2011) 5,80 (1,94-17,35) 0,002
Family size (≥ 5 family members) 1,63 (0,74-3,61) 0,23
Smoking (active or passive) 0,61 (0,30-1,23) 0,17
Presence or history of wheezing 1,96 (0,93-4,13) 0,08
Daycare attendance 0,84 (0,37-1,89) 0,67
Diagnosis (LRTI) 1,05 (0,46-2,42) 0,91
Hospitalisation 1,54 (0,52-4,60) 0,44
LRTI Lower respiratory tract infection. The variable ‘Immunisations’ was not entered in the regression analysis 
because the vast majority of the children were immunized (> 95%). Symptoms and signs were not entered 
in the regression analysis because these are represented in the variable ‘Diagnosis’.
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We found that the prevalence of a positive ELISA for anti-M. pneumoniae IgM antibod-
ies was not significantly different in the asymptomatic group (12.6%, 95% CI: 9.4% 
- 15.8%, n=43) and the symptomatic group (9.2%, 95% CI: 6.0% - 12.4%, n=26) (p 
= 0.23). The prevalence of a positive ELISA for anti-M. pneumoniae IgG antibodies 
differed significantly (p <0.001) between the asymptomatic group (25.1%, 95% CI: 
20.9% - 29.3%, n=85) and the symptomatic group (14.2%, 95% CI: 10.4% - 18.0%, 
n=40). However, when adjusted for age, there was no significant difference in the 
prevalence of anti-M. pneumoniae antibodies between the two groups. The prevalence 
of a positive ELISA for anti-M. pneumoniae IgM and IgG was low among children 
below the age of five (7.3%, 95% CI: 3.5% - 11.1% and 8.3%, 95% CI: 4.3% - 12.3%) 
in the asymptomatic group vs. 6.7%, 95% CI: 0.0% - 13.4% and 5.0%, 95% CI: 
0.0% - 5.9% in the symptomatic group) and much higher among children above the 
age of five (20.4%, 95% CI: 14.1% - 26.7% and 50.7%, 95% CI: 42.8% - 58.5% 
A      Pharyngeal B          Nasopharyngeal C
D      Pharyngeal E          Nasopharyngeal
figure 3. M. pneumoniae DNA loads
In panel A the pharyngeal bacterial loads (Genomic copy number per millilitre on the y-axis) of M. pneu-
moniae PCR-positive participants in the asymptomatic group (indicated by open squares) and the symptom-
atic group (indicated by filled triangles) are represented. In panel B the nasopharyngeal bacterial loads 
(Genomic copy number per millilitre on the y-axis) of M. pneumoniae PCR-positive participants in the asymp-
tomatic group and the symptomatic group are shown. The bacterial load distribution was compared using 
the Mann-Whitney U test. Panel C shows the comparison of the bacterial loads in pharyngeal samples and 
nasopharyngeal samples for the participants that were positive in both. Correlation was calculated using the 
Spearman rank test. In panel D and E, the distribution of bacterial loads is shown for upper and lower RTIs 
in the pharyngeal and nasopharyngeal samples. The horizontal line in each graph represents the median.
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in the asymptomatic group and 11.9%, 95% CI: 7.7% - 16.1% and 47.6%, 95% CI: 
41.1% - 54.1% in the symptomatic group).
The median levels of IgM- and IgG-antibodies did not differ significantly between 
the two groups (Figures 5A and 5B). The prevalence of a positive ELISA for anti-M. 
pneumoniae IgA antibodies was very low in both groups (2.0%, 95% CI 0.6% - 3.4% vs. 
A Asymptomatic B Symptomatic
= =
figure 4. M. pneumoniae DNA loads in the longitudinal study.
The bacterial DNA loads in the study participants during the follow-up study. In panel A, each open square 
represents one visit of one participant and is connected by a line to the square representing the next visit. 
On the y-axis the bacterial DNA load (Genomic copy number per millilitre) is shown. On the x-axis the 
consecutive visits are represented. Panel B shows the bacterial DNA loads for the symptomatic group. Each 
filled triangle represents one participant on one single time-point.
table 4. Agreement between PCR and serology
Asymptomatic Symptomatic
PCR Kappa PCR Kappa
Positive Negative Positive Negative
Serology IgM
Positive 11 32 7 13
Negative 55 242 0.06 40 215 0.12
Serology IgA
Positive 4 3 0 1
Negative 62 271 0.08 46 224 -0.01
Serology IgG
Positive 16 68 6 25
Negative 50 203 -0.01 41 202 0.02
Immunoglobulin class switch
Positive NA NA 7 19
Negative NA NA 31 176 0.10
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0.4%, 95% CI 0.0% - 1.1%), and none of the children below the age of five tested posi-
tive for anti-M. pneumoniae IgA. The serological data did not correspond significantly 
with the PCR results (Figures 5C, 5D and Table 4). Interestingly, a higher percentage 
of asymptomatic PCR-positive children tested positive for IgG compared to symptomatic 
PCR-positive children (Table 4: 32% vs. 15%). However, this difference was not found to 
be statistically significant when adjusted for age.
A IgM B IgG
C IgM D IgG
figure 5. Anti-M. pneumoniae serum antibody levels.
Serum IgM (panel A) and IgG (panel B) antibody levels (in U/ml) are compared between the asymptomatic 
group and the symptomatic group (using the Mann-Whitney U test). In panel C and D, IgM and IgG anti-
body levels, respectively, are plotted against the bacterial DNA load (Genomic copy number per millilitre) 
in all samples. Open squares indicate asymptomatic participants. Filled triangles indicate symptomatic 
participants. The horizontal line in each graph represents the median.
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Because an immunoglobulin class-switch from IgM to IgG is generally accepted as 
evidence for a recent M. pneumoniae infection, a second serum sample was collected 
from 233 (72.6%) of the symptomatic children. From this group, 26 (11.2 %) children 
developed an immunoglobulin class switch. The agreement between an immunoglobulin 
class switch and a positive PCR result was poor (Kappa = 0.10) (Table 4). Besides age, 
we did not find any determinants of an immunoglobulin class switch or a single positive 
test for IgM, IgG or IgA.
Bacterial and viral pathogens do co-exist in the respiratory tract and co-infection may 
influence severity of disease. Therefore, we determined the presence of 4 other bacterial 
respiratory pathogens in all children and the presence of 15 viral respiratory pathogens 
in a selection of the children (n = 202). Two or more pathogens were found in 56% 
(63/112) of the asymptomatic children and in 55.5% (50/90) of the symptomatic 
children. The prevalence of the four bacterial pathogens is shown in Table 5. As reported 
previously, the prevalence of these bacterial species was largely age-dependent 20. We 
found a significant higher prevalence of S. aureus in the asymptomatic group compared 
to the symptomatic group. However, when adjusted for age this difference in prevalence 
was not significant. An association between the presence of any of these four bacterial 
species and M. pneumoniae was not detected. Almost all the viruses screened for were 
detected in both groups (Table 6).
We did not perform a statistical analysis to detect differences in the distribution of 
Ct-values since our study was not powered for this purpose. Rhinovirus, bocavirus and 
parainfluenzavirus 4 were detected more frequently in asymptomatic children than in 
symptomatic children. In contrast, Influenzaviruses A and B, hMPV and RSV were predomi-
nantly detected in symptomatic children. The majority of the children (from both groups) 
tested positive for more than one pathogen (Figure 6). Group-specific combinations of 
pathogens could not be identified. In addition, none of the viruses were associated with 
the presence of M. pneumoniae. Due to the limited number of M. pneumoniae-positive 
children without bacterial and/or viral co-infection it was not possible to analyse the 
influence of bacterial and viral co-infection on disease severity.
table 5. Bacterial results in 714 study participants
Asymptomatic Symptomatic P-value
Bacterium N = 393 N = 321
S. pneumoniae 109 (27.7) 87 (27.1) 0.92
S. aureus 84 (21.4) 32 (10.0) <0.001*
M. cattharalis 71 (18.1) 74 (23.1) 0.12
H. influenzae 57 (14.5) 51 (15.9) 0.68
Data are n (%). The p-values compare the difference in prevalence between the two groups indicated by 
χ2-test. p<0.05 is considered a significant difference (indicated by *).
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figure 6. Number of detected viral and bacterial pathogens
The dot plot shows the percentages of participants with 0 to 3, or more than 3 pathogens present in the 
upper respiratory tract. On the x-axis the percentages are shown, on the y-axis the number of pathogens is 
shown. The filled and open triangles show respectively the M. pneumoniae (Mpn) PCR positive symptomatic 
children (n = 44) and the M. pneumoniae PCR negative symptomatic children (n = 46). The filled and open 
squares show respectively the M. pneumoniae PCR positive asymptomatic children (n =57) and the M. 
pneumoniae PCR negative asymptomatic children (n = 52).
table 6. Virology results in 202 study participants
Virus
Asymptomatic Symptomatic
Ct-value, Median 
(IQR)
N = 112 Ct-value, Median 
(IQR)
N = 90 P-value
Influenza A virus 20.1 1 (0.9) 23.0 (18.0-33.8) 6 (6.7) 0.03*
Influenza B virus Undetectable 0 (0.0) 26.0 1 (1.1) 0.26
hMPV 36.7-38.7 2 (1.8) 24.6 (23.0-30.5) 7 (7.8) 0.10
RSV A 27.9 1 (0.9) 22.0 (20.0-29.6) 11 (12.2) 0.001*
RSV B 35.4 1 (0.9) 22.0 (17.3-29.5) 9 (10.0) 0.003*
Parainfluenzavirus 1 36.3 (22.0-37.6) 7 (6.3) 25.3 (20.0-26.5) 3 (3.3) 0.34
Parainfluenzavirus 2 35.8 (34.6-35.9) 3 (2.7) 31.1 1 (1.1) 0.43
Parainfluenzavirus 3 20.7, 35.8 2 (1.8) 30.6 (25.1-39.6) 3 (3.3) 0.48
Parainfluenzavirus 4 36.5 (31.9-37.4) 10 (8.9) 38.7 1 (1.1) 0.02*
Rhinovirus 26.5 (23.1-31.1) 35 (31.2) 24.7 (22.3-29.4) 17 (18.9) 0.04*
Coronavirus 229E Undetectable 0 (0.0) 17.6 1 (1.1) 0.26
Coronavirus OC43 35.6 (28.7-37.3) 5 (4.5) 29.0 (24.1-32.9) 5 (5.6) 0.72
Coronavirus NL63 37.5 (34.8-38.6) 6 (5.4) 27.5 (27.0-38.0) 7 (7.8) 0.49
Bocavirus 30.9 (26.5-34.0) 16 (14.3) 32.0 (28.8-34.0) 3 (3.3) 0.008*
Adenovirus 31.9 (27.9-33.8) 17 (15.2) 27.0 (26.2-30.5) 9 (10.0) 0.28
Data are n (%). The p-values compare the difference in prevalence between the two groups indicated by 
χ2-test. p<0.05 is considered a significant difference (indicated by *). IQR Inter-quartile range, Ct-value 
Cycle threshold value.
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discUssion
statement principal findings
To our knowledge, our study demonstrates for the first time that M. pneumoniae is car-
ried at high rates in the URT of healthy children, and that this asymptomatic carriage 
cannot be differentiated from symptomatic RTI by serology or quantitative PCR. 21% 
of 405 healthy children tested positive for M. pneumoniae in the URT by PCR. As a 
result of this high prevalence, the inclusion of children was terminated at an earlier 
time-point than anticipated at the start of the study. For now we can conclude that M. 
pneumoniae carriage is detectable and its prevalence is higher than expected, but the 
actual prevalence of carriage is unreliable. Prevalence varied between year and season 
of sampling from 3% during the spring of 2009 to 58% during the summer of 2010. 
These data suggested that carriage follows a cyclic epidemic pattern. It is tempting 
to speculate that this fluctuation in prevalence is related to the known cyclic epidemic 
pattern of M. pneumoniae infections that occurs at 3-7 year intervals, in addition to 
a background endemic pattern 4, 21. Longitudinal sampling of M. pneumoniae-positive 
asymptomatic children indicated that M. pneumoniae can be present in the URT without 
causing disease, followed by clearance within several weeks.
While previous studies have demonstrated the presence of M. pneumoniae in seem-
ingly healthy individuals, none of these studies could draw clear conclusions concerning 
the actual existence of carriage of M. pneumoniae 8-15. Instead, some studies explained 
the presence of M. pneumoniae in an asymptomatic individual as a consequence of a 
recent infection with this bacterium 14, 15. Other studies were inconclusive due to lack of 
a specific study design or due to the use of relatively insensitive diagnostic tools such as 
culture 9-12.
strengths and weaknesses
Although we have demonstrated the existence of asymptomatic carriage with M. pneu-
moniae in children, there are several limitations to our study. These include the single 
study site at one city in the Netherlands and a limited sample size. Although the sample 
size was adequate to address our research questions, it is not large enough to unravel 
the dynamics of colonisation by M. pneumoniae. Furthermore, we performed exploratory 
analyses that show that M. pneumoniae prevalence is determined by season and year of 
sampling, although these analyses did not form part of the original design of the study. 
Finally, we have performed a longitudinal follow-up study that shows the persistence 
of M. pneumoniae in a small number of children for up to four months. Although this 
strongly suggests the existence of carriage, we only enrolled a small number of children 
in this part of the study. Future studies are needed to confirm our results and should aim at 
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finding determinants of M. pneumoniae carriage. These studies should preferably have 
a multicenter design.
Furthermore, we aimed to assess the association between severity of disease and M. 
pneumoniae subtype and genomic copy load. Although we did not find this association 
in the symptomatic group, it should be noted that M. pneumoniae subtype 2 positive 
participants were underrepresented overall (as shown in Table S4). This small number 
hampered the analysis of this secondary research question. It might also be argued 
that these results are negatively influenced by a general low severity of disease in our 
study population and the limited number of participants with lower RTI (20.9 % of all 
symptomatic children). Indeed, none of our children were admitted to an intensive care 
unit or required respiratory support by mechanical ventilation. Still, we did find a differ-
ence between asymptomatic and symptomatic children for well-established respiratory 
pathogens such as influenza A and RSV. We feel that this underlines the appropriateness 
of our study population with regard to severity.
In agreement with recent other studies on M. pneumoniae infections, a poor correlation 
was found between data obtained by PCR and serology 22, 23. Given the excellent 
performance of the PCR assay in Quality Control for Molecular Diagnostics (QCMD) 
panels, and the validation of the commercial ELISA used, we are confident that the 
data obtained by both assays are reliable. It is possible that the positive serological 
results simply reflect one or more previous encounters with M. pneumoniae and are not 
necessarily related to a current RTI or carriage of M. pneumoniae as determined by PCR. 
However, we have not collected convalescent serum samples in the asymptomatic group, 
therefore we can only speculate on the prevalence of immunoglobulin class switch or the 
levels of convalescent antibodies in this group.
Meaning of the study
As the pathogenicity of M. pneumoniae has been well-documented in studies with volun-
teers in the 1950s 24, one can speculate that asymptomatic carriage of M. pneumoniae 
may in some cases lead to symptomatic infection as is well known for other pathogens 25. 
Obviously, the finding of asymptomatic carriage of M. pneumoniae has major implica-
tions for the interpretation of the diagnosis of M. pneumoniae infections and its impact for 
clinical management, as well as the interpretation of studies on the aetiology of RTD in 
children. We searched Medline with the terms ‘Mycoplasma pneumoniae’, ‘respiratory 
tract infection’, ‘asymptomatic carriage’ and ‘diagnosis’ and found that many studies and 
some reviews have addressed the performance and clinical value of different diagnostic 
methods for M. pneumoniae. It is striking, however, that these methods are used inter-
changeably and almost each positive result is regarded as indicative for a symptomatic 
M. pneumoniae infection. In addition, the occasional presence of M. pneumoniae 
in respiratory secretions of healthy individuals has often been explained either as the 
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first sign of a developing symptomatic infection or as bacterial persistence following 
symptomatic infection 3, 11, 26-28. Current guidelines on community-acquired pneumonia 
recommend testing for M. pneumoniae in patients with a high pre-test probability 1, 2. 
As we have shown, the available procedures for diagnosis of M. pneumoniae RTIs in 
children do not discriminate between carriage of M. pneumoniae in the respiratory tract 
and symptomatic M. pneumoniae infection. Therefore we may have to re-address the 
clinical significance of a positive test result.
Our data indicate that the aetiology of RTI in children is complex. The mere presence 
of one or more putative pathogens in the URT does not seem to be the sole determining 
factor in the development of a symptomatic RTI. The host immune response, the timing of 
colonization, the presence of other pathogens and the initial bacterial or viral load may 
collectively determine whether carriage proceeds to infection or not. Future studies will 
therefore have to focus on how an RTI can be accurately defined and whether or not it 
requires treatment.
conclusion and future studies
The results of this study suggest that M. pneumoniae behaves similar to many other 
bacterial species in the respiratory tract. Future studies at different sites and in different 
populations are required to confirm our findings. This is important because these findings 
imply that the daily clinical practice of diagnosing M. pneumoniae RTI is not adequate. 
Specifically, it does not seem appropriate to use the detection of M. pneumoniae in the 
URT by PCR as a method to diagnose symptomatic RTIs caused by this bacterium. Thus, 
M. pneumoniae-induced RTD can not be based exclusively on serology or the detection 
of M. pneumoniae DNA in the URT, and caution should be taken in the interpretation of 
diagnostic tests for M. pneumoniae. Future studies should address this diagnostic chal-
lenge and aim at finding diagnostic tools that can differentiate carriage from infection 
as well as the factors that may determine progression from asymptomatic carriage of M. 
pneumoniae to symptomatic infection.
sUpportive inforMation (online availaBle on WWW.
plosMedicine.org)
Table S1. This table shows the comparison between the children for which consent was 
given (enrolled in the study) and the children for which consent was not given.
Table S2. In this table the results are shown from the bivariate analysis in the asymptom-
atic group. The table shows the prevalence of M. pneumoniae as determined by PCR for 
the variables age, gender, immunisations, season of enrolment, year of enrolment, family 
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size, smoking, presence or history of wheezing, day-care attendance, respiratory tract 
infections prior to enrolment and respiratory tract infection in the month after enrolment.
Table S3. In this table the results are shown from the bivariate analysis in the symptom-
atic group. The table shows the prevalence of M. pneumoniae as determined by PCR for 
the variables age, gender, immunisations, season of enrolment, year of enrolment, family 
size, smoking, presence or history of wheezing, day-care attendance, symptoms present 
at the time of enrolment, diagnosis (presence of a lower respiratory tract infection) and 
hospitalisation.
Table S4. The distribution of the different genotypes (i.e. subtype 1 and 2) in the 
asymptomatic and symptomatic group is shown.
Text S1. Study protocol, online available.
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aBstract
Mycoplasma pneumoniae is a common cause of respiratory tract infections (RTI) in 
children. We recently demonstrated that this bacterium can be carried asymptomatically 
in the respiratory tract of children. To identify potential genetic differences between M. 
pneumoniae strains that are carried asymptomatically and those that cause symptomatic 
infections, we performed whole-genome sequence analysis of 20 M. pneumoniae strains. 
The analyzed strains included 3 reference strains, 3 strains isolated from asymptomatic 
children, 13 strains isolated from clinically well defined patients suffering from an upper 
(n=4) or lower (n=9) RTI and one strain isolated from a follow-up patient who recently 
recovered from an RTI. The obtained sequences were each compared to the sequences 
of the reference strains. To find differences between strains isolated from asymptomatic 
and symptomatic individuals, a variant comparison was performed between the differ-
ent groups of strains. Irrespective of the group (asymptomatic versus symptomatic) from 
which the strains originated, subtype 1 strains formed a separated cluster from subtype 
2 strains. We could not identify a specific genotype associated with M. pneumoniae 
virulence. However, we found marked genetic differences between clinical isolates and 
the reference strains, which indicates that the latter strains may not be regarded as 
appropriate representatives of circulating M. pneumoniae strains.
BacKgroUnd
Mycoplasma pneumoniae is a human bacterial pathogen that has been estimated to 
cause pneumonia in up to 40% of children hospitalized because of community-acquired 
pneumonia 1. A recent study has shown that this bacterium can also be carried as-
ymptomatically: M. pneumoniae was detected in the upper respiratory tract of 21% of 
children that did not show any signs of a respiratory tract infection (RTI) 2. The finding of 
asymptomatic carriage of a potential bacterial or viral pathogen is a well known, and 
common phenomenon in the general population. Other pathogens, such as Streptococ-
cus pneumoniae, Staphylococcus Aureus, and Rhinovirus, can cause RTIs, but can also 
be carried asymptomatically. Clearly, it is important to identify the determining factors, 
both from pathogen and host, involved either in the control of an asympomatic carriage 
status or in triggering symptomatic infection. In the case of S. pneumoniae, specific 
bacterial gene clusters were found to be associated with invasive disease 3. In contrast, 
genes associated with carriage and/or pathogenicity have not yet been identified in M. 
pneumoniae. Moreover, little is known about the genetic variability of clinical isolates of 
M. pneumoniae and the relationship between bacterial genotype and virulence.
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Until a few years ago, only a single genome sequence was available for M. 
pneumoniae4. This sequence was derived from laboratory strain M129. Since 2013, 
several other genomic sequences have been published 5-7. Most of these sequences were 
obtained in two independent studies. One of these studies reported the comparative 
genome analysis of 15 M. pneumoniae strains isolated form respiratory tract samples 
and cerebrospinal fluid samples collected from patients between 1940 and 2009 in the 
USA, China and England 5. The other study reported the sequences of 23 clinical M. 
pneumoniae strains isolated between 1964 and 2011 in six different countries 6.
Despite the availability of a significant set of M. pneumoniae genome sequences, 
it is currently difficult to determine the association between M. pneumoniae genotype 
and virulence. This is mainly due to the fact that all known M. pneumoniae sequences 
were exclusively obtained from strains isolated from patients with RTI symptoms. Clearly, 
this precludes determination of the putative genetic differences between strains causing 
symptomatic infections and strains carried by asymptomatic individuals. The recent isola-
tion of a set of M. pneumoniae strains from both asymptomatic children and children 
suffering from RTI 2, however, allows a direct comparison of the genetic make-up of 
strains associated with bacterial carriage and those involved in symptomatic infection. 
We therefore set out to determine the genome sequence of 3 reference strains (M129, 
FH and R003), 3 strains from asymptomatic individuals, and 13 strains from clinically 
well-defined patients suffering from either an upper or lower RTI. The analysis and com-
parison of the obtained sequences did not reveal a specific genotype associated with M. 
pneumoniae virulence. However, we did find striking differences between the genomes 
of clinical isolates and those of the M. pneumoniae reference strains.
Methods and Materials
patient samples
Most of the patient samples were collected as part of a clinical study designed to investi-
gate the existence of M. pneumoniae asymptomatic carriage in children 2. This study was 
carried out in Rotterdam, the Netherlands between 2008 and 2012. Patient information 
was collected and documented prospectively as part of the study. All M. pneumoniae 
culture positive samples from the different groups (asymptomatic, symptomatic, and 
follow-up group) were selected for analysis as part of this study. The other samples from 
symptomatic patients were collected by the Regional Laboratory of Public Health Ken-
nemerland, Haarlem, The Netherlands, and kindly provided for analysis. These samples 
were taken from patients with suspected M. pneumoniae infection as part of the medical 
work-up ordered by the treating physician. All samples with a positive culture for M. 
pneumoniae were selected and used in this study. The Medical Ethics Review Board of 
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the Erasmus MC approved the study on asymptomatic carriage (NL20418.078.08) and 
written informed consent was obstained in this study from all parents and children above 
the age of 12 years. The Medical Ethics Review Board of the Erasmus MC approved the 
use of the samples collected during routine medical work-up in the Regional Laboratory 
of Public Health Kennemerland (MEC 2013-344).
culture and dna isolation
Culture was performed in the laboratory of pediatrics of the Erasmus MC, as previously 
described 8. In short, 100 µl original sample and 10-fold dilutions were used for cultur-
ing. Culturing was performed in Mycoplasma medium containing 1.4% DifcoTM PPLO 
broth (Becton Dickinson), 0.15% DifcoTM TC Yeastolate, UF (Becton Dickinson), 1.4% 
glucose, 20% horse serum, 1,000 U/ml Penicillin G, 500 U/ml Polymyxine B, and 
0.02 mg/ml phenol red. The pH of the medium was adjusted to 7.8-8.0 using a solution 
of 2 N NaOH, followed by filter-sterilization. Strains were grown in 3 ml of medium 
at 37oC/5% CO2 in 25 cm2 tissue culture flasks (Greiner). Cells were harvested upon 
color change of the medium (from red/orange to yellow). DNA was isolated form the 
harvested cells as described previously 9.
sequencing, de novo assembly and scaffold alignment
The sequencing of all strains including re-sequencing of the reference strains was per-
formed at the Center for Biomics of Erasmus MC using next-generation sequencing on 
a HiSeq2000 platform from Illumina. A paired-end 100-bp sequencing protocol was 
used. Between 0.9 and 2.5 gigabases of DNA sequence was generated for each of the 
isolates. Thus, a 1,224- to 3,300-fold genome coverage was obtained.
Reads were purged from the Illumina sequence adapter and renamed according to the 
standards expected by Abyss (Software Abyss 1.3.4). After the initial processing, Abyss 
was run for each of the samples individually. This resulted in files containing unitigs, 
contigs and scaffolds. The unitig files hold the assemblies that were generated without 
taking the pair information into account. The contigs are the assemblies generated with 
the pair information taken into account. Scaffolds are the contigs after being merged 
based on read pairs, and differ from the contigs as they may contain unresolved repeats. 
For all downstream analysis, the scaffolds with a minimum PHRED score of 30 were used 
(base call accuracy ≥ 99.9%).
After de novo assembly, potential open reading frames (ORFs) were identified by 
Glimmer 3.02 software, using standard parameters except for the codon translation 
table (which was adjusted for the Mycoplasma-specific genetic code). The predicted 
ORFs were aligned to the genes identified in the genome of M. pneumoniae reference 
strain M129. The ORFs that could not be aligned to the known genes were subjected to 
BLAST analysis using the NCBI non-redundant database.
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In addition to the gene-based analysis, MUMmer 3.23 software was used to align the 
scaffolds to the M. pneumoniae M129 genome, to find unique and absent regions as 
well as structural rearrangements. Results of these analysis were further processed and 
compared using R 2.15.2
variant comparisons
To discover differences in strains isolated from asymptomatic and symptomatic individuals, 
samples were arranged in 4 groups as depicted in Table 1. The three reference strains 
(Group 1) are M. pneumoniae M129 (subtype 1, ATCC 29342), M. pneumoniae FH 
(subtype 2, ATCC 15531) and M. pneumoniae R003 (subtype 2). The other groups 
consisted of strains isolated from asymptomatic children (Group 2), patients with an 
upper RTI (Group 3) and patients with a lower RTI (Group 4). Reads were mapped to the 
M. pneumoniae M129 reference genome (NCBI accession number NC_000912.1) 
using BWA 0.5.9.
resUlts
selection of strains and isolates of M. pneumoniae
We have determined the complete genome sequences of a total of 20 strains or isolates 
of M. pneumoniae. The isolates were obtained either from asymptomatic children (n=3), 
from patients with an upper RTI (URTI; n=4), or from patients with a lower RTI (LRTI; 
n=9). The names (ID) and origins of the isolates are listed in Table 1. Two of the isolates 
from the LRTI group were obtained at the same time from a single patient (C036-1 and 
C036-2). These two isolates were selected because they differed in colony morphology 
on agar plates. Two other samples from the LRTI group were also collected from a single 
patient, one at the moment of RTI (HAP157) and one collected 4 weeks later, after 
recovery of the clinical symptoms (HAP157FUP). In addition to the clinical isolates, three 
reference laboratory strains were included in this study, i.e. subtype 1 strain M129, and 
subtype 2 strains FH and R003.
dna sequencing and de novo genome sequence assembly
The genomic sequences of the 20 M. pneumoniae strains were determined using a 
paired-end 100-bp sequencing protocol on the HiSeq2000 platform (Illumina). For 
each of the strains, genome assemblies were generated that ranged between 777 kb 
(HAP157) and 834 kb (HAP111) in length (Table 1). These genome lengths are similar 
to the published genome length of reference strain M129 (816 kb) 4. For strain M129, 
which was also included in our study, the total amount of sequence contained in scaf-
folds larger than 200 bp was found to be ~17 kb lower than the previously published 
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genome size of this strain (Table 1). Thus, approximately 2% of the M129 genome 
could not be retrieved with the procedures used in this study. The sequences of the other 
strains could have similar gaps, because all but one of the sequences are smaller than 
800 kb. It is likely that these gaps are caused by the significant number of repetitive 
sequences (RepMP sequences) in the genome of M. pneumoniae, which are known to 
pose problems for short read sequencers such as the Illumina HiSeq 2000.
sequence differences between strains isolated from asymptomatic 
and symptomatic individuals
In order to compare the genome sequences of the different M. pneumoniae isolates, 
the sequences were subjected to hierarchical clustering analysis based on Euclidian 
distance (Figure 1). This analysis clearly distinguished two major families of strains, 
table 1. Sample ID, patient information and strain information.
Group
Strain/
patient ID
Diagnose group Sequence ID Size (bp) a Subtype
1 M129 Reference 1 798,964 1
FH Reference 2 784,762 2
R003 Reference 3 798,075 2
2 B174 Asymptomatic 11 796,334 1
B247 Asymptomatic 12 797,815 1
B406 Asymptomatic 14 788,600 2
3 A016 Upper RTI 4 799,326 2
A058 Upper RTI 6 790,906 1
C024 Upper RTI 15 793,805 1
H030 Upper RTI 19 796,875 1
4 A035 Lower RTI 5 797,591 2
A103 Lower RTI 7 780,444 1
HAP111 Lower RTI 10 834,662 2
HAP157 Lower RTI 9 777,116 1
H010 Lower RTI 18 797,111 1
H016 Lower RTI 20 797,503 1
H026 Lower RTI 13 784,292 2
C036-1b Lower RTI 16 796,987 1
C036-2b Lower RTI 17 796,664 1
HAP157FUP Follow-up 8 796,422 1
a Total amount of sequence contained in scaffolds over 200 bp in length
b Morphologic different colonies of the same patient sample. Both a large (C036-1) and a small colony 
(C036-2) were sequenced.
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which correspond to the known major subtypes of M. pneumoniae, i.e. subtype 1 and 
2. Notably, the strains were not classified according to the clinical groups of patients 
they were isolated from (Groups 1-4 in Table 1). Instead, some strains show high degrees 
of similarity, while being isolated form different groups of patients. For example, strain 
B406, which was isolated form an asymptomatic child (group 2), shows a high degree 
of similarity with strain H026, which was isolated from an adult with a LRTI (group 4). 
The hierarchical clustering does therefore not indicate that the overall genome similarity is 
greater among the strains within each group than between strains from different groups.
To investigate whether the strains within each of the four groups can still be grouped 
together on the basis of relatively subtle similarities in their genomes, the genome se-
quences were compared as follows. Reads were aligned to the reference genome using 
BWA 0.5.9 and an in-house developed variant caller was used to determine small 
sequence variants for the sequenced samples. Variants are variant is differences between 
the sequenced sample and the reference genome that are typically less than 10 bp in 
length and are typically divided in 2 categories, namely single nucleotide polymorphisms 
(SNPs) and short insertions and deletions (InDels). The in-house variant caller takes the 
output from samtools mpileup 10 and counts the number of reference and non-reference 
bases (including InDels). With these counts, variant frequencies were determined. We 
used the following criteria in this procedure: (1) variants were compared with a frequency 
greater than 0.20 (which means that a variant is present in more than 20% of the reads 
for a single strain), (2) all variants with a low coverage (less than 21 times covered 
sequence) are filtered in each sample, (3) variants present in the asymptomatic group 
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figure 1. Hierarchical clustering based on Euclidean distance.
The Euclidean distance between variant frequencies (on the y-axis) is plotted against the different strains 
sequenced in this study. The strains are indicated by their sequence ID listed in Table 1. Only the variants 
with a frequency above 0.2 were used in this analysis (see the text for details). Hierarchical clustering was 
applied to the calculated Euclidean distances using the average linkage method (hclust).
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are filtered from those in the other groups except the reference group (since variants in 
the asymptomatic group are unlikely to cause a ‘phenotype’), (4) all variants present in 
the reference group are filtered from those in the other groups except the asymptomatic 
group, and (5) only variants are analyzed that are present in all samples in one group. 
Using this procedure, we were unable to identify variants that were shared between all 
samples from the same group. Although a number of variants were shared between some 
samples from the same group (Table 2), we did not find specific sequence differences 
between the strains from the group of symptomatic patients (Group 3 and 4) and those 
from the other groups (Groups 1 and 2). Variant frequencies for the different comparisons 
are shown in Tables 2-4.
variation in follow-up samples of a single patient
Two of the genome sequences that were determined were obtained from isolates 
that were obtained at two different time-points from a single patient. The first isolate, 
HAP157, was obtained when this patient suffered from a lower RTI. The other isolate, 
HAP157FUP, was obtained 4 weeks later, after resolution of the infection following a 
table 2. SNV frequencies of the isolates from symptomatic groups
Upper RTI group
SNV Strain/patient ID Locus
(NC_000912.1) 05 07 09 10
111954-111954:C-A 0.28 0.00 0.24 0.20 MPN089
528806-528806:G-GT 0.38 0.42 0.33 0.05 NA
536132-536132:A-ACC 0.67 0.00 0.00 0.71 MPN442
622601-622601:G-GTT 0.38 0.40 0.10 0.33 NA
706408-706408:A-ACC 0.21 0.01 0.00 0.22 NA
Lower RTI group
SNV Strain/patient ID Locus
(NC_000912.1) 05 07 09 10 13 16 17 18 20
41006-41006:G-A 0.00 0.00 0.00 0.00 0.00 0.99 1.00 1.00 0.00 MPN034
140960-140960:C-A 0.00 0.00 0.00 0.00 0.00 1.00 0.99 1.00 0.00 MPN108
171528-171528:A-AG 0.00 0.00 0.00 0.00 0.00 0.67 0.68 0.66 0.00 MPN132
171529-171529:C-CCCAAG 0.00 0.00 0.00 0.00 0.00 0.66 0.67 0.65 0.00 MPN132
405692-405692:A-T 0.00 0.00 0.00 0.00 0.00 0.99 0.99 1.00 0.00 MPN341
428005-428005:A-G 0.00 0.00 0.00 0.00 0.00 1.00 0.99 1.00 0.00 MPN358
536132-536132:A-ACC 0.68 0.00 0.00 0.01 0.00 0.73 0.70 0.71 0.67 MPN442
622601-622601:G-GTT 0.18 0.06 0.40 0.39 0.01 0.04 0.06 0.30 0.33 NA
733651-733651:G-A 0.00 0.00 0.00 0.00 0.00 0.99 0.99 1.00 0.00 MPN612
NA Not applicable
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course of antibiotics (azithromycin). Eight significant differences were found between 
strains HAP157 and HAP157FUP (Table 3). One of these differences was localized to 
the P1 gene (MPN141); in contrast to strain HAP157, HAP157FUP was found to have 
a deletion of an AGT triplet at position 182,792-182,794 within the P1 gene. This AGT 
is part of a tandem repeat in this gene. The significance of this repeat, which has been 
described before, is yet unknown 11.
Two of the strains (C036-1 and C036-2) were isolated from the same patient at 
a single time point. These strains were analyzed separately because they displayed 
different colony morphologies on agar plates. The sequences of these strains were found 
to be highly similar (Fig. 1); as shown in Table 4, only 5 SNPs were identified between 
these strains.
table 3. Variant frequencies of strains HAP157 and HAP157FUP
SNV Strain/patient ID Locus
(NC_000912.1) 08 09
182792-182794:AGT- 0.66 0.01 MPN141
195459-195459:C-CA 0.25 0.04 NA
570767-570767:G-T 0.89 0.62 NA
570769-570769:A-G 0.88 0.61 NA
570770-570770:C-G 0.85 0.61 NA
622601-622601:G-GTT 0.04 0.40 NA
622601-622601:G-GT 0.41 0.14 NA
649041-649041:G-T 0.91 0.00 NA
NA Not applicable
table 4. Variant frequencies of the isolates C036-1 and C036-2 with different colony morphologies
SNV Strain/patient ID Locus
(NC_000912.1) CO36-1 C036-2
195459-195459:C-CA 0.03 0.25 NA
626378-626378:G-T 0.00 0.35 NA
649044-649044:G-C 0.99 0.00 NA
649047-649047:G-T 0.00 0.99 NA
716850-716850:C-A 0.00 0.38 MPN594
NA Not applicable
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discUssion
We determined the complete genome sequences of M. pneumoniae isolates obtained 
from asymptomatic M. pneumoniae carriers, and patients suffering from an upper or 
lower RTI caused by M. pneumoniae. In addition, we analyzed the genomes of 3 M. 
pneumoniae reference strains. We could not identify a specific genotype that can be 
associated with M. pneumoniae virulence or asymptomatic bacterial carriage.
Our previous findings on sequence variation among M. pneumoniae strains, which 
mainly focussed on the P1 gene and RepMP sequences of M. pneumoniae, indicate that 
sequence variation is very common in M. pneumoniae 9, 13. In the current study, we did 
not find large rearrangements. These findings are concordant with those of Xiao et al. 5. 
In their analysis, the sequences of 15 M. pneumoniae strains seem very stable over time 
and at different locations in the world. Similarly, Lluch-Senar et al. found a low number 
of non-synonymous SNPs among the genome sequences analysis of 23 strains from 6 
different countries. However, they do describe a high rate of variation among repetitive 
elements in the M. pneumoniae genomes 6. Our study differs from those of Xiao et al. 
and Lluch-Senar et al. due to the open sequence technique used. Instead of mapping 
the generated sequences to the reference genomes, as was done by Xiao et al.5 and 
Lluch-Senar et al.6, we analyzed, scaffolds in an unbiased fashion. Consequently, we did 
not generate artificial circular genomes.
Although, we provided a well-defined group of patients and were able to reach a 
great coverage in sequencing, the most important drawback of our study is the relatively 
small sample set. Only in future studies, we aim to obtain more M. pneumoniae isolates 
from asymptomatic patients. This should provide more insight in the physiology of asymp-
tomatic colonization of the human respiratory tract by M. pneumoniae. Furthermore, for 
the analysis in this study we assumed that M. pneumoniae was the causative agent in the 
patients suffering from RTI. This is an assumption because recent studies have indicated 
that multiple pathogens can be present in the respiratory tract of children and adults 
with RTI 2, 14-16. Therefore, other pathogens might have played a role in the symptomatic 
patients and it is possible that we wrongly attributed the symptomatic ‘phenotype’, i.e. 
being the causative agent of an upper or lower RTI, to M. pneumoniae.
In conclusion, in this study we have shown that there is no specific genotype that can be 
associated with M. pneumoniae virulence or asymptomatic carriage. Second, we found 
marked genetic differences between clinical isolates and the reference strains, which 
indicated that the latter strains may not be regarded as appropriate representatives of 
circulating M. pneumoniae strains.
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aBstract
Macrolide (ML) antibiotics play an important role in the treatment regimens for My-
coplasma pneumoniae infections. In the past few years, however, a steady increase 
has been detected in the worldwide prevalence of ML-resistant M. pneumoniae strains. 
It is obvious that this increase necessitates a continuous monitoring of ML resistance 
(MLR) and, when detected, modification of antibiotic treatment modalities. Previously, 
we developed a pyrosequencing-based assay system for the genetic determination of 
MLR as well as molecular typing of M. pneumoniae. In this study, the system was ap-
plied to 114 M. pneumoniae-positive specimens that were obtained from a collection 
of 4390 samples from patients with acute respiratory tract infections. These samples 
were collected between 1997 and 2008 in The Netherlands. The pyrosequencing 
system produced reliable data in 86-92% of the specimens that contained >500 M. 
pneumoniae genome copies/ml patient sample. Each of these samples contained DNA 
of the ML-sensitive genotype. While 43% of the samples were found to harbor the M. 
pneumoniae subtype-1 genotype, 57% contained the subtype-2 genotype. We conclude 
that the pyrosequencing-based assay system is a useful tool for MLR determination and 
molecular typing of M. pneumoniae in patient samples. MLR-associated M. pneumoniae 
genotypes, however, were not found in the current study population.
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introdUction
Mycoplasma pneumoniae is a pathogen of the human respiratory tract and one of the 
most prevalent causes of community-acquired pneumonia. General treatment options for 
M. pneumoniae infections include macrolides (MLs), tetracyclines and fluoroquinolones. 
In young children, however, tetracyclines and fluoroquinolones are contra-indicated 
due to unfavorable effects, such as discoloration of teeth by tetracyclines and putative 
cartilage damage induced by fluoroquinolones. The antibiotics of choice for this patient 
group are therefore ML antibiotics, such as clarithromycin and azithromycin. In the past 
decade, however, increasing numbers of M. pneumoniae clinical isolates were found 
to be resistant against these antibiotics. ML-resistance (MLR) was first reported in Japan 
in 2002 1, and since then it has also been detected in the United States 2, 3, Europe 4-7, 
Eastern Asia 8 and the Middle East 9. The prevalence of MLR varies widely from 1-2% 
in Denmark 5 to as high as 90% in China 10. Clearly, the emergence of MLR poses a 
significant threat to the use of MLs in the treatment of M. pneumoniae infections. It is 
therefore important that MLR among M. pneumoniae isolates is rapidly and efficiently 
monitored in order to allow effective antibiotic treatment.
Because M. pneumoniae is difficult to culture, the monitoring of MLR in this species is 
most efficiently performed using molecular assays. These assays are aimed at the detec-
tion of specific point mutations in the bacterial 23S rRNA gene, which determine the 
MLR phenotype. Since the first report of MLR in M. pneumoniae, several molecular assays 
have been developed to detect the MLR-associated point mutations. In most cases, these 
assays rely either on time-consuming Sanger sequencing of PCR products or on real-time 
PCR followed by high-resolution melting analysis, which requires a high level of expertise 
in interpretation of the results 3, 6.
Previously, we described a pyrosequencing system to assess MLR and to determine 
the genotype (i.e. subtype 1 or subtype 2) of cultured M. pneumoniae strains 11. This 
system consists of four separate assays (two assays to assess MLR and two assays to 
determine genotype) and was found to be highly useful when applied to cultures of M. 
pneumoniae. In order to develop a culture-independent pyrosequencing system that is 
suitable for the determination of both MLR and the genotype of M. pneumoniae in clinical 
specimens, we modified the original pyrosequencing system by increasing its sensitivity. 
In the current study, we applied this modified system to M. pneumoniae-positive clinical 
specimens collected during a 12-year surveillance period in the Netherlands.
Here we demonstrate that the pyrosequencing system is highly convenient for molecular 
characterization of M. pneumoniae directly on patient material. The system can be used 
in parallel with a PCR-based surveillance system and can be applied in the monitoring 
of epidemics. In addition, the pyrosequencing system can serve as a guide for clinicians 
in the diagnosis and treatment of acute respiratory infections (ARIs) caused by M. pneu-
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moniae. Finally, we show that all M. pneumoniae-positive specimens from the collection 
contained bacterial isolates with an ML-sensitive genotype. Thus, MLR was not detected 
among M. pneumoniae strains circulating in the Netherlands between 1997 and 2008.
Materials and Methods
surveillance network, patients and clinical specimens.
The nationwide ‘Continuous Morbidity Registration at the Dutch Sentinel General Practice 
Network’, coordinated by NIVEL (the Netherlands Institute for Health Service Research), 
continuously monitors consultations for influenza-like illness (ILI) in The Netherlands. In 
addition, this network aims to monitor the circulation of influenza viruses and other patho-
gens, including M. pneumoniae, among patients with ILI or other ARI. Sixty-one general 
practitioners (GPs) of 45 general practices participate in this surveillance network. To-
gether they serve about 0.8% of the Dutch population, nationally representative by age, 
gender, geographic distribution, and population density 12. The GPs weekly report the 
number of patients consulting their practice with ILI, and are asked to collect a nose swab 
and a throat swab on a weekly basis from two patients with ILI. Preferably, one of these 
patients is younger than 10 years of age. If the GPs do not encounter patients with ILI, 
they are asked to sample two patients with another ARI 13-15. From 2001 until 2003, 
healthy controls were asked to participate in the surveillance as part of a case-control 
study on environmental risk factors for ARI 13.
In this study, we used the data and all M. pneumoniae-positive specimens collected 
in this surveillance network from 1997 to 2008. M. pneumoniae was monitored during 
each year of the surveillance, except for week 40-52 in 2003, entire 2004, and week 
1-36 in 2005. For each patient, a questionnaire was completed, which includes age, 
gender, time of onset of illness, clinical symptoms, and diagnosis. The nose and the throat 
swab were combined and transported in 4 ml gelatine-lactoalbumin-yeast (GLY) medium 
containing 0.1 mg/ml pimaricin and 0.2 mg/ml gentamycin at ambient temperature. 
The specimens were sent by regular mail to the Virology Department of the Laboratory 
for Infectious Diseases and Perinatal Screening of the National Institute for Public Health 
and the Environment for analysis.
M. pneumoniae strains.
All M. pneumoniae strains used in this study, including reference strains M129 (ATCC® 
no. 29342), PI 1428 (ATCC® no. 29085), FH (ATCC® no. 15531), MAC (ATCC® 
no. 15492) as well as clinical strains R035, P05/132, M688/98 and T79 11 were 
cultured in Mycoplasma medium, as described previously16.
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detection and quantification of M. pneumoniae dna.
Patient specimens were analyzed prospectively for the presence of M. pneumoniae 
DNA by nested PCR, as described by Dorigo-Zetsma et al. 17. Residual material of the 
original specimen was stored at -80ºC for future purposes. For this study, all stored M. 
pneumoniae-positive specimens were retrieved. DNA was extracted from each original 
specimen (200 µl) using the QIAamp DNA mini kit (QIAGEN, the Netherlands) ac-
cording to the manufacturer’s recommendations. Phocine herpesvirus was added before 
isolation as an internal control for real-time PCR, as described before 18. The DNA was 
eluted in a final volume of 50 µl. A quantitative real-time (TaqMan®) PCR assay was used 
to quantify the M. pneumoniae DNA load, as previously described 11.
Mlr genotype identification and subtype determination by 
pyrosequencing.
To identify genotypes (point mutations) associated with either MLR or ML sensitivity (MLS), 
two pyrosequencing assays targeting the M. pneumoniae 23S rRNA were used 11. These 
assays were originally designed to be performed on cultured bacteria. In this study, 
we aimed to use these assays directly on DNA isolated from clinical specimens. We 
therefore designed a nested PCR protocol to improve the detection limit and specificity of 
the original protocol 11. PCR and sequence primers for both assays are listed in Table S1. 
The first (external) PCR was identical for both assays. The PCR mixtures (25 µl) contained 
0.4 µM of each primer, 0.2 mM of each dNTP, 2 mM MgSO4, 0.02 U/µl Pfu DNA 
polymerase (Fermentas), 1×Pfu buffer (Fermentas) and 5 µl template DNA. The following 
cycling conditions were used: 5 min at 94°C, followed by 35 cycles of 30 sec at 94°C, 
30 sec at 55°C and 30 sec at 72°C. The (internal) PCRs were performed as previously 
described 11, using 1 µl of template from the first PCR. A negative control was taken along 
in each PCR run. The resulting (biotinylated) PCR products from the second PCR were 
immobilized to Streptavidin Sepharose™ High Performance beads (GE healthcare) and 
processed to yield high-quality, single-stranded DNA using the PyroMark™ Vacuum Prep 
Workstation 11. The pyrosequencing reactions and sequence analysis were performed 
using the PyroMark™Q96MD sequencer (Qiagen) and accompanying software.
To discriminate between the two major M. pneumoniae subtypes (i.e. subtype 1 and 
2), we previously developed two different pyrosequencing assays 11. The first assay 
targets a subtype-specific nucleotide located in a conserved region near the 3’ end of 
the MPN141 gene, whereas the second targets a subtype-specific nucleotide in the 
MPN528a gene. Both assays were improved by a nested protocol in a similar fashion 
as described above for the MLR/MLS assays, using similar conditions. The primers used 
in each assay are listed in Table S1.
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statistical analysis.
The analysis of a possible association between genomic copy load and either patient 
characteristics or subtype, was performed using the Mann-Whitney U test. To analyze the 
relationship between subtype and age groups, or the presence of clinical symptoms, we 
used the Chi-Square test. Significance was set at P = 0.05. All statistical analyses were 
performed using SPSS statistical software version 16.0.1.
resUlts
Prevalence of M. pneumoniae in The Netherlands between 1997 and 2008 among 
patients with ARI. Of the 4390 specimens that were collected between 1997 and 2008 
from patients with ILI or another ARI, 114 (2.6%) tested positive for M. pneumoniae using 
a conventional, nested PCR assay. Of 588 specimens that were collected from healthy 
individuals, five were positive for M. pneumoniae. These specimens were not included 
in this study. From three of the 114 M. pneumoniae-positive specimens (each originat-
ing from 1997), original material was no longer available. The M. pneumoniae DNA 
load in the remaining 111 M. pneumoniae-positive specimens was determined using a 
quantitative, real-time PCR assay 11. In 15 of these specimens, the real-time PCR assay 
was negative. These specimens were therefore not analyzed further. In the other 96 
specimens, the M. pneumoniae genomic DNA could be quantified. The genomic copy 
loads in these specimens ranged from 250 genomic copies/ml up to 1.2´106 copies/
ml original patient sample. As shown in Fig. 1, the prevalence of M. pneumoniae fluctu-
ated over the years and was highest in 2005 (11.5%). Most M. pneumoniae cases were 
observed in two groups of patients, i.e. patients aged 0-15 years (32.3%) and patients 
aged 31-45 years (31.3%, Table 1). The symptom that was reported most frequently was 
coughing. A relation between the genomic copy loads, age and clinical symptoms was 
not found. There was also no relation between the genomic copy load and the delay 
between the date of onset of illness and the moment of specimen collection.
Generation and evaluation of a highly sensitive pyrosequencing system. Previously, 
we described the design and use of four pyrosequencing assays for determination of 
both MLR and genotype of M. pneumoniae strains 11. A major drawback of these assays 
is, however, that they can only be applied to cultured bacterial isolates, as their lower 
detection limit is relatively high (5000 copies per ml original sample). We therefore set 
out to improve the detection limit of the four assays, which will be referred to here as the 
‘pyrosequencing system’, such that they can be performed directly on clinical specimens 
from M. pneumoniae-positive patients. To this purpose, the initial PCR reactions of the 
pyrosequencing system were converted into nested reactions (as described in Materials 
and Methods).
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To determine the lower detection limit of the system on patient specimens, we per-
formed experiments in which throat swabs from healthy persons were spiked with known 
quantities of M. pneumoniae DNA. The swabs were rinsed in 1 ml phosphate-buffered 
saline and, after DNA extraction, the M. pneumoniae DNA load was measured by 
real-time PCR. The detection limit for each of the four assays from the pyrosequencing 
system was found to be ~5×102 genomic copies per ml sample (which is ~10-fold more 
sensitive than the original protocol). At copy numbers below 5×102 genomic copies 
per ml, the assays failed to provide reliable results. In these cases, the amount of gener-
ated PCR product was too low to allow the generation of high-quality, reproducible 
pyrosequencing data.
To test whether the modifi ed pyrosequencing system is able to detect the genotypes 
associated with either ML resistance (MLR) or ML sensitivity (MLS), and to discriminate 
between the two different subtypes of M. pneumoniae, we applied the system to different 
isolates from our M. pneumoniae strain collection. These isolates included four strains 
with an MLR genotype (the subtype 1 strains R035 and P05/132, and subtype 2 strains 
M688/98 and T79) and four strains with an MLS genotype (subtype 1 strains M129 
and PI1428, and subtype 2 strains MAC and FH). Similar to the original pyrosequenc-
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figure 1. M. pneumoniae-positive specimens (96) and M. pneumoniae subtype detected per year.
Upper panel: absolute numbers of M. pneumoniae PCR-positive specimens. The white and black areas in 
each bar represent the number of subtype 1 and subtype 2 genotypes, respectively. The grey areas depict 
the number of specimens in which a subtype could not be determined (‘Undetermined’). Middle panel: 
prevalence of M. pneumoniae PCR-positive specimens per year in the sentinel surveillance network. Lower 
panel: the total number of collected specimens each year. No specimens were tested for M. pneumoniae 
in week 40-52 of 2003, entire 2004 and in week 1-36 of 2005 (indicated by *).
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table 1. Characteristics of 96 confirmed M. pneumoniae PCR-positive patients
Variable Total (%) a Distribution per genomic copy load (%) b
< 500 500 - 5000 > 5000
N=96 n=12 n=37 n=47
Age (years)
0-15 31 (32.3) 7 (58.3) 13 (35.1) 11 (23.4)
16-30 16 (16.7) 2 (16.6) 5 (13.5) 9 (19.1)
31-45 30 (31.3) 1 (8.3) 12 (32.4) 17 (36.2)
45-60 15 (15.6) 1 (8.3) 4 (10.8) 10 (21.3)
>60 4 (4.2) 1 (8.3) 3 (8.1) 0 (0.0)
Gender
Female 55 (57.3) 7 (58.3) 20 (54.1) 28 (59.6)
Male 41 (42.7) 5 (41.7) 17 (45.9) 19 (40.4)
Duration of Illness at the time of sampling
< 7 days 83 (88.3) 9 (75.0) 31 (86.1) 43 (93.5)
> 7 days 11 (11.7) 3 (25.0) 5 (13.9) 3 (6.5)
Symptoms
Fever 60 (69.8) 8 (72.7) 27 (77.1) 25 (62.5)
Malaise 50 (58.1) 6 (54.5) 22 (62.9) 22 (55.0)
Headache 22 (33.8) c 0 (0.0) 10 (38.5) 12 (38.7)
Muscle pains 31 (36.0) 2 (18.2) 13 (37.1) 16 (40.0)
Sore throat 31 (36.0) 6 (54.5) 16 (45.7) 9 (22.5)
Cough 76 (88.4) 9 (81.1) 32 (91.4) 35 (87.5)
Shortness of breath 2 (8.7) c 0 (0.0) 2 (25.0) 0 (0.0)
Rhinorrhea 17 (27.0) c 2 (22.2) 12 (44.4) 3 (11.1)
Diagnosis
ARI 43 (44.8) 8 (66.7) 16 (43.2) 19 (40.4)
ILI 53 (55.2) 4 (33.3) 21 (56.8) 28 (59.6)
a. Questionnaires were not complete for all patients.
b. Genomic copy loads per ml original specimen determined by real-time PCR. None of the patient charac-
teristics were associated with low or high genomic copy load.
c. The symptom ‘shortness of breath’ was only recorded from 1997 through 1999. The symptom ‘frontal 
headache’ was not recorded from 2000 through 2003. The symptom ‘rhinorrhea’ was recorded from 
2000 onwards.
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ing system, the modified system correctly determined the subtypes as well as MLR/MLS 
genotype of each of the tested strains (data not shown).
MLR/MLS and M. pneumoniae subtype determination in clinical specimens. The 
modified pyrosequencing system was applied directly to DNA isolated from the 96 M. 
pneumoniae real-time PCR-positive patient samples. Seventy-seven of these specimens 
(80.2%) yielded a reliable result in the MLR/MLS assays from the pyrosequencing system. 
As expected from the spiking experiments, the performance of the tests was highly de-
pendent on the genomic load in the original sample. In specimens with a load above 
5´102 genomic copies/ml, the MLR/MLS assays generated reliable data in 86% of the 
cases. At genomic copy numbers lower than 5´102 genomic copies/ml, however, results 
were obtained in only 41% of the cases. All specimens that produced reliable data in the 
MLR/MLS assays were found to carry the MLS genotype. Thus, the MLR genotype was not 
detected in the current sample collection.
The two M. pneumoniae subtyping assays from the pyrosequencing system were slightly 
more sensitive than the MLR/MLS assays: in 85 of the 96 M. pneumoniae DNA-positive 
specimens (88.5%), the subtype could be determined. Similar to what was reported for 
the MLR/MLS assays, the success of the subtyping assays was highly dependent on the 
M. pneumoniae genomic load in the original specimens (Fig. 2).
In specimens with a load above 5´102 per ml, the genotype could be reliably de-
termined in 92% of the cases. In specimens with loads of 5´102 genomic copies/
ml or lower, the subtype was determined in 67% of the cases. The majority of the 
specimens obtained during the entire sample period contained M. pneumoniae subtype 
figure 2. Genomic copy loads of 96 M. pneumoniae positive specimens.
The Y-axis shows the genomic copy load per ml original specimen as determined by real-time PCR. Subtype 
determination was successful in the majority of the specimens containing more than ~500 genomic copies 
per ml. The horizontal cut-off line represents this lower limit of detection.
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2 sequences (57%). This percentage varied over the years and was highest in 1998 
and 2001 (Fig. 1). We did not find a relation between subtype, patient age and clinical 
symptoms, or between subtype and genomic copy load.
discUssion
In this study, a modified pyrosequencing system was used for MLR determination and mo-
lecular typing of M. pneumoniae directly in clinical specimens. We found this modified 
system to generate reliable results in 92% of the samples that carried >5000 M. pneu-
moniae genome copies/ml. The main modification made to the original pyrosequencing 
protocol (20) was the inclusion of a nested PCR instead of a single PCR reaction. Clearly, 
the use of a nested PCR protocol may also have drawbacks. First, a higher PCR sensitivity 
may lead to increased problems related to contamination. However, strict guidelines 
were followed in the handling and containment of PCR products, i.e. each step of the 
pyrosequencing system was performed in a separate room. As a consequence, we 
have not experienced problems with DNA contamination during the course of this study. 
Second, a nested PCR step may increase the risk of generating PCR errors, which may 
lead to incorrect sequencing results and incorrect assignment of subtype or MLR/MLS 
genotype. To avoid this problem, a heat-stable DNA polymerase with proofreading 
activity was used throughout this study, and we have not experienced any (PCR-induced) 
sequence variation in any of the analyzed amplicons.
Although ML-resistant M. pneumoniae isolates have recently been detected in many 
European countries (Germany, Denmark, France and Italy), we did not detect any geno-
types associated with MLR in the Dutch patient cohort that we studied. This apparent 
discrepancy may be explained by the nature of our study population, which consists of 
ambulant patients. It might be that the prevalence of MLR is higher among (hospitalized) 
patients that are subjected to antibiotic treatment. It is also possible that MLR among M. 
pneumoniae strains in The Netherlands emerges more slowly than in other countries due 
to the restricted use of antibiotics in The Netherlands 19. Thus, the selection for strains with 
an MLR genotype may not be as strong in this country as neighboring countries, in which 
antibiotics are administered with a higher frequency. However, the easy administra-
tion and the favorable pharmacokinetic profile of newer MLs, like clarithromycin and 
azithromycin, will likely stimulate their prescription. It should therefore be considered that 
MLR will also emerge in The Netherlands in the near future.
In our study population, a remarkable fluctuation was observed in the prevalence of 
M. pneumoniae over time. Similar fluctuations have been reported in epidemiologi-
cal studies from other countries 5, 20, 21. A possible explanation for this phenomenon is 
periodic antigenic variation of surface-exposed proteins of M. pneumoniae, such as the 
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P1 protein 22. Antigenic variation may result in a temporary reduction of the immunity 
against M. pneumoniae in the population 23. It is also possible that the specific immuno-
logical memory against M. pneumoniae wanes rapidly, allowing the bacteria to re-infect 
individuals within one to two years after the previous infection 21.
Another notable epidemiological observation in this study was the relatively low 
prevalence of M. pneumoniae in our patient population. This may, at least in part, be 
explained by the age distribution of the population and the seasons in which sampling 
was performed. More specifically, the burden of M. pneumoniae infections lies primar-
ily in childhood 24, whereas the specimens in the surveillance network were collected 
regardless of age. In addition, the primary aim of the surveillance network is to monitor 
influenza virus infections, which are most prevalent during fall and winter. Most specimens 
from the collection were therefore obtained during these seasons and not in seasons in 
which M. pneumoniae may be detected more frequently among patients with respiratory 
tract infections 25.
As a consequence of the relatively low prevalence of M. pneumoniae in our study 
population, it was difficult to analyze the putative relation between the detection of either 
subtype 1 or subtype 2 isolates. Shifts in the prevalence of these subtypes have been 
reported to occur, such that the subtype that predominates in the human population is 
replaced by the other subtype every 8-10 years 21. In this study, however, such shifts 
were not observed, which may also be due to the length of the sampling period being 
too small. Regardless, the clinical implications of the detection of either subtype 1 or 
subtype 2 strains are still unclear. In this study, we did not find any correlation between 
the subtype of the infecting M. pneumoniae strain, the pathogenesis of infection and 
bacterial load. As a consequence, molecular (sub)typing of M. pneumoniae isolates is 
currently only useful for epidemiological purposes.
In conclusion, pyrosequencing is a valuable tool for the molecular characterization 
of M. pneumoniae. Using this system, we did not detect any MLR-associated M. pneu-
moniae genotypes in patient specimens collected between 1997 and 2008 in the 
Netherlands. However, as MLR is increasing in neighboring countries, either due to local 
antibiotic pressure or due to actual spread, it is important that MLR be monitored not only 
in countries with a high prevalence of MLR but also in countries with a low prevalence of 
antibiotic resistance, such as The Netherlands.
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aBstract
M. pneumoniae is a common cause of respiratory tract infections (RTI’s), especially in 
children. While severe M. pneumoniae infections are generally treated with antibiotics, 
the diagnosis as well as treatment of these infections should be reconsidered in the 
light of recent clinical findings. First, M. pneumoniae was found to be carried in the 
upper respiratory tract of a relatively high percentage of healthy, asymptomatic children. 
Clearly, this complicates the diagnosis of a suspected M. pneumoniae RTI and, thus, the 
decision when to initiate treatment. Another complication in the treatment of these infec-
tions is that data on the efficacy of antibiotic treatment of M. pneumoniae RTI’s are sparse 
and derived exclusively from comparative studies. A recent Cochrane review concluded 
that there is insufficient evidence about the efficacy of antibiotics for M. pneumoniae 
lower respiratory tract infections (LRTI) in children. Due to side effects associated with 
the use of tetracyclines and quinolones in children, only macrolides can be used to treat 
M. pneumoniae infections in young patients. The general applicability of macrolides, 
however, is currently threatened by the worldwide increase in macrolide-resistant M. 
pneumoniae strains. Finally, limited evidence is available that corticosteroids might have 
an additional benefit in the treatment of M. pneumoniae infections. In this review, the 
current issues related to the diagnosis and treatment of M. pneumoniae infections will 
be discussed.
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introdUction
Respiratory tract infections (RTI’s) form a major burden of disease worldwide in children. 
The World Health Organization estimates that there are 150.7 million cases of pneumo-
nia each year in children younger than 5 years of age, with as many as 20 million cases 
severe enough to warrant hospital admission 1. A wide range of pathogens may cause 
respiratory tract infections. One of the most common bacterial causes of both upper 
and lower RTI is Mycoplasma pneumoniae. This bacterium is of particular importance 
in children, in which it is the second most common bacterial cause of pneumonia after 
Streptococcus pneumoniae 2. In this review, we will focus on the treatment of RTI’s caused 
by M. pneumoniae in children.
Biological characteristics of M. pneumoniae.
M. pneumoniae is a human pathogen from the bacterial class of Mollicutes (lat. soft 
skin). The common features shared by the bacteria in this class are: (1) the permanent 
lack of a rigid cell wall, (2) relatively small cellular dimensions, and (3) a relatively 
small genome 3-5. As a consequence of the limited genomic size, M. pneumoniae has a 
limited metabolic capacity; the bacterium is thus dependent on its host for the production 
of crucial biomolecules, such as purines and pyrimidines 3. It is therefore imperative that 
M. pneumoniae be in close contact with its host to scavenge for nutrients. To establish a 
close association with the host respiratory epithelium, M. pneumoniae contains a special-
ized attachment organelle. This organelle consists of a number of adhesion proteins 
and accessory proteins that are essential for attachment 6-8. Loss of function of one of 
these proteins results in a non-virulent bacterium that is unable to attach to the human 
respiratory epithelium 9, 10.
diagnosis of M. pneumoniae.
The clinical signs and symptoms of an M. pneumoniae RTI and available diagnostic as-
says have recently been reviewed elsewhere 11. In short, there are no clinical, biochemi-
cal or radiological findings that are pathognomonic or specific for an M. pneumoniae 
RTI. Although a clinical syndrome has previously been described that was considered 
to be characteristic for M. pneumoniae infections (i.e. ‘walking pneumonia’), a recent 
Cochrane review did not reveal any M. pneumoniae-specific clinical symptoms and 
signs 12. The diagnosis of an M. pneumoniae RTI therefore has to be supported by 
microbiological findings. At present, different diagnostic techniques are available, but all 
of these have drawbacks that should be taken into consideration before starting treatment 
for a presumed M. pneumoniae RTI.
Although culture media have been optimized over the years, bacterial culture is still an 
insensitive tool to detect M. pneumoniae in clinical samples. In addition, it has a long 
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turnaround time and is both laborious and expensive. The culturing of M. pneumoniae is 
therefore rarely used as a diagnostic method for clinical purposes. The current diagnosis 
of M. pneumoniae RTI relies either on the detection of serum antibodies against M. 
pneumoniae (serology) or on the detection of bacterial DNA in samples from the upper 
respiratory tract, as recommended in the guidelines published by the British Thoracic 
Society and the Infectious Disease Society of America 13, 14.
From a clinical point of view, serology is an inconvenient diagnostic tool since it 
requires a serum sample in the acute phase of the disease and a convalescent serum 
sample taken 2-4 weeks later to provide reliable results. This inherent retrospective aspect 
of serology is not helpful for clinicians to make a therapeutic management decision in the 
acute phase of the infection. As a consequence, clinicians often rely on single-sample 
IgM and IgG antibody titers in order to diagnose acute M. pneumoniae infections. Such 
a procedure, however, lacks predictive power. This was recently demonstrated in a study 
performed in the Netherlands, in which a similar range of single-sample M. pneumoniae 
IgM and IgG antibody titers was found in children with and without symptoms of an 
RTI 15.
In the past two decades, a solution to the drawbacks of culture and serology has seem-
ingly been provided by molecular diagnostic methods (based on nucleic acid amplifica-
tion techniques, such as PCR), which can provide fast, sensitive, and specific results in 
the acute phase of an infection. Consequently, molecular methods are increasingly used 
in clinical practice, as well as in clinical studies for the detection of M. pneumoniae 
DNA. However, the abovementioned observational study on a population of children 
with and without signs of an RTI detected a similar prevalence of M. pneumoniae by 
real-time PCR in asymptomatic children and symptomatic children with 21.2% [95% CI 
17.2%–25.2%] versus 16.2% [95% CI 12.2%–20.2%], respectively 15. Moreover, a 
difference in M. pneumoniae genomic copy load in respiratory tract samples was not 
detected between the symptomatic and asymptomatic group. Real-time PCR therefore 
does not represent an unambiguous method for the diagnosis of symptomatic M. pneu-
moniae infections. Moreover, the diagnostic accuracy did not improve when the PCR 
results were combined with serological data 15. Thus, at this moment, it appears that 
there is no definitive procedure that allows the reliable diagnosis of acute (symptomatic) 
infections with M. pneumoniae. Clearly, this notion has major consequences for the 
management of children with a symptomatic RTI and calls for novel procedures that 
allow discrimination between (harmless) carriage of M. pneumoniae and symptomatic 
infections caused by this bacterium.
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treatMent of M. PNEUMONIAE respiratory tract infections
choice of antibiotics based on biological characteristics.
M. pneumoniae lacks a rigid bacterial cell wall, but is instead protected by a sterol-
containing membrane. As a direct result, M. pneumoniae has an innate resistance to any 
antibiotic that is directed at the destruction or disruption of a bacterial cell wall, such as 
beta-lactams and glycopeptides. In contrast, antibiotics that are directed at the inhibition 
of DNA metabolism and protein synthesis do have appropriate inhibitory activity against 
M. pneumoniae. The antibiotics with the best minimum inhibitory concentration (MIC) 
values include macrolides, tetracyclines and fluoroquinolones. Although the latter two 
have a good in vitro inhibitory effect against M. pneumoniae, tetracyclines may cause 
teeth discoloration and fluoroquinolones may affect the developing cartilage in young 
children 16, 17. That is why they are not recommended by current guidelines in young 
children (age limit tetracyclines: ≥8 years; fluoroquinolones: adolescence with skeletal 
maturity) 13. However, the occurrence of arthropathy due to fluoroquinolones is uncertain, 
and all musculoskeletal adverse effects reported in the literature have been reversible 
following withdrawal of treatment 17. Macrolide antibiotics have a more favorable side 
effect profile and are therefore the preferred choice for treatment of children with a M. 
pneumoniae RTI.
clinical effectiveness of antibiotic treatment.
Although antibiotics are effective against M. pneumoniae in vitro 18, there is a lack of 
evidence on the effectiveness of antibiotics against M. pneumoniae in vivo. A recent Co-
chrane review by Mulholland et al. 19 evaluated the effectiveness of antibiotic treatment 
of M. pneumoniae LRTI. The authors selected and evaluated 7 studies on the antibiotic 
treatment of LRTI. These studies differed significantly concerning: (1) the diagnostic cri-
teria for an M. pneumoniae infection, (2) the type and duration of antibiotic treatment, 
(3) inclusion criteria, and (4) outcome measures. Only one of the included studies was 
designed as a randomized clinical trial (RCT). In this study, efficacy was shown in a 
group of children with a LRTI due to either M. pneumoniae or Chlamydophila pneu-
moniae, but these children were not evaluated separately. Consequently, this Cochrane 
review did not result in a conclusive answer concerning the effectiveness of antibiotic 
treatment of M. pneumoniae LRTI. Therefore, the efficacy of treatment with antibiotics 
for M. pneumoniae infection has yet to be established. Mulholland et al. underline the 
need for well-designed, randomized and controlled trials on this topic, and conclude that 
there is insufficient evidence about the efficacy of antibiotics for M. pneumoniae LRTI in 
children 19.
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antibiotic resistance of M. pneumoniae.
As mentioned above, the preferred choice of antibiotics in children are protein synthesis 
inhibitors of the macrolide class. However, due to the widespread use of these antibiot-
ics, the past decade has witnessed a worldwide increase in the incidence of macrolide-
resistant M. pneumoniae (MRMP) strains, primarily in children. MRMP strains were first 
reported in Asia (in ~2000) and later in Europe (~2005) and the USA (~2007). The 
most recent literature from 2013 reports MRMP incidences of 50%-90% in Japan 20, 21, 
63%-97% in China 22-24, 23% in Taiwan 25, 8.7%-62,9% in South Korea 26, 27, 12.1% in 
Canada 28, 3.6% in Germany 29 and 8.3% in France 30. Recently, MRMP isolates were 
also reported in Scotland 31, but the actual incidence was not determined.
Macrolide resistance of M. pneumoniae is the result of specific point mutations in the 
peptidyl transferase loop of the V domain of the bacterial ribosome that causes ineffective 
attachment of the macrolide molecules. The mutations with the highest incidence and 
a high level of resistance are A2063G, A2063C and A2064G 18. A low level of 
resistance is induced by the mutations A2067G, C2617G and C2617A 32, 33, which 
were first found after in vitro challenge of M. pneumoniae strains with erythromycin 
and other macrolides and now in low prevalence in vivo. Because specific mutations 
correlate well with susceptibility testing results (i.e. MIC values for various antibiotics 18), 
the detection of specific mutations (e.g. by real-time PCR) is generally sufficient for clinical 
purposes. Moreover, due to the slow growth of M. pneumoniae, susceptibility testing for 
an individual patient will not provide reliable results in a realistic time frame and will 
therefore not be helpful for clinical decision-making.
It is generally accepted that pressure selection in vivo is the main reason for the 
rapid emergence of resistance in the past decade. Different findings support this notion. 
First, the prevalence of resistance seems to be highest in areas where M. pneumoniae 
infections are highly prevalent and, thus, macrolides are prescribed on a regular basis 18. 
Second, in vitro selection of MRMP strains has been described long before the actual 
isolation of MRMP strains from clinical samples 34. Third, the emergence of MRMP strains 
during macrolide treatment has been documented in children 35-37. And fourth, recent 
studies could not find a clear correlation between MLVA typing and macrolide resistance, 
which supports polyclonal expansion of MRMP and the absence of a single resistant 
clone 30, 38. Because there are no appropriate antibiotic alternatives in young children, 
a reduction of macrolide antibiotic usage may be the only solution to control the further 
emergence of MRMP.
Signs or symptoms of patients infected with an MRMP strain do not seem to differ 
from those in patients infected with a macrolide-susceptible strain, on initial presenta-
tion. However, it has been shown that disease progresses more severe in patients 
infected with MRMP and treated with macrolide antibiotics than in those infected with 
macrolide-susceptible M. pneumoniae. This is reflected in a prolonged period of fever 
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and coughing in the first patient group, in combination with more prominent chest X-ray 
changes and a prolonged hospitalization 39-42. Recent studies reported that a switch in 
treatment from macrolides to a different class of antibiotics was beneficial to the recovery 
of MRMP-infected patients 43-45.
There has been debate about the relevance of MRMP, since M. pneumoniae generally 
causes mild disease, and some patients benefit from macrolide antibiotics even in the 
presence of resistance 46. Indeed, Kawai et al. observed defeverescence in patients 
infected with MRMP within 48 hours after the initiation of macrolide antibiotics in 41 - 
48% 44. There are at least two possible explanations for this latter phenomenon. First, as 
discussed above, the accurate diagnosis of M. pneumoniae RTI is difficult to perform. 
A proportion of the cases referred to as symptomatic M. pneumoniae infections in the 
literature may therefore not have been diagnosed correctly. Clearly, this may confound 
the analysis of the patient data. Second, there might be an important role for the known 
anti-inflammatory effects of macrolides in recovery of patients with an RTI caused by 
MRMP. Indeed, there is substantial evidence that the immune response plays an important 
role in the development of severe M. pneumoniae RTI 5, 11 and it is possible that macro-
lides suppress this response47.
conclUsion
At present, there is no clear evidence that antibiotic treatment of presumed M. pneu-
moniae RTI is effective. This lack of evidence, however, may be caused by (1) the lack 
of appropriate diagnostic tools to diagnose symptomatic M. pneumoniae infections, and 
(2) the lack of well designed randomized controlled trials on antibiotic treatment for M. 
pneumoniae RTI. Studies on treatment results in children infected with MRMP demonstrate 
a significant reduction of duration of disease when treated with tetracyclines or fluoro-
quinolones compared to treatment with macrolides, suggesting that antibiotic treatment 
may be beneficial in children infected with M. pneumoniae. The worldwide increase 
in MRMP infections that is associated with increase in the use of macrolides, however, 
warrants deliberate use of macrolides. The lack of specific signs and symptoms and 
the lack of diagnostic tools that differentiate asymptomatic carriage from symptomatic 
infection with M. pneumoniae underlines the importance of following the latest guidelines 
on community acquired pneumonia and start macrolide antibiotics at any age if there is 
no response to first-line empirical treatment or in very severe disease.
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the position of thesis in the field of pediatric infectioUs 
diseases
“Without urgent, coordinated action (…), the world is headed for a post-antibiotic era, 
in which common infections (…) which have been treatable for decades can once again 
kill.”
(Dr. Keiji Fukuda, WHO Assistant Director-General for Health Security)
This warning in the WHO report on antibiotic resistance (April 2014), points to the 
serious threat of global antibiotic resistance due to the overuse of broad-spectrum 
antibiotics 6. To handle this threat, WHO suggests that health care workers should only 
prescribe “antibiotics when they are truly needed” and “the right antibiotic(s) to treat the 
illness” 6. Although these suggestions seem obvious, they surpass the fact that the trigger 
to prescribe antibiotics is more often than not merely the suspicion of a, possibly severe, 
bacterial infection.
In children, bacterial pneumonia, is a common and serious infection 8, 9. Approximately 
1.1 million children under the age of five years die worldwide every year as a result of 
pneumonia 14. It is therefore not surprising that in the field of pediatrics the suspicion of 
bacterial pneumonia is the most frequent reason to prescribe antibiotics 15.
Based on recent studies 2-4, including our own 16, it is save to state that multiple 
pathogens co-inhabit the respiratory tract of both healthy children and children suffering 
from pneumonia. It is known that true pneumonia can be caused by pneumococci, 
staphylococci and Mycoplasma pneumoniae. However, considering the fact that mul-
tiple pathogens may be part of the upper respiratory tract microbiome (panel), it remains 
difficult to identify a single responsible pathogen in a child that suffers from pneumonia. 
Moreover, it is possible that a combination of multiple pathogens may cause disease, 
with each pathogen having its own role in breaching parts of the human immune system 
at specific stages of disease. At this point, however, this notion is only based on specula-
tion. Novel diagnostics modalities to address this issue are needed. Nonetheless, in 
understanding of the cause and pathogenesis of respiratory tract infections, the main 
question should not be ‘who is the culprit?’ (adapted quote by Prof. R. Dagan, ESPID 
meeting 2012) but ‘who are the culprits, and at which stage of the disease are they 
important pathogens?’ In this regard, the WHO’s aim to prescribe the right antibiotics 
‘when they are truly needed’ seems an insurmountable task.
The main subject of the studies described in this thesis is the pathogen M. pneumoniae. 
This bacterium is responsible for responsible for up to 40% of children hospitalized 
because of community-acquired pneumonia (CAP)17 and is even becoming a more 
important pathogen in the post-pneumococcal vaccination era 18. Two main aspects 
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of this pathogen were addressed, i.e. (1) genetic variation of M. pneumoniae, and (2) 
colonization of the respiratory tract of children by this pathogen. The overall aim of these 
studies was to increase the understanding of the pathophysiology of M. pneumoniae in-
fections and the value of current methods available to diagnose M. pneumoniae disease. 
In the discussion of the consequences of our results, we will first focus on M. pneumoniae 
colonization of the respiratory tract.
iMplications of the resUlts of this thesis
M. pneumoniae colonization or disease
In the MymIC study, we found asymptomatic colonization by M. pneumoniae in children 
in a single-population, single-center study. This study is the first to describe asymptomatic 
colonization by M. pneumoniae in a systematic fashion. Furthermore, we showed that 
it is impossible to distinguish the carrier state from actual acute infection using state-of-
the-art diagnostic tests. This finding is of major importance for clinical practice because 
these tests are used in virtually every clinical microbiological laboratory to detect either 
M. pneumoniae DNA in respiratory tract samples or to detect antibodies against M. 
pneumoniae in serum of children (or adults) with a suspected RTI. In light of our findings, 
it is likely that M. pneumoniae-positive children with an RTI are administered antibiotics 
for an alleged M. pneumoniae RTI, while there is a significant chance that in at least part 
of these children, the symptoms are caused by pathogens other than M. pneumoniae.
Apart from the clinical consequences, our findings are highly relevant for past, present 
and future research of M. pneumoniae. As described in chapter 6, we searched the 
literature for papers that described and evaluated current diagnostic tests. We found that 
diagnostic tests were used interchangeably and positive results are easily interpreted as 
indicative for infection. However, this does no longer suffice. Instead, a more detailed 
interpretation of results for each individual patient is warranted. A good first theoretical 
start for such an interpretation can be based on a recent proposition of different states of 
M. pneumoniae disease19.
five states of M. pneumoniae disease
In a recent review, our group proposed different pathogenic states of M. pneumoniae 
starting at the site of the respiratory tract19. The key to M. pneumoniae disease might 
be the first colonizing step. First contact of M. pneumoniae with the respiratory tract 
may then either lead to a primary colonizing state or acute infection with local cytotoxic 
effects. Dependent on the host pathogen interaction, both states may lead to either 
clearance of M. pneumoniae, antigenic variation resulting in a chronic infection, direct 
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invasiveness of M. pneumoniae cells or an infl ammatory response. The latter two may 
lead to dissemination of M. pneumoniae cells or antibodies and may result in different 
extra-pulmonary disease states 19. All these different M. pneumoniae disease states are 
shown in Fig. 1. It is important to notice that PCR techniques are mainly suitable to detect 
the presence of M. pneumoniae at a certain site in the human body. Used on respiratory 
secretions this might merely refl ect colonization. However, used on blood or secretions 
from within the deeper pulmonary system, a positive PCR might refl ect direct invasiveness 
or dissemination. The detection of antibodies in serum could refl ect a number of patho-
genic states, e.g. acute infection with local infl ammatory effects, chronic infection or a 
systemic infl ammatory reaction. Fig. 1 also clarifi es that the current detection techniques 
to identify M. pneumoniae are insuffi cient to discern the different disease states in an 
individual patient.
genetic variation of M. pneumoniae
Our studies on molecular variation of M. pneumoniae had two major outcomes. First, 
each M. pneumoniae strain can be classifi ed as either a subtype-1 strain or a subtype-2 
strain based on sequence differences present throughout the genome. This fi nding sug-
gests that the two subtypes represent genetically distinct lineages. Based on the fi ndings 
1 colonizing state 
M. pneumoniae 
3 
4 
5 
Antigenic variation resulting in a 
chronic (disseminated) infection 
Direct invasiveness of M. 
pneumoniae cells 
A systemic inflammatory response 
2     acute infection with local cytotoxic effects  
Clearance 
Progression to disease 
figure 1. Different potential disease states with M. pneumoniae
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presented in chapter 2 and 3, it is unlikely that combined subtype 1 and 2 sequences 
will be found in the future.
Second, we found a high potential for variation in the genes encoding the adhesion 
proteins P1 and P40/90 at the surface of the attachment organelle of M. pneumoniae. 
The genes encoding these proteins, MPN141 and MPN142, respectively, contain 
repetitive sequence elements (RepMP elements) of which numerous variants can be found 
throughout the M. pneumoniae genome. We detected novel putative recombination 
events between RepMP variants, as well as previously unknown variations in MPN142. 
Furthermore, we were able to explain the origins of all MPN141 variants that were previ-
ously detected, and we found a genetic variation and in the genomes of M. pneumoniae 
strains recently isolated form patients (chapter 8, manuscript in preparation).
To investigate whether inter-RepMP recombination events also take place in vitro, 
we performed a multiple passage study, in which a small number of strains were seri-
ally cultured for about one year. After each passage, a sample was taken to study 
recombination events. Because we were unable to detect any new recombination events 
(unpublished), we hypothesize that these events are relatively infrequent in the absence 
of immunological pressure.
RTI Clinical assessment 
Supportive care 
No antibiotics 
Pathogen specific signs 
or symptoms?  
Yes 
Examples: 
Influenza symptoms  or  
RS-virus symptoms 
Treat as such 
No Severe illness 
No 
Yes 
Treat infection with penicillin antibiotics 
Treatment failure +/- 
M. pneumoniae antibodies or 
DNA detected 
Start treatment with 
macrolide antibiotics 
Recovery 
figure 2. Schematic proposal for treatment decisions in RTI.
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the importance of genetic variation of M. pneumoniae for 
individual human hosts and the population
We studied M. pneumoniae from a microbial and clinical viewpoint. This translational 
set-up enabled us to combine research questions from both perspectives and make a 
first attempt to determine the clinical impact of genetic variation of M. pneumoniae. A 
significant outcome of our studies was that we were unable to link colonization or severity 
of disease to either of the two major subtypes of M. pneumoniae. The occurrence of 
these subtypes in the population, however, does seem to be related to the long-term 
epidemiological pattern of M. pneumoniae infections. Kenri et al. observed this in a 
study published in 200820. Subtype-specific epidemics occur every 3-7 years on top 
of an endemic background and in each epidemic wave a change in dominant subtype 
occurs. Thus, during a period of approximately 10 years, subtype-1 strains are highly 
prevalent and subtype-2 strains are endemically present. Such a period is then followed 
by a period in which subtype-2 strains become highly prevalent and subtype-1 strains 
gradually decline 20.
Although there is no direct benefit for an individual patient, it is important to monitor the 
prevalence M. pneumoniae in a certain population for several reasons. First, monitoring 
the prevalence of M. pneumoniae creates awareness. At this point the prevalence is 
highly variable spanning 7-10 years20, 21. Knowing that the prevalence is increasing 
at a certain time is valuable because this might guide create awareness for clinicians. 
Second, it is important to monitor genetic variation. We showed that subtype 2 strains 
have higher levels of variation. Consequently, these strains may have more potential 
for antigenic variation. This is important for future studies on severity of disease and 
possibly for future vaccine development. Third, it is important to monitor the prevalence of 
macrolide-resistance M. pneumoniae. This might guide antibiotic usage and eventually 
may result in a more directed therapy. The first choice antibiotics for M. pneumoniae 
infections in children are ML antibiotics. Current treatment strategies for community-
acquired pneumonia are based on the notion that the incidence and prevalence of M. 
pneumoniae infection is higher above the age of five and that M. pneumoniae infections 
are almost non-existent below the age of five. Therefore, to treat suspected pneumonia, 
it is recommended to prescribe beta-lactam antibiotics as a first choice below the age 
of five and ML-antibiotics as a first choice above the age of five 8. Based on our results, 
these treatment strategies seem no longer valid, as the presence of M. pneumoniae in the 
upper respiratory tract did not differ between the different age groups.
Importantly, as described in chapter 7 and 8, ML-resistance has become a widespread 
problem throughout the world, which has a direct link with the use of ML. Morozumi et 
al. demonstrated in 2005 that a higher degree of ML usage results in a higher degree 
of ML-resistance 22. This has clinical consequences as outlined in chapter 8. In the 
Netherlands, we have so far not found any M. pneumoniae strains that harbored a 
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known ML-resistant genotype. However, because ML are easy to administer to children 
and have a favorable pharmacokinetic profile, these antibiotics are frequently prescribed 
to children. Moreover, a recent study showed that early administration of ML to children 
with upper RTI could help to prevent lower RTI23. If these results are incorporated in 
clinical practice or in guidelines, it will be a matter of time before the first ML-resistant 
M. pneumoniae strains will emerge in the Netherlands. It is therefore important to keep 
testing M. pneumoniae-positive samples for ML-resistant genotypes. The pyrosequencing 
technique developed and used in our studies can serve as the basis for the detection of 
the most common ML-resistant genotypes in M. pneumoniae.
should we treat a presumed M. pneumoniae infection?
First of all, it is difficult to determine whether an RTI is caused by M. pneumoniae, be-
cause there are no specific symptoms or signs of M. pneumoniae RTI. In addition, results 
from ancillary laboratory or radiologic investigations are not helpful in the diagnosis 
of M. pneumoniae RTI24. Nevertheless, historically, a clear delineated clinical course, 
described as a ‘walking pneumonia’, is well known for M. pneumoniae infections. This 
clinical course tends to be more severe (prolonged period of fever and coughing) in 
patients infected with ML-resistant M. pneumoniae strains versus patients infected with 
ML-susceptible strains. And, patients infected with ML-resistant strains recover more 
quickly when treated with doxycycline or quinolones 25-27.
Based on the results in this thesis we should at least be very cautious to prescribe 
antibiotics to a child with a positive PCR for M. pneumoniae. Such a positive test might 
just as well reflect bacterial colonization. There are no studies that show clear benefit 
from a ML-antibiotic for a presumed M. pneumoniae infection.
Without a reliable microbiological test and a clear phenotype to lean on, we are left 
without a well-defined recommendation whether or not to treat M. pneumoniae RTI. How-
ever, there are pathogens that do cause a clear RTI phenotype, such as S. pneumoniae, 
S. aureus, influenza virus, RS virus and human metapneumovirus. S. pneumoniae gener-
ally causes a much more severe infection and can be treated effectively with penicillin. 
In addition, in high-risk patients (e.g. with impaired mucociliary clearance), it might be 
beneficial to prescribe antiviral agents early during influenza virus infections.
Thus, without good alternatives, a reasonable path to follow while managing a child 
with an RTI is to prescribe an antibiotic of the penicillin class in order to treat the most seri-
ous possible infection. When this treatment fails, and either M. pneumoniae or anti-M. 
pneumoniae antibodies are detected, ML antibiotics should be prescribed. A possible 
scheme to follow for an RTI in children is presented in Fig. 2
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fUtUre prospects
Future studies on M. pneumoniae should focus on the following aspects.
1. Epidemiology
It is important to study the prevalence of M. pneumoniae in different countries and in 
different seasons and years, because this will indicate whether or not M. pneumoniae 
should be considered as a likely etiological agent of RTI.
Monitoring of M. pneumoniae should also focus on antigenic variation and the preva-
lence of ML resistant M. pneumoniae strains. First this is important to create a better 
understanding of M. pneumoniae variation and in time it will be important to adjust 
antimicrobial therapy and also provide data for possible vaccine development in the 
future.
2. Immunology and improved diagnostic tools
Future studies should aim to increase the understanding of the pathophysiological pro-
cesses that occur after potential pathogens have entered in the human respiratory tract. 
The focus of these studies should lie on the triggered immune responses. Consecutively 
the studies should be aimed at unraveling the posed different disease states (as shown in 
Fig. 1). This should give more insight in the triggered immune responses and maintained 
immune response that serve in protection from future encounters with M. pneumoniae. 
A similar strategy could be performed for different respiratory tract infection pathogens.
Currently, diagnostic studies are purely based on the presence of a pathogen or specific 
antibodies and not per se on the (local) host immune response and consequences of 
the presence of a microorganism. Thus, the future studies should aim at diagnosing the 
immune response that has been triggered by a specific microorganism in a specific 
disease state instead of merely identifying the microorganism in a specific disease state. 
This should aid in new, targeted therapies for RTI and also aid clinicians to prescribe 
antibiotics when truly needed.
In short, future studies should focus on the development of a fast and minimally invasive 
diagnostic tool that identifies the bacterial pathogen causing pneumonia and that defines 
its role as invasive infection-causing microorganism.
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This thesis focuses on bacterial genetic variation and colonization of the respiratory tract 
of children by Mycoplasma pneumoniae. M. pneumoniae is an endemic cause of RTI un-
bound to a specific season and is regarded as a common cause of community acquired 
pneumonia. Besides RTIs, M. pneumoniae has been associated with a number of extra-
pulmonary manifestations. This bacterium has some notable biological characteristics. It 
is one of the smallest free living micro-organisms, but needs to be in close human contact 
to scavenge for important nutrients, due to its small size and genome and its limited 
metabolic capacities. In order to accomplish this, M. pneumoniae has an attachment 
organelle, which consists of multiple attachment proteins. These proteins are encoded by 
genes of which there are multiple copies throughout the genome. Rearrangement of these 
genes may result immune evasion by antigenic variation of the attachment organelle.
The current diagnosis of M. pneumoniae RTIs relies on the detection of either serum 
antibodies against M. pneumoniae or bacterial DNA in samples of the upper respiratory 
tract (URT). Due to drawbacks of serology, detection of bacterial DNA with PCR is mostly 
used. However, if M. pneumoniae would be commonly carried asymptomatically in 
the URT of children, the detection (of DNA) of this bacterial species may not indicate a 
symptomatic infection.
M. pneumoniae has an innate resistance to any antibiotic that is directed to the destruc-
tion or disruption of a bacterial cell wall. In general, antimicrobials that are directed at 
the DNA metabolism and protein synthesis have a good inhibitory activity against M. 
pneumoniae. In the past decades a growing number of reports show an increase of 
antimicrobial resistance against macrolide (ML) antibiotics, especially in Asia.
We posed the hypothesis that M. pneumoniae is able to colonize the human respiratory 
tract in an asymptomatic fashion and, assuming that our hypothesis could be confirmed, 
we also set out to study whether possible asymptomatic carriage could be distinguished 
from infection. Specifically, we aimed to: 1. identify asymptomatic colonization by M. 
pneumoniae using current available microbiological tools, 2. find host factors associated 
with asymptomatic carriage versus symptomatic disease, 3. classify genetic variation 
in M. pneumoniae in a concise understandable manner and 4. to find specific genetic 
pathogen variation that is associated with disease and disease severity. In addition we 
aimed to investigate the upcoming ML-resistance in the Netherlands.
A summary of the most important findings of PART 1: genetic variation of Mycoplasma 
pneumoniae
• M. pneumoniae subtype-1 and subtype-2 represent genetically distinct lineages and 
are not associated with severity of M. pneumoniae respiratory tract infection.
• Besides the subtype division, a high potential for variation is present in the genomes 
of different M. pneumoniae strains (Chapters 3, 4 and 5).
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• Gene conversion, a form of homologous DNA recombination, of RepMP elements 
results in antigenic variation of major adhesion proteins. It is probably immunologi-
cally governed (Chapter 3 and 4).
• Macrolide-resistance is governed by mutations in the ribosome of M. pneumoniae 
which can be identified using pyrosequencing (Chapter 6).
A summary of the most important findings of PART 2: clinical aspects of Mycoplasma 
pneumoniae
• Asymptomatic colonization by M. pneumoniae of the respiratory tract in children 
seems to exist (Chapter 7).
• The prevalence of M. pneumoniae detected by PCR is just as high in asymptomatic 
children as in symptomatic children but changes over time and season (Chapter 7).
• The strains found in asymptomatic and symptomatic children do not differ genetically 
(based on subtype-1 and subtype-2 sequencing and whole genome sequencing) 
(Chapter 7 and 8).
• M. pneumoniae macrolide resistance strains are prevalent throughout the world, but 
have not been identified in the Netherlands (Chapter 9).
• It is questionable whether treatment should be given to children with mild infections 
supposedly caused by M. pneumoniae. Future studies are needed on this subject 
(Chapter 10).
• The choice which antibiotic should be prescribed for an alleged M. pneumoniae 
infection in a child is limited. Macrolides are still the first choice (Chapter 10).
This thesis ends with a general discussion on our findings on M. pneumoniae coloniza-
tion, and discuss that diagnostic tests for an alleged M. pneumoniae infection should be 
interpreted with caution and should take in consideration the recently proposed different 
states of M. pneumoniae disease. The key to M. pneumoniae disease might be the first 
colonizing step.
Concerning the genetic variability we discuss and conclude that there is no direct 
benefit for an individual patient. However, it is important to monitor the prevalence M. 
pneumoniae to create clinical awareness, to monitor genetic variation and to monitor the 
prevalence of macrolide-resistance M. pneumoniae. This might guide antibiotic usage 
and eventually may result in a more directed therapy.
Finally we discuss whether a presumed M. pneumoniae infection should always result 
in antibiotic treatment. We end this discussion concluding that without good alternatives, 
a reasonable path to follow while managing a child with an RTI is to prescribe an 
antibiotic of the penicillin class in order to treat the most serious possible infection. When 
this treatment fails, and either M. pneumoniae or anti-M. pneumoniae antibodies are 
detected, ML antibiotics should be prescribed.
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We conclude the general discussion with some future prospects which should include 
studies on epidemiology and genetic variation to monitor ML resistance in the Nether-
lands and world-wide and immunological studies to increase the understanding of the 
pathophysiological processes that occur after potential pathogens have entered in the 
human respiratory tract.
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Het onderwerp van dit proefschrift is bacteriële genetische variatie en kolonisatie van de 
luchtwegen van kinderen door Mycoplasma pneumoniae.
M. pneumoniae is een endemisch oorzaak van luchtweginfecties en wordt be-
schouwd als een veel voorkomende oorzaak van longontsteking. Deze bacterie heeft 
een aantal opmerkelijke biologische kenmerken. Het is één van de kleinste vrij levende 
micro-organismen, maar moet in nauw contact staan met zijn menselijke gastheer om 
belangrijke voedingsstoffen te vergaren, vanwege zijn kleine formaat en kleine genoom 
en daarmee beperkte metabole capaciteit. Om dit te bereiken, heeft M. pneumoniae 
een aanhechtingsorganel, bestaande uit meerdere oppervlakte eiwitten. Deze eiwitten 
worden gecodeerd door genen waarvan meerdere kopieën gelegen zijn in het genoom. 
Verandering van deze genen door recombinatie kan leiden tot een verandering van 
oppervlakte eiwitten en daardoor antigene variatie het aanhechtingsorganel.
De diagnose van M. pneumoniae luchtweginfecties is gebaseerd op de detectie van 
serum- antilichamen tegen M. pneumoniae of bacterieel DNA in samples vanuit de 
bovenste luchtwegen. Vanwege nadelen van serologie (meerdere bloedafnames nodig 
en daarna een retrospectieve diagnose) wordt de detectie van het bacteriële DNA met 
PCR tegenwoordig steeds vaker gebruikt. Indien M. pneumoniae ook bij asymptomati-
sche kinderen in de bovenste luchtwegen voorkomt, zou een positieve PCR op materiaal 
vanuit de bovenste luchtwegen ook kunnen duiden op dragerschap en dus niet op een 
symptomatische infectie.
M. pneumoniae is intrinsiek resistent tegen antibiotica die zijn gericht op de vernieti-
ging of verstoring van een bacteriële celwand. In het algemeen hebben antibiotica die 
gericht zijn op het DNA en de eiwitsynthese een goede remmende activiteit tegen M. 
pneumoniae. In de afgelopen decennia blijkt een toename van antimicrobiële resistentie 
tegen macrolide (ML) antibiotica, vooral in Azië.
In dit proefschrift wordt de hypothese gesteld dat M. pneumoniae in staat is de men-
selijke luchtwegen te koloniseren op een asymptomatische wijze en ervan uitgaande 
dat onze hypothese kan worden bevestigd, stellen we ook dat asymptomatisch drager-
schap kan worden onderscheiden van infectie. Specifieke doelen waren 1. identifi-
ceren asymptomatische kolonisatie door M. pneumoniae met de huidige beschikbare 
microbiologische testen, 2. Het vinden van gastheer factoren die samenhangen met 
asymptomatisch dragerschap versus symptomatische ziekte, 3. Classificeren van gene-
tische variatie in M. pneumoniae in een beknopte begrijpelijke manier en 4. specifieke 
pathogeen genetische variatie die is geassocieerd met de luchtweginfectie te vinden. 
Daarnaast was het doel om de komende ML-resistentie in Nederland te onderzoeken.
Een samenvatting van de belangrijkste bevindingen van Part 1: the genetic variation 
of Mycoplasma pneumoniae
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• M. pneumoniae subtype-1 en subtype-2 vertegenwoordigen genetisch verschillende 
lijnen en zijn niet geassocieerd met de ernst van M. pneumoniae luchtweginfectie.
• Naast het subtype onderscheid, is een sterk vermogen tot variatie aanwezig in de 
genomen van verschillende M. pneumoniae stammen (hoofdstuk 3, 4 en 5).
• genconversie, een vorm van homologe recombinatie DNA van RepMP elementen 
leidt tot antigene variatie van grote adhesie-eiwitten. Het is waarschijnlijk immunolo-
gisch bepaald (hoofdstuk 3 en 4).
• macrolide-weerstand wordt geregeld door mutaties in het ribosoom M. pneumoniae 
die kunnen worden geïdentificeerd met behulp pyrosequencing (hoofdstuk 6).
Een samenvatting van de belangrijkste bevindingen van Part 2: clinical aspects of 
Mycoplasma pneumoniae
• asymptomatische kolonisatie door M. pneumoniae luchtwegen bij kinderen lijkt te 
bestaan  (hoofdstuk 7).
• De prevalentie van M. pneumoniae gedetecteerd door PCR is net zo hoog bij asymp-
tomatische kinderen als bij symptomatische kinderen, maar varieert in de tijd en per 
seizoen (hoofdstuk 7).
• De stammen gevonden bij asymptomatische en symptomatische kinderen zijn niet 
genetisch verschillend (gebaseerd op subtype-1 en subtype-2 sequencing en whole 
genome sequencing) (hoofdstuk 7 en 8).
• M. pneumoniae macrolideresistentie stammen zijn niet geïdentificeerd in Nederland 
(hoofdstuk 9).
• Het is de vraag of de behandeling moet worden gegeven aan kinderen met milde 
infecties vermoedelijk veroorzaakt door M. pneumoniae. Toekomstige studies zijn 
nodig over dit onderwerp (hoofdstuk 10).
• De keuze in antibiotica die kunnen worden voorgeschreven aan kinderen voor een 
vermeende M. pneumoniae infectie is beperkt. Macroliden zijn nog steeds de eerste 
keuze (hoofdstuk 10).
Dit proefschrift eindigt met een algemene discussie over onze bevindingen op M. 
pneumoniae kolonisatie, en bespreekt dat diagnostische tests voor een vermeende M. 
pneumoniae infectie moet met voorzichtigheid dienen te worden geïnterpreteerd. Er moet 
rekening gehouden worden met de onlangs voorgestelde verschillende stadia van de 
ziekte van M. pneumoniae. Als sleutel tot ziekte voor M. pneumoniae zou de eerste stap 
kolonisatie (dragerschap) kunnen zijn.
Betreffende de genetische variabiliteit worden de conclusies besproken dat er geen 
rechtstreeks consequentie lijkt te zijn voor een individuele patiënt. Het is echter van belang 
om de prevalentie M. pneumoniae te blijven volgen voor klinische bewustwording, om 
genetische variatie volgen en de prevalentie van macrolide-resistentie M. pneumoniae 
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controleren. Dit zou het gebruik van antibiotica kunnen leiden en uiteindelijk resulteren in 
een meer gerichte therapie.
Tot slot bespreken we de vraag of een veronderstelde M. pneumoniae infectie altijd 
zou moeten leiden tot een behandeling met antibiotica. We eindigen deze discussie 
concluderend dat zonder goede alternatieven, bij ernstige luchtweginfecties als eerste 
een penicilline antibioticum zou moeten worden gebruikt. Wanneer deze behandeling 
niet leidt tot verbetering, en of M. pneumoniae of anti-M. pneumoniae antilichamen 
worden gedetecteerd, kan ML antibiotica worden voorgeschreven.
We sluiten de algemene discussie met enkele toekomstperspectieven. Dit betreft 
met name studies over de epidemiologie en genetische variatie van M. pneumoniae. 
Daarnaast is het belangrijk om ML resistentie te blijven controleren in Nederland en 
wereldwijd en immunologische studies uit te voeren om het begrip van de pathofysiolo-
gische processen die optreden na contact met potentiële ziekteverwekkers te vergroten.
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sUppleMentary taBles chapter 2
table s1. Names and genome locations of the RepMP2/3 and RepMP4 elements and sequences of 
primers used for amplification of the elements.
Elementa Genome positionb
Element 
length (bp)
Primer 1 (5’-3’) Primer 2 (5’-3’)
RepMP2/3-a 127355-128821 1467 TTCCGTGCTAACTTAGGTTC AAATGGAGGTAGAGC-
GAATTG
RepMP2/3-b 168051-168681 631 TCTCTACATAAAACTAGCATTG CCCACTAACTTTCCCATAAG
RepMP2/3-c 169920-171370 1451 GGGAATTGGTTTGACCG-
GAG
GCACTTGAAAGAGTTAGTT-
GAT
RepMP2/3-d 182860-184769 1910 GTCCAATCCAAAATGTGGTTG ACTACTGAGGTTACCAC-
TACTCG
RepMP2/3-e 190154-191782 1629 TAAGAGAGAAGTGATGCAGC CACCACTAAGCACACTGC-
CAAT
RepMP2/3-f 245562-247243 1701 GAAATTAGAAAGTCT-
CAAATCTC
GGTGACAGTTGATTGGTGGT
RepMP2/3-g 341759-343166 1408 GAACCCGCATCCACTTTTTC CGTCCCAAATACCGGTGTGA
RepMP2/3-h 441236-442915 1680 GGCACTTGAAAGAGTTAGT-
TAAC
TGCCAATGTTACCACTATTCG
RepMP2/3-i 492620-494206 1587 TTGAACAACAATTAGGTCAAG GTGTCGTTGTTTTGAGCGAC
RepMP2/3-j 606031-607756 1726 CCTAGTGTGGCGAAAATCAG TTGACCTGAGCCTGAAGAAC
RepMP4-a 130355-131994 1640 TCCCACTAAATAAATTGAGTTG ATCAGTGGTGGTATTGGAATC
RepMP4-b 165770-167046 1277 ACAACTATTAGTAG-
TAGAAGAC
CAACTTACTGTTTAAAAGTTGC
RepMP4-c 180820-182441 1622 ATTGCCAAAAGCAAATTGCTG ATAGCGCACCCTAAAGACAC
RepMP4-d 248448-249818 1371 TCCCACTAAATAAATTGAGTTG CCTAAAAGTGACTGCCTTTAC
RepMP4-e 443048-444372 1325 TTAAAAGTGTGCAAGACACTC ACACGGTAAACAAATCTAA-
CAG
RepMP4-f 496473-497560 1088 AAAACCGCCAAAAAGAT-
TAAAG
ATCCAGCCCCCCATTGAT
RepMP4-g 565050-566094 1045 CCTAACGACAAGAATAAG-
TAC
GTGAGGTAATTAATC-
CATAGAC
RepMP4-h 609094-610639 1564 TCCCACTAAATAAATTGAGTTG GCGCCACCAACTTGGTATCC
a The RepMP2/3 and RepMP4 elements were individually named by the suffixes -a to -j and -a to -h, 
respectively.
b The genome positions and sequences were derived from GenBank file U00089.
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table s2. GenBank accession numbers of the sequences generated in this study.
Strain
RepMP4 elements
a b c d e f g h
M129 FJ603705 FJ603706 FJ603707 FJ603708 FJ603709 FJ603710 FJ603711 FJ603712
MAC FJ603723 FJ603724 FJ603725 FJ603726 FJ603727 FJ603728 FJ603729 FJ603730
P1 1428 FJ604101 FJ604102 FJ604103 FJ604104 FJ604105 FJ604106 FJ604107 FJ604108
Mp5 FJ603741 FJ603742 FJ603743 FJ603744 FJ603745 FJ603746 FJ603747 FJ603748
Mp22 FJ603759 FJ603760 FJ603761 FJ603762 FJ603763 FJ603764 FJ603765 FJ603766
Mp72 FJ603777 FJ603778 FJ603779 FJ603780 FJ603781 FJ603782 FJ603783 FJ603784
Mp1042 FJ603795 FJ603796 FJ603797 FJ603798 FJ603799 FJ603800 FJ603801 FJ603802
Mp1116 FJ603813 FJ603814 FJ603815 FJ603816 FJ603817 FJ603818 FJ603819 FJ603820
Mp1286 FJ603831 FJ603832 FJ603833 FJ603834 FJ603835 FJ603836 FJ603837 FJ603838
Mp1397 FJ603849 FJ603850 FJ603851 FJ603852 FJ603853 FJ603854 FJ603855 FJ603856
Mp1842 FJ603867 FJ603868 FJ603869 FJ603870 FJ603871 FJ603872 FJ603873 FJ603874
Mp2004 FJ603885 FJ603886 FJ603887 FJ603888 FJ603889 FJ603890 FJ603891 FJ603892
Mp2018 FJ603903 FJ603904 FJ603905 FJ603906 FJ603907 FJ603908 FJ603909 FJ603910
Mp2157 FJ603921 FJ603922 FJ603923 FJ603924 FJ603925 FJ603926 FJ603927 FJ603928
Mp4599 FJ603939 FJ603940 FJ603941 FJ603942 FJ603943 FJ603944 FJ603945 FJ603946
Mp4817 FJ603957 FJ603958 FJ603959 FJ603960 FJ603961 FJ603962 FJ603963 FJ603964
Mp5181 FJ603975 FJ603976 FJ603977 FJ603978 FJ603979 FJ603980 FJ603981 FJ603982
Mp5191 FJ603993 FJ603994 FJ603995 FJ603996 FJ603997 FJ603998 FJ603999 FJ604000
Mp5192 FJ604011 FJ604012 FJ604013 FJ604014 FJ604015 FJ604016 FJ604017 FJ604018
Mp5194 FJ604029 FJ604030 FJ604031 FJ604032 FJ604033 FJ604034 FJ604035 FJ604036
Mp5196 FJ604047 FJ604048 FJ604049 FJ604050 FJ604051 FJ604052 FJ604053 FJ604054
Mp5245 FJ604065 FJ604066 FJ604067 FJ604068 FJ604069 FJ604070 FJ604071 FJ604072
Ofo FJ604083 FJ604084 FJ604085 FJ604086 FJ604087 FJ604088 FJ604089 FJ604090
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table s1. Primer sequences and genomic positions and lengths of the RepMP5 elements within strains 
M129 and FH
Element
Genome 
positiona
Primer 1 (5’ - 3’) Primer 2 (5’ - 3’)
Amplicon 
length (bp)
Element Length 
(bp)b
M129 FH M129 FH
RepMP5-a 113676-
116092
tga tgg cat taa tta cta 
ttg c
cta cta ata gtt aga tgg 
agt
2417 2415 2417 
(2050)
2415
RepMP5-b 131974-
133863
gat tcc aat acc acc act 
gat
ttc aaa agt gaa aac 
cct act
1891 1891 1891 
(1787)
1891
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RepMP5-c 185648-
188602
cag tgc ggc taa acc 
agg a
tgt gag gtc gtc ctg act g 2955 2754 2701 
(2701)
2500
RepMP5-d 196236-
199306
aca cat cag ggt act cat 
cag
gaa cac aat ttg aac 
tag ctg
3071 3071 3071 
(725)
3071
RepMP5-e 435836-
439626
tga gag gtt taa tgc ctc 
tca
tcg cct tgg ctt tga agt gt 3791 3792 3360 
(1997)
3361
RepMP5-f 497466-
499820
ggt gtt tgg gat ttg ttt gtc ttc ttt tta aca cta cta 
gcg aa
2373 2373 2373 
(2035)
2373
RepMP5-g 566089-
568240
gtc tat gga tta att acc 
tca c
ctc tac atc aaa cta acg 
gct
2168 2168 2168 
(2067)
2168
RepMP5-h 609094-
612464
ccc act aaa taa att 
gag ttg
att tag tgg gag cag 
aca g
3371 3371 1825 
(1764)
1825
aGenomic positions are derived from GenBank file U00089.2.
bExcept for RepMP5-c, the lengths of all RepMP5 elements were redefined as opposed to the originally 
published sequences (in parentheses) from M. pneumoniae M129 U00089.2.
table s2. Sequence identity of RepMP5 elements
M. pneumoniae strain M129 M. pneumoniae strain FH
RepMP5 a b c d e f g h RepMP5 a b c d e f g h
a 100 a 100
b 73 100 b 72 100
c 73 64 100 c 72 63 100
d 64 78 48 100 d 65 78 54 100
e 73 77 65 56 100 e 73 77 56 63 100
f 75 62 70 59 59 100 f 74 62 76 59 59 100
g 87 61 85 70 72 91 100 g 87 61 90 70 72 91 100
h 76 74 70 83 80 85 81 100 h 76 74 82 83 80 85 81 100
sUppleMentary taBles chapter 6
table s1. Prevalence of age, gender and season at enrolment for the group for which consent was given 
versus the group for which consent was not given
Category Subcategory
Asymptomatic % (n/N) Symptomatic % (n/N)
Consent No consent a,b p-value Consent No consent c,d p-value
Age
< 5
50.1 
(230/459)
49.9 
(229/459)
0.15
46.4 
(260/560)
53.6 
(300/560)
0.14
≥ 5
55.3 
(182/329)
44.7 
(147/329)
40.1 
(61/152)
59.9 (91/152)
Gender
F
52.8 
(272/515)
47.2 
(243/515)
0.31
47.8 
(153/320)
52.2 
(167/320)
0.88
M
51.3 
(140/273)
48.7 
(133/273)
48.0 
(168/350)
52.0 
(182/350)
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Season
Winter
46.4 
(84/181)
53.6 
(97/181)
0.32
42.5 
(122/287)
57.5 
(165/287)
0.10
Spring
55.3 
(135/244)
44.7 
(109/244)
38.0 
(84/221)
62.0 
(137/221)
Summer
51.6 
(79/153)
48.4 
(74/153)
41.5 
(22/53)
58.5 (31/53)
Autumn
53.8 
(114/212)
46.2 
(98/212)
55.0 
(93/169)
45.0 (76/169)
a. Of 2 children in the asymptomatic no consent group, age was not recorded. b. Of 2 children in the asymp-
tomatic no consent group, gender was not recorded. c. Of 18 children in the symptmatic no consent group, 
age was not recorded. d. Of 60 children in the symptomatic no consent group, gender was not recorded.
table s2. Prevalences of M. pneumoniae in the asymptomatic group
Category Subcategory M. pneumoniae PCR positive % (n/N)
Age < 5 21.4 (48/224)
≥ 5 20.8 (37/172)
Gender F 19.2 (51/265)
M 24.8 (34/137)
Immunizations Complete 21.6 (83/384)
Incomplete or none 0.0 (0/5)
Season Winter 14.6 (12/82)
Spring 10.5 (14/133)
Summer 43.8 (32/73)
Autumn 23.9 (27/113)
Year of enrolment 2009 14.7 (26/177)
2010 23.4 (29/124)
2011 30.0 (30/100)
Family size < 5 18.8 (61/325)
≥ 5 30.7 (23/75)
Smoking No 22.8 (56/246)
Active or passive 18.5 (28/151)
Presence or history of wheezing None 20.8 (78/375)
Yes 30.4 (7/23)
Daycare attendance No 21.7 (59/272)
Yes 20.2 (25/124)
RTI prior enrolment No 22.3 (61/274)
Yes 18.4 (23/125)
RTI post enrolment No 26.4 (68/258)
Yes 18.6 (16/86)
RTI respiratory tract infections
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table s3. Prevalences of M. pneumoniae in the symptomatic group
Category Subcategory M. pneumoniae PCR positive % (n/N)
Age < 5 14.6 (37/253)
≥ 5 23.0 (14/61)
Gender F 17.2 (26/151
M 15.3 (25/163)
Immunizations Complete 16.7 (50/300)
Incomplete or none 0.0 (0/3)
Season Winter 19.7 (24/122)
Spring 19.5 (15/77)
Summer 9.1 (2/22)
Autumn 10.8 (10/93)
Year of enrolment 2008 3.6 (1/28)
2009 6.5 (5/77)
2010 20.9 (34/163)
2011 23.9 (11/46)
Family size < 5 15.0 (36/240)
≥ 5 20.8 (15/72)
Smoking No 16.2 (29/179)
Active or passive 15.5 (20/129)
Presence or history of wheezing None 15.5 (32/207)
Yes 19.0 (19/100)
Daycare attendance No 20.0 (30/150)
Yes 12.2 (19/156)
Rhinorrhea No 23.2 (26/112)
Yes 12.4 (25/202)
Sore throat No 16.5 (43/261)
Yes 17.0 (8/47)
Earache No 14.5 (37/256)
Yes 24.6 (14/57)
Headache No 16.3 (49/300)
Yes 14.3 (2/14)
Myalgia No 16.0 (50/312)
Yes 50.0 (1/2)
Cough No 16.9 (14/83)
Yes 16.0 (37/231)
Fever No 15.8 (15/95)
Yes 16.4 (36/219)
Lower respiratory tract infection No 15.6 (10/64)
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Yes 16.6 (40/241)
Hospitalisation No 17.1 (7/41)
Yes 16.5 (41/248)
table s4. M. pneumoniae subtypes in asymptomatic and symptomatic children
Asymptomatic Symptomatic
M. pneumoniae subtype 1 31 (75.6) 25 (83.3)
2 10 (24.4) 5 (16.7)
table s1. Primers
Assay/Targets Primers Sequence (5’®3’) and labels
Amplicon size 
(bp)
MPN141 External Forward primer GAA ACA CCT CCT CCA CCA AC 151
Reverse primer CCA TCT AAC AGT TCA GCG AG
Internal Forward primer GAA TGA TGT GGT GGG GGT TG 84
Reverse primer Biotin-GGG GTG CGT ACA ATA CCA 
TCA A
Sequence primer CAA CGC CGC AAA GAT
MPN528a External Forward primer TAC GAC TAG GAG ATC ATC CAG 232
Reverse primer TTA AGG TGT TTG AGT TGG TGT
Internal Forward primer ATC TAC CGA TTC AAC CAA CTG CT 166
Reverse primer Biotin -GCT AAC TGC GCT AGA GCA 
AAA T
Sequence primer AGA AAT CGA AAA CTG ACT AT
23S rRNA (assay 
1)
External Forward primer ACC ATC TCT TGA CTG TCT CG 183
Reverse primer CAT CAA CAA GTC CTA GCG AAC
Internal Forward primer TCG GTG AAA TCC AGG TAC G 130
Reverse primer Biotin -CAT CGA TTG CTC CTA CCT 
ATT CTC
Sequence primer AGG CGC AAC GGG ACG
23S rRNA (assay 
2)
External Forward primer GAT TAA AGA GAT ACG TGA GTT G 175
Reverse primer ATA GAC ACG TTA CTA CCC AG
Internal Forward primer Biotin -TTC AAA CCG TCG TGA GAC 
AG
113
Reverse primer AAC TGG AGC ATA AGA GGT GTC 
CT
Sequence primer CTA CGG GCA CAA TAG AT
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-  Macrolide resistance determination and molecular typing of 
M. pneumoniae by pryosequencing on clinical samples. Poster 
presentatie. European Society for Pediatric Infectious Diseases 
2011 0.4 
-  Macrolide resistance determination and molecular typing of M. 
pneumoniae by pryosequencing on clinical samples. Voordracht. 
Nederlandse vereniging voor Microbiologie, Papendal, Arnhem, 
2011 0.9 
-  Detection of Mycoplasma pneumoniae in healthy children by 
real time PCR – preliminary data from the MymIC study. Poster 
presentatie. Nederlandse vereniging voor Microbiologie 
2011 0.4 
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-  Variation in a surface-exposed region of the Mycoplasma 
pneumoniae P40 protein as a consequence of homologous DNA 
recombination between RepMP5 elements. Poster presentatie. 
Nederlandse vereniging voor Microbiologie, Papendal 
2011 0.4 
-  Macrolide resistance determination and molecular typing of 
M. pneumoniae by pryosequencing. Voordracht. Molecular 
Medicine (MolMed) day 
2011 0.9 
-  Detectie van Mycoplasma pneumoniae met real time PCR in 
gezonde kinderen – preliminaire data uit de MymIC-studie. Poster 
presentatie. NVK congres, Veldhoven 
2010 0.4 
-  Macrolide resistance determination and molecular typing of 
M. pneumoniae by pryosequencing. Voordracht. International 
Organization for Mycoplasmology Congress 
2010 0.9 
-  Rapid antibitiotic resistance determination and genotyping of 
Mycoplasma pneumoniae by pyrosequencing, Poster presentatie. 
European Society for Pediatric Infectious Diseases 
2010 0.4 
-  Variatie in repeterende DNA elementen in Mycoplasma 
pneumoniae: een bron voor antigene variatie. Poster presentatie. 
NVK congres, Veldhoven, november 2009. 
2009 0.4 
-  Repetitive elements in the respiratory pathogen Mycoplasma 
pneumoniae: a pool for antigenic variation. Voordracht. 
Onderzoeksdag kindergeneeskunde, Erasmus MC – Sophia 
2009 0.9 
-  Sequence Variations in RepMP2/3 and RepMP4 Elements 
Reveal Intragenomic Homologous DNA Recombination Events in 
Mycoplasma pneumoniae. Poster presentatie. European Society 
for Pediatric Infectious Diseases 
2009 0.4 
-  Sequence Variations Reveal Intragenomic Homologous DNA 
Recombination Events in Mycoplasma pneumoniae. Voordracht. 
NVK, Sectie Pediatrische infectieziekten en immunologie 
2009 0.9 
International conferences
-  ESPID (European Society for Pediatric Infectious Diseases) Annual 
Conference attendance 2009, 2010, 2011, 2012 
 5.7 
-  IOM (International Organization for Mycoplasmology) Biannual 
Conference attendance 2008, 2010 
 2.9 
Workshops and seminars
- Mycoplasma Techniques Workshop, IOM Conference 2008 1.0 
Didactic skills
Other
-  Article review for Journal of Medical Microbiology, Respiratory 
Journal, and Nederlands tijdschrift voor geneeskunde 
2008-2012  
2. Teaching activities
Supervising master theses
- D. Bierschenk, HLO student 2010-2011  
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PhD Portfolio
Project 1: Macrolide resistance determination and molecular 
characterization of Mycoplasma pneumoniae strains isolated in the 
Netherlands in a 12 years period. 
  
Project 2: Characterization of two putative helicases of Mycoplasma 
pneumoniae. 
  
- N. van de Kreeke, MLO student (november 2009 – juli 2010) 2009-2010  
Genetische variatie van het ORF6 gen Mycoplasma pneumoniae als 
gevolg van homologe DNA recombinatie tussen RepMP5 elementen. 
  
Supervisising Research students MymIC study
- L. Spadon 2009-2012  
- I. Gondrie   
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Dankwoord
danKWoord
Tot slot het dankwoord. Het ligt voor de hand om de kinderen en de ouders van kinderen 
die hebben deelgenomen aan mijn onderzoek hier in het begin te bedanken daarvoor. 
Het is fijn om te merken dat er zoveel mensen openstaan voor het meedoen aan weten-
schappelijk onderzoek. Ik hoop dat het zo blijft. Zonder jullie bestaat er geen onderzoek. 
Het heeft even geduurd tot ik aan dit dankwoord toekwam. Het voelt dan ook bijzonder 
dat ik dit nu toch eindelijk zit te schrijven. In de afgelopen jaren zijn er veel mensen 
betrokken geweest bij mijn promotie onderzoek en mijn persoonlijke ontwikkeling als 
onderzoeker. Misschien te veel om op te noemen en als ik hier zit, komen herinneringen 
boven en lijkt de lijst steeds langer te worden. Dank aan de wereld gaat misschien wat 
ver. Veel mensen hebben echter een grote of kleinere rol gespeeld. Sommigen mensen 
zijn meer in het begin betrokken geweest en anderen meer aan het einde. Een aantal 
zijn op de voorgrond behulpzaam geweest of begeleidend, en anderen meer op de 
achtergrond. Een hele hoop mensen beseffen misschien niet eens dat ze belangrijk voor 
me waren in de afgelopen tijd en nog steeds. Het zijn soms de kleine, onopvallende 
dingen die het doen. Niettemin waren een hele hoop mensen belangrijk voor mij en mijn 
onderzoek en daarvoor wil ik ze bedanken. Een paar nemen natuurlijk een bijzondere 
plaats in.
Dr. A.M.C. van Rossum, beste Annemarie, jij bent de aanstichter van dit alles. Jij bent 
vanaf het begin een stimulans geweest in alles wat ik deed en hebt me met de kansen 
die je me hebt gegeven een geweldige tijd bezorgd. Als copromotor wist jij mij altijd 
de juiste input te geven om me weer op weg te helpen of verdieping te brengen. Je bent 
een geweldig mens en onderzoeker en ik ben er trots op dat ik bij jou onderzoek heb 
gedaan. Naast het onderzoek heb je ook altijd aandacht getoond voor mijn persoonlijke 
ontwikkeling. Ik heb meer dan alleen dit onderzoek aan jou te danken. Bedankt voor je 
begeleiding en voor al het andere. 
Dr. C. Vink, beste Kees, dank je voor je begeleiding in het laboratorium. Als iedereen 
jou enthousiasme in het lab zou kennen en dat zo zou kunnen beleven zoals ik dat heb 
gedaan, dan zou niemand meer klinisch onderzoek willen doen. Ik heb veel van je 
geleerd en kijk terug op een mooie onderzoekstijd in het lab waar je me altijd wist te 
motiveren om door te gaan. Het lukte, meer dan eens, niet meteen om een proef goed 
te krijgen. Jou woorden daarbij zal ik niet snel vergeten: ‘als het makkelijk was, dan 
kon iedereen het’. Ook bij het schrijven van een artikel denk ik nog vaak terug aan die 
uitspraak. Ik wil je bedanken voor jou kritische kijk op mijn wetenschappelijke artikelen. 
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Wat ik ook schrijf, van jou heb ik geleerd dat het altijd een beetje beter kan. Dank 
daarvoor. 
Prof.dr. H.A. Moll, beste Henriette, dank dat je mijn promotor wilde zijn. Je hebt vanaf 
het begin af aan gezegd dat je actief betrokken wilde zijn bij mijn proefschrift ondanks 
de begeleiding van twee geweldige copromotoren. Vooral aan het eind is dat goed 
gelukt en daar ben ik je ook zeer dankbaar voor. Ik wil je hier graag ook bedanken voor 
je begeleiding aan het einde van mijn opleiding tot kinderarts. Je gaf me de vrijheid die 
ik nodig had. Dank je wel.
Aan de leden van de kleine commissie. Prof.dr. J.C. de Jongste, beste Johan, dank 
dat je als secretaris wilde optreden in mijn kleine commissie en dank voor het kritisch 
beoordelen van mijn proefschrift. Prof.dr. M.P.G. Koopmans, dank voor de beoordeling 
van mijn proefschrift en de kritische noten toen er op het laatste moment een grote wijzig-
ing moest worden doorgevoerd. Prof.dr. L.J. Bont, beste Louis, dank voor je inspirerend 
enthousiasme tijdens mijn tijd als onderzoeker. Ik ben blij dat je plaats wilde nemen in 
mijn commissie.   
Prof.dr. E.A.M. Sanders, Prof. dr. P.J.E. Bindels, Prof.dr. M.D. de Jong, dank voor het 
plaats willen nemen in mijn promotie commissie. 
Prof.dr. J. Stülke, dear Jörg, thank you for reading my thesis and taking place in the 
committee. My visit in your lab was brief, but nevertheless fruitful. Thank you for your 
hospitality and your help in finding and creating M. pneumoniae mutant strains.
Dr. P.L.A. Fraaij, beste Pieter, dank je wel voor je vele goede adviezen gevraagd en 
ongevraagd. Ik heb veel van je geleerd en waardeer je kritische blik en je ervaring in 
het doen van onderzoek. Dank je dat je in mijn commissie wilt plaats nemen. Ik kijk er 
naar uit. Het wordt mooi!
Dr. N.G. Hartwig, beste Nico, jij was betrokken bij de start van mijn onderzoek. Ik wil 
je bedanken voor je vertrouwen en voor het kritisch beoordelen van mijn werk. Ik heb 
veel van je geleerd zowel als onderzoeker als als arts.
Eline, ik herinner me nog de dag dat je aan mijn deur stond. Mijn deur, die niet zoveel 
later jou deur werd. Je hebt veel voor mij en mijn onderzoek gedaan en betekend. Ik heb 
met plezier met je samen gewerkt. Heel erg bedankt voor alles en succes in de toekomst. 
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Ivar en Leandra, jullie kwamen als onderzoeksstudenten bij mij werken. Dank jullie wel 
voor het vele praktische werk dat jullie hebben verricht. Ik hebt geboft met jullie.
Theo, dank je wel voor je vele praktische werk en hulp aan mijn onderzoek. Jou onge-
looflijke vermogen om een grote hoeveelheid werk te plannen en door te zetten heeft 
meer dan eens geleid tot mooie resultaten. Het is niet voor niets dat de kaft van dit 
boekje is geïnspireerd op M. pneumoniae kolonies. Jij hebt me die in het echt laten zien. 
Marcel, jij hebt me veel geleerd in het lab en was betrokken bij de moleculaire kant 
van mijn onderzoek. Dank daarvoor en voor het feit dat ik je altijd kon vragen om hulp. 
Silvia, jij werd pas later meer direct betrokken bij mijn onderzoek. Niettemin wil ik je 
daarvoor erg bedanken. Aan jullie alle drie, Theo, Marcel en Silvia, dank je wel voor 
jullie steun en het bezorgen van een geweldige tijd in het lab. Het heeft wat tijd gekost, 
maar het is toch een boekje geworden. Dear Patrick, thank you for all your help, support 
and critical comments. Thank you for your friendship. I wish you all the best.
Alle collega’s in het laboratorium kindergeneeskunde wil ik bedanken voor een leuke tijd 
in het lab, de gezellige sfeer en leuke herinneringen die er nu bij mij van overblijven. 
Het was erg waardevol.
Veel afdelingen hebben me geholpen in de afgelopen jaren. Al deze afdelingen wil ik 
daarvoor bedanken. In het bijzonder dank aan de collega’s van de afdeling virologie en 
medische microbiologie voor de adviezen over het opslaan van patiëntenmateriaal en 
alle PCRs en kweken die zijn verricht. Ook wil ik hier de collega’s van de spoedeisende 
hulp en de huisartsenpost bedanken waar veel van de kinderen met luchtweginfecties 
zijn geïncludeerd. Ook wil ik mijn dank uitspreken aan alle onderzoekers van de afdel-
ing algemene kindergeneeskunde die betrokken zijn geweest bij mijn onderzoek. Veel 
van de gezonde kinderen zijn geïncludeerd op de dagbehandeling van het Erasmus MC 
Sophia en hebben materiaal afgestaan onder narcose. Een bijzondere ervaring. Ik wil 
de medewerkers van de dagbehandeling, de anesthesie en anesthesiologen bedanken 
voor hun hulp en gastvrijheid. Natuurlijk horen daarbij ook de hoofdbehandelaars van 
deze kinderen, die het mede mogelijk hebben gemaakt om dit voor elkaar te krijgen. 
Dank voor jullie vriendelijke hulp. Daarmee wil ik ook dank uitspreken aan alle mede 
auteurs. Dank voor jullie samenwerking.
Aan de arts-assistenten kindergeneeskunde. Dank voor een mooie tijd. Aan alles komt 
een eind, zo ook aan onderzoekstijd. Ik had me voorgenomen om eerst te promoveren 
en daarna kinderarts te worden. Dat is niet gelukt, maar ik ben blij dat ik met jullie bijna 
de helft van mijn hele onderzoekstijd heb mogen doorstaan. Dank voor jullie steun en 
het op gezette tijden herhalen van de vraag of ik al een datum had. Het is gelukt. Aan 
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mijn opleiders kindergeneeskunde. Prof.dr. M. de Hoog, beste Matthijs, en Dr. R.C.J. 
de Jonge, beste Rogier, als opleiders zijn jullie bij mijn onderzoek nauwelijks betrokken 
geweest, maar jullie zijn wel een geweldige steun geweest tijdens mijn opleiding en 
toen het moeilijk werd kon ik altijd bij jullie terecht. Heel erg bedankt daarvoor.
Aan al mijn huidige collega’s, dank voor jullie interesse en jullie adviezen. Dank voor 
de goede werksfeer. 
Mijn paranimfen, Rob en David, dank dat jullie er vandaag bij zijn en dank voor jullie 
steun in de afgelopen jaren. Jullie betekenen veel voor me. 
Het geluk van het hebben van familie en vrienden is veel waard. Lieve familie en vrien-
den, bedankt voor jullie interesse in mijn werk, alle steun en voor de nodige afleiding.
Rob, Wouter, Marieke en Clio, dank voor jullie vriendschap en de vele etentjes die er 
nu overheen zijn gegaan om te komen tot deze dag. Ik hoop dat we daar nog lang mee 
door kunnen gaan. Adrie en Hannelore, Daphna, Sam en Kitty, dank voor jullie interesse 
en luisterend oor. David en Angelique, Marieke en Eelko, dank voor jullie interesse en 
voor jullie geduld. Raf en Noud, grote jongens, dank voor de logeerpartijtjes. Het was 
een leuke afleiding.
Mijn ouders, papa en mama, het is gelukt. Op de achtergrond hebben jullie alles 
gevolgd en gesteund. Het duurde even, maar het is het wachten waard. Dank voor jullie 
steun. Door jullie ben ik hier vandaag gekomen.
Lieve Isabella, je beseft het niet, en je kunt dit misschien over een tijdje pas lezen. Toch 
wil ik je nu al bedanken. Dank dat je er bent, en dank voor je vrolijkheid en lach. Dank 
je dat je hebt gekozen voor kleur. Lieve Ilana, met Isabella ben je gedeeld laatste, hoe 
kan het ook anders. Jij hebt alles van heel dichtbij thuis meegemaakt. Dank je wel voor 
het luisteren, het commentaar, het afremmen, het geduld, de rust, de liefde, het geluk. 
Ik hou van je. 
Emiel
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M. pneumoniae is regarded as a 
common cause of community ac-
quired pneumonia. We posed the 
hypothesis that M. pneumoniae is 
able to colonize the human respi-
ratory tract and, assuming that our 
hypothesis could be conﬁ rmed, we 
also set out to study whether pos-
sible asymptomatic carriage could 
be distinguished from infection. In 
the ﬁ rst part the ﬁ ndings of bacterial 
genetic variation are described. We 
describe that M. pneumoniae sub-
type-1 and subtype-2 represent ge-
netically distinct lineages with a high 
potential for variation by homologous 
DNA recombination. The second 
part describes the prevalence of M. 
pneumoniae detected by PCR, which 
is just as high in asymptomatic chil-
dren as in symptomatic children but 
changes over time and season. The 
strains found in asymptomatic and 
symptomatic children do not seem 
to diﬀ er genetically. M. pneumoniae 
macrolide resistant strains have not 
been identiﬁ ed in the Netherlands. 
Finally we discuss the consequences 
of our ﬁ ndings on M. pneumoniae 
colonization and bacterial genetic 
variation. We discuss that diagnostic 
tests for an alleged M. pneumoniae 
infection should be interpreted with 
caution and we question whether 
a presumed M. pneumoniae infec-
tion should always result in antibiotic 
treatment.
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